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ABSTRACT 
Monoclonal antibodies (mAbs) have become a class of therapeutic protein-based 
drugs of high importance for treating numerous human diseases. As a complex, delicate 
three dimensional molecule, a mAb can be sensitive to ambient environments and thus 
often display colloidal/conformational instability during manufacturing, storage, and 
administration. The use of formulation strategies, such as employing specific excipients 
and/or particular solution conditions (e.g., pH and buffers), can significantly improve a 
mAb’s pharmaceutical stability properties. In this Ph.D. thesis research work, both 
formulation/storage stability as well as stability during in vitro models of mAb 
administration in vivo are evaluated with two different of classes of immunoglobulin 
molecules (IgG and IgA). In addition, the effect of specific classes of excipients and 
solution conditions are examined by using a wide variety of physicochemical and 
immunological binding analytical techniques.  
Specifically, the second and third chapters of the Ph.D. thesis work focus on the 
formulation development of high-concentration mAb dosage forms for subcutaneous (SC) 
injections. Reversible self-association (RSA) of mAbs, which is primarily due to 
intermolecular protein-protein interactions (PPIs) between mAb molecules, has emerged 
as an important formulation challenge in terms of significantly increasing solution viscosity 
and turbidity as well as initiating phase separation. In these two chapters, two different 
human IgG1 molecules (mAb-J and mAb-C), which showed strong RSA propensity at 
relatively high protein concentrations, were comprehensively studied to better understand 
their solution properties and molecular behaviors by both biophysical techniques as well 
as hydrogen-deuterium exchange mass spectrometry (HX-MS). The aim is to not only 
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characterize mAb molecular properties and solution behavior at relatively high protein 
concentrations, but also to develop a better mechanistic understanding by identifying 
peptide segments within the mAb involved PPIs in solution.  
In these two studies, both elevated solution viscosity and turbidity as well as 
reduced relative solubility and increased protein-protein interaction propensity (as 
measured by light scattering profiles and observations of phase separation) were 
determined for two different mAbs (mAb-J and mAb-C) at comparatively high protein 
concentrations. Concomitantly, based on the amino acid sequence of each mAb’s RSA 
sites (as determined by lyophilization-reconstitution-based HX-MS methodology), two 
different dominant non-covalent forces (electrostatic and hydrophobic) are proposed to 
be the major driving force for PPIs of the two different mAbs (consistent with previous 
results). More importantly for this work, varying effects of different excipients were 
investigated particularly for their ability of promote or disrupt PPIs of each mAb. For mAb-
J (electrostatic driven RSA), selected ionic excipients showed the ability to disrupt liquid-
liquid phase separation and reduce intermolecular interactions to varying extents, with 
arginine hydrochloride possessing the highest efficiency. For mAb-C (hydrophobic driven 
RSA), opposing effects were observed for sodium sulfate versus selected hydrophobic 
additives (e.g., specific salts, amino acids, solvents), showing both enhanced and 
reduced PPI propensity, respectively. In both studies, not only was the RSA of mAbs 
shown to be mAb concentration dependent, but the excipient’s ability to mitigate the RSA 
of mAbs RSA also displayed an excipient concentration dependent pattern. 
The fourth chapter focuses on the possibility of using various classes of mAbs, 
including secretory IgA (sIgA) and IgG1, as potential drug candidates for oral delivery to 
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prevent enteric diseases in infants. Specifically, the use of mAbs against enterotoxigenic 
Escherichia coli (ETEC) is examined with the idea that passive immunization by 
pathogen-specific immunoglobulins, by oral delivery to infants, is promising approach to 
provide “instant” protection against ETEC. Secretory IgA (sIgA) is of particular interest 
because it is naturally found in the mucosal surfaces within the GI tract, is relatively more 
resistant to proteolysis by digestive enzymes (vs. IgG), and can protect against enteric 
bacteria by directly neutralizing virulence factors. In this study, three different mAbs, 
(sIgA1, sIgA2 and IgG1) against heat labile toxin (LT, one of the major virulence factors 
of ETEC), were used as a model for developing analytical techniques to characterize the 
structural integrity of the mAbs and to assess their stability profiles under various solution 
conditions (using physicochemical and immunochemical binding assays).  
In this work, very different total carbohydrate levels and N-linked glycosylation 
oligosaccharide composition profiles were observed between sIgAs and IgG1 made from 
CHO cell lines. According to SDS-PAGE, SE-HPLC, and SV-AUC results, heterogeneous 
mixtures of higher molecular weight species were observed for sIgAs, while IgG1 samples 
showed less heterogeneity with more than 90% monomer in solution. The overall physical 
stability results at both pH 7.2 and pH 3.0 demonstrated that both sIgA1 and sIgA2 were 
more stable than IgG1, with sIgA1 displaying the best stability profile. The relative 
solubility profile of each molecule was pH dependent with higher solubility noted at the 
lower pH. Furthermore, an in vitro digestion model was adapted in the laboratory to mimic 
in vivo oral gastric degradation conditions using minimal material, and was utilized to 
monitor the oral delivery stability of the three mAbs. It was shown that F(ab’)R2R was the 
major digestion product by pepsin digestion. Both sIgAs displayed better resistance to 
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degradation by proteases at low pH compared to IgG1. Moreover, the sIgAs showed 
greater retention of LT-antigen binding activity than that of IgG1, confirming the superior 
pharmaceutical properties of sIgAs for oral delivery. In summary, we hope to use the 
information gained by these preformulation characterization studies for the long-term goal 
to design stable, low-cost liquid formulations for oral delivery of sIgAs to protect against 
enteric diseases currently affecting infants in the developing world.  
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Introduction 
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1.1. Overview of Classes of Immunoglobulin 
1.1.1. General Description of 5 Immunoglobulin Classes 
Immunoglobulins (Igs), also known as antibodies, are a key part of the human 
immune system. These protein molecules specifically recognize and bind to particular 
pathogens, such as toxins, viruses, and bacteria. They are produced by plasma cells, a 
specific type of B cell in the immune system, in response to immune challenges. A typical 
Ig molecule has the following basic molecular structureP1,2P: four polypeptide chains, 
including two identical light chains (LC) and another two identical heavy chains (HC). 
There are variable and constant regions to each heavy and light chain. The variable 
region contains the amino acid sequences responsible for antigen binding (see below). 
Based on differences in the primary amino acid sequence in the constant regions, the 
light chains are classified as either the "kappa" (κ) or "lambda" (λ), while the heavy chains 
fall into as "alpha" (α), "gamma" (γ), "delta" (δ), "epsilon" (ε), and "mu" (μ) class, 
representing the IgA, IgG, IgD, IgE, and IgM classes, respectively. Distinct biological 
functions and physical properties have been discovered for each of the five Ig classes 
(Table 1). Nonetheless, different types of Ig molecules have same basic structure of four 
polypeptide chains (Figure 1), including aforementioned two light and two heavy chains, 
which are connected together by a combination of disulfide bonds as well as non-covalent 
interactions, forming a Y-shaped structure. The hinge region on the heavy chain divides 
whole Ig molecule into Fab and Fc parts, meaning antigen-binding and crystallizable 
fragments, respectively. Just as its name implies, the Fab fragment contains variable 
sections that determine the specific target that Ig molecule can bind. By contrast, the Fc 
fragment of Ig molecules (within a specific class) is the same for each species, can be 
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recognized by particular macrophage receptors for initiating potential immune responses. 
Based on the variability of primary sequence, heavy chain is further divided into four 
domains, including variable domain (VRHR), constant domain one (CRHR1), constant domain 
two (CRHR2), and constant domain three (CRHR3). Light chain, on the other hand, has two 
distinct domains, including variable domain (VRLR) and constant domain (CRLR). Three 
complementarity-determining regions (CDRs) are located on each of the variable region, 
which are the particular places within the antibody that binds to different antigens, usually 
referred as paratope. Furthermore, albeit varying considerably across types of Ig 
molecules, post translational modifications such as glycosylation (N-linked, O-linked or 
both types) can be attached to at least one site on each heavy chain of all Ig molecules. 
Figure 1. The basic structure of immunoglobulin Ig molecules. The distribution of both 
interchain and intrachain disulfide bonds are shown. Purple-labelled carbohydrate point 
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to localization of potential N-glycosylation in CRHR2 domain.3 (This website was accessed 
on January 7th, 2019, and figure reprinted). 
Table 1. Biological and physical properties of Ig classes.2 (Table reprinted) 
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1.1.2. Brief Introduction to IgG and IgA Molecules 
Immunoglobulin G (IgG) is the most common class of immunoglobulins found in 
blood circulation. Among all serum antibodies, approximately 75% are belonging to this 
class.4 IgG has four subclasses (IgG1, 2, 3, 4) in humans, which have the nomenclature 
based on their relative abundance in serum. By binding and neutralizing different kinds of 
pathogens such as bacteria, fungi, and viruses, IgG plays a critical role in protecting the 
human body from infection. More details of IgG structure and biological functions will be 
described in 1.2. section below.  
Immunoglobulin A (IgA), the second most prevalent Ig protein in human serum 
(after IgG) and the preeminent antibody class (as secretory IgA, sIgA) in the mucosa 
community that bathes mucosal surfaces, acts as the first line of body defense and plays 
a crucial role in immune protection. Two subclasses of (s)IgA have been found in human, 
including (s)IgA1 and (s)IgA2, and (s)IgA2 is also with two allelic variants [A2m(1) and 
A2m(2)]. Further details about IgA physical structure, body distribution, and biological 
properties will be discussed in 1.3. section below. 
1.1.3. Structure and Function of IgM, IgD, and IgE Molecules 
Immunoglobulin M (IgM), among the 5 major antibodies in human serum, is the 
largest and most complex (macroglobulin). It is not only he first antibody developed during 
human fetal development at about 5 months, but it also the first to react in the response 
to initial exposure to a pathogenic antigen. The concentration of IgM in human serum is 
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about 1.2 mg/mL. Although the basic structure of IgM monomer is same as IgG, IgM 
usually appears to be pentameric assembly of these monomers (or rarely hexamers) in 
human serum. Therefore, a pentameric IgM comprises of 10 heavy chains, 10 light 
chains, and usually a joint chain, called J chain. The polymeric property of IgM is primarily 
due to J chain mediated connections by disulfide bonds involving cysteines in the 
tailpieces. However, unlike IgA, it is not necessary to have a J chain to form polymeric 
IgM, since the tailpiece cysteine of IgM heavy (µ) chain can also form covalent bond with 
other µ chain.5-8 Although a rare occurrence, two or three J chains can exist in one IgM 
molecule.9-12 Hexameric IgM can also be produced by B cells, but usually in the absence 
of J chain, and only less than 5% of total IgM in human serum are hexamers.2 
Theoretically, 10 antigens can bind to one IgM molecule at the same time because of 
predominantly pentameric structure. However, due to steric effects, approximately 5 large 
antigens can bind simultaneously. Both monomeric (like IgG structure) and polymeric 
(pentameric or hexameric) IgM have significant effects in the immune system. As an 
antigen-specific component of the antigen receptor, monomeric IgM associates on the B-
cell surface and plays key roles on natural development of unstimulated B lymphocytes. 
The polymeric IgM can activate the classical pathway by binding to complement 
component (C1qR and Fcα/µR), recruiting phagocytic cells for immune responses, and 
lead to antigen opsonization and cytolytic reactions. Furthermore, IgM can also be 
secreted to mucosal surfaces by a function of J chain for potential immune reactions, for 
example secreted into breast milk or gut lumen. In summary, IgM antibodies provide 
“natural immunity” as the first protection and thus commonly initiate an immune response 
against invading microorganism.  
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Immunoglobulin D (IgD) is a minor antibody component that makes up less than 
0.25% of total antibody concentration in serum. IgD is usually present in serum in a 
monomer state, comprising of two heavy (2δ) and two light chains, without any other 
polypeptide chains involved. The half-life of IgD is relatively short, only about 2.8 days.13 
Because of a highly extended hinge region, IgD is extremely sensitive to proteases.2 
Moreover, as primarily a membrane bound protein, IgD can anchor on B-cell surface by 
a glycosyl phosphatidylinositol linkage, serving as an antigen-specific part of B-cell 
receptors. IgD will not be expressed until B cell leaves the bone marrow to further settle 
down and grow in the peripheral lymphoid tissues. Collaborating with IgM on the surface 
of B cell, IgD plays certain key roles in the immune signalling cascade. However, it has 
been found that only repetitive multivalent immunogens can trigger IgD signalling, while 
both soluble monomeric or multivalent immunogens can initiate IgM immune signalling.14 
The quantity of IgD on B-cell surface, on the other hand, is about one order of magnitude 
higher than that of IgM.2 Recently, additional biological functions have been found for IgD 
which can bind to basophiles and mast cells, activating them to produce antimicrobial 
factors that control respiratory immune defense.15 Finally, IgD might also be involved in 
allergic reactions in humans. 
 Immunoglobulin E (IgE) is generally synthesized by plasma cells (in mammals 
only), but as another minor class of antibody in humans, it is present at very low 
concentration in serum. As a normally monomeric form, IgE is comprised of two heavy 
chains (2ε) and two light chains, where the ε chain contains four constant domains (Cε1-
Cε4). IgE acts as the most important participants for allergic and inflammatory reactions, 
in which the Fc part of antibody has very high affinity for mast cells and can bind to Fcε 
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receptors, including FcεRI and FcεRII, on the surface of mainly mast cells and basophils. 
Also, it has been found that monocytes, eosinophils, platelets, and macrophages in 
humans have such Fc receptors in humans.16 The binding of multivalent antigens with 
membrane-bound IgE initiates the release of many active mediators, such as 
leukotrienes, histamine, prostaglandins, and chemotactic factors, to trigger corresponding 
allergic and inflammatory reactions. Plasma concentrations of IgE are usually elevated 
by several hundredfold due to allergic conditions or infection by Necator americanus and 
nematodes.2,17,18 Elevation of IgE level is also been reported in various autoimmune 
disorders, including rheumatoid arthritis and psoriasis, leading to hypersensitivity 
reactions with pathogenic effects.19,20 Furthermore, the presence of specific IgE 
molecules can potentially be used in allergy diagnosis when conducting a blood or skin 
test.21 
1.2. More Detailed Description of Physicochemical and Biological Properties of 
IgG Class 
Of the five major immunoglobulin classes, IgG is the most abundant one, 
accounting for approximately 75% of serum antibodies present in humans. It is found in 
all body fluids and plays a critical role in protecting humans from pathogenic infections 
due to viruses, bacteria, and other microorganisms. The Y-shaped IgG molecule not only 
binds antigens via the Fab regions of the protein, but it also possesses many immune 
triggering properties and functions (after antigen binding) which are dictated by the 
glycosylation pattern within the Fc region.  
1.2.1. Basic Structure  
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1.2.1.1. Chain Composition and Molecular Weight 
Two identical polypeptide heavy chains (2γ) and two identical polypeptide light 
chains assemble to form a three dimensional Y-shaped IgG molecule with a molecular 
weight of about 150 kDa (see Figure 2 below). As outlined above,1,2 four domains are 
distinguished on the IgG heavy chain including VRHR, CRHR1, CRHR2, and CRHR3. The molecular 
weight of the heavy chain is about 50 kDa, with some minor differences between IgG 
molecules based on the sequence on the variable region. As for the light chains of IgG, 
two basic domains have been defined including VRLR, and CRLR. The light chain has a 
relatively lower molecular weight of about 25 kDa, which also fluctuates between IgG 
molecules due to various sequences especially on the variable region. These polypeptide 
chains of IgG are connected by inter-chain disulfide bonds, including the linkages at the 
hinge region for connecting two heavy chains, and the linkage between CRHR1 and CRLR 
domains for connecting between heavy and light chains. Intra-chain disulfide bonds are 
also formed for IgG, usually one disulfide bond per defined domain.  
An important feature revealed by comparing the primary sequence is that only the 
approximately first 110 amino acids for each polypeptide chain, corresponding to the VRHR 
or VRLR domain (also called variable region), varies greatly between different IgG 
antibodies.2,22 The remaining sequence, however, is essentially constant between 
antibody chains for each subclass of IgG, called constant region. Complementarity-
determining regions (CDRs) are part of both heavy chain and light chain variable chains 
of IgG molecule, where the sequence differs a lot between IgG molecules in order to bind 
to different epitopes on various antigens present on pathogenic toxins, bacteria, or 
viruses. A particular set of CDRs and surrounding sequences constitutes an antibody 
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paratope, while the region on the antigen where paratope binds is called epitope. Three 
CDR loops are on each variable domain (heavy or light) of IgG molecule. And total of six 
CDRs (from both heavy and light chain) can collectively dictate the sequence that defines 
the three dimensional structure that binds an antigen. Thus, two identical antigen-binding 
sites are on Y-shaped IgG molecule by two Fab arms, and IgG has ability to bind two 
identical epitopes simultaneously (see Figure 2). In terms of the hinge region of IgG, it is 
the most flexible region on the molecule, which allows independent movement of the two 
Fab arms as well as the Fc fragment. The high flexibility and exposed properties of IgG 
hinge region also contribute to its susceptibility of proteolysis.23 Both papain and pepsin 
can cleave IgG molecules at the hinge region by via proteolysis at the amino-terminal 
side and carboxy-terminal side, respectively. Fab, F(ab’)2, and Fc fragments are obtained 
after cleavage with these two proteases (see Figure 2). Both Fab and F(ab’)2 could be 
functional fragments in terms of antigen-binding activity,23 but probably to different 
extents. Thus, although loss of ability of interacting with any effector molecule due to lack 
of Fc fragment, Fab domains are of potential value in antibody therapeutic applications, 
such as direct neutralization of antigens. Several Fab (with/without PEGylation) drugs are 
currently on market, such as Ranibizumab, abciximab, and certolizumab pegol.24 
1.2.1.2. Glycosylation 
All IgG antibodies have a conserved N-linked glycosylation site at Asn297 in each 
of the two heavy chains (CRHR2 domain) within the Fc region of the antibody, with 
glycosylation accounting for about 3% of total weight of an IgG molecule. There is a core 
heptasaccharide structure in IgG antibodies from humans consisting of N-
acetylglucosamine and mannose units, combined with a varying other monosaccharide 
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units, that form into a complex biantennary shape. Because of differences in terminal 
sugars such as galactose and sialic acid, as well as varying levels of fucose, there are a 
large number post translational glycosylation types that have been identified between 
various IgG molecules and even within the two sites of the same IgG molecule.25 There 
are theoretically 32 potential glycosylation types for IgG molecule, which can be grouped 
into three subsets, including G0, G1, and G2.26,27 The two N-linked carbohydrate chains, 
unlike many other glycoproteins which expose their oligosaccharides on the surface, face 
inside the cavity between the Fc polypeptide monomers.28,29 In addition to playing a key 
biological role30 (see next section), N-linked glycosylation of Asn297 in IgG molecules is 
of high importance for stabilizing Fc domain by interacting with a hydrophobic patches 
and keeping proteins in their native structure.31,32  
Figure 2. Three dimensional structure including glycosylation model of IgG molecules. 
Red dots show the N-glycans on the CRHR2 domain of IgG antibody.26 (Figure reproduced) 
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The N-linked glycosylation on Asn297 of IgG molecule profoundly influences the 
binding activity between Fc domain and Fc receptors, such as FcγR. Such binding plays 
a critical role in antibody-dependent cellular cytotoxicity (ADCC), where antibody-antigen 
complexes first bind to the FcγR receptor and then activate immune functional cells such 
as monocytes and natural killer cells. The type and extent of ADCC activity varies based 
on the composition of oligosaccharide glycan structure at the Asn297 site. Furthermore, 
another effector function of IgG has been recognized as complement-dependent 
cytotoxicity, in which after binding of antigen via the Fab region, the Fc region of IgG binds 
to the complement protein (C1q) to activate the complement cascade process leading to 
direct lysis of a pathogen. Glycosylation pattern of the Asn297 in the Fc domain has 
substantial effect on their binding efficiency, and it is reported that a complicated glycan 
structure is usually required, including at least 2 N-acetylglucosamines with multiple 
galactoses and sialic acids.25 Finally, IgG half-life (the longest serum half-life of all 
immunoglobulin classes) is also greatly influenced by glycosylation. Fast clearance has 
been detected for IgG molecule glycosylated with high mannose structures at Asn297.33 
The shorter half-life is presumably due to lower binding affinity between IgG Fc domain 
and the neonatal Fc receptor (FcRn), in which in turn is due to the high mannose glycan 
structure.  
From a pharmaceutical perspective, controlling and reproducibly producing the 
Asn297 glycosylation pattern plays a key role in process development for a given 
monoclonal antibody candidates. In terms of formulation development and stability, as 
discussed in more detail below, the glycan structures present at Asn297 in IgG antibodies 
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have been shown to influence solubility, chemical and physical stability, aggregation 
propensity, etc.34  
1.2.2. Body Distribution and Percentage Level 
The concentration of IgG in human serum is about 10 mg/mL (shown in Table 1), 
which is the highest among all five immunoglobulins. More than three-quarters of total 
immunoglobulins are in the IgG class.4 The body distribution of IgG is determined by both 
their size and biological functions, which for example, enables them to engage particular 
transporters for delivery across epithelia. Specifically, IgG is the most dominant antibody 
species found in the blood and extracellular fluid (in the body tissue with accessory cells 
and molecules available for immune response). Furthermore, serum IgG levels are 
related to both age and sex. It has been reported that higher serum IgG level was 
observed in females than in males, showing a constant difference throughout all age 
ranges.35 Interestingly, the serum IgG levels tend to increase with age for both males and 
females.35 
1.2.3. IgG Subclasses 
Four subclasses of IgG exist in human serum, including IgG1, IgG2, IgG3, and 
IgG4. The nomenclature is primarily based on the abundance in serum, where 
approximately ~66%, ~23%, ~7%, and ~3% are determined for IgG1, IgG2, IgG3, and 
IgG4, respectively. Except for IgG2, the other three subclasses of IgG can cross placenta 
easily, thereby having biological functions of providing immunity and protecting a new 
born baby. Furthermore, the half-life of the subclasses is also different, especially IgG3, 
in which the half-life is about 7 days while others are about 21 days.36  
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Although four IgG subclasses share more than 95% similarity between their Fc 
regions, substantial variations are observed primarily via the hinge region, molecular 
weight, and the position and number of disulfide bond. As shown in Table 2, there are 12 
amino acid residues in the IgG2 and IgG4 hinge region, whereas IgG1 has 15, while IgG3 
has 62 (depends on IgG allotype) residues. Also, there are only 2 inter-heavy chain 
disulfide bonds for IgG1 and IgG4, but IgG2 and IgG3 have 4 and 11 disulfide bonds, 
respectively. Moreover, IgG3 has a relatively higher molecular weight (170 kDa), while 
others have average molecular weight about 146 kDa. 
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Table 2. Physical and biological properties of human IgG subclasses.37 (Table 
reproduced) 
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1.2.4. Biological Functions 
Varying biological roles have also been identified for different IgG subclasses. 
Specifically, IgG1 and IgG3 are predominantly responsible for immune responses 
targeting polypeptide and protein antigens, and IgG1 is also fundamentally involved in 
opsonization and activation of the complement cascade. As for IgG2, it plays an important 
role in immune responses against carbohydrate and polysaccharide antigens. The 
immunological roles of IgG4 are still actively being investigated.38 
The main role of IgG is to increase the detection efficiency and the promotion of 
clearance of pathogens toxins, microorganisms, and viruses in human serum and body 
tissues. IgG molecules can bind and neutralize pathogenic substances to prevent them 
from performing their biological functions. Furthermore, clearance of pathogens from the 
body is usually performed via IgG-antigen complexes by FcγRs activating phagocytosis 
and degradation. Moreover, the surface of pathogenic virus and bacteria can be coated 
by IgG, in a process named opsonization, in order to optimize complement fixation or 
phagocytosis. The binding of FcγRs with Fc-antigen complexes will initiate phagocytosis 
and finally degrade the antigens in endosome. Furthermore, for pathogenic 
microorganisms, fixation of complement could also be performed by binding of some 
IgGs, improving efficiency of cell killing by primarily punching holes on the cell membrane 
via the complement cascade of proteins. The IgG-antigen complex bind to C1q, a protein 
complex involved in the complement system as part of the innate immune system, to first 
activate C1q, and thus to initiate the classical complement pathway of the complement 
system. However, only three IgG subclasses (IgG1, IgG2, and IgG3) are able to interact 
with C1q, with IgG3 having the highest efficacy. Finally, the pathogen infected cells in 
17 
 
human tissue can also be killed or cleared by IgG-antigen-activated natural killer (NK) 
cells, called ADCC. 
1.3. More Detailed Description of Physicochemical and Biological Properties of IgA 
Class 
IgA is another important antibody class found in human serum as well as mucous 
membranes, especially in the respiratory and digestive tracts. It is the predominant 
antibody type in external secretion compartment, acting as the “First Line” of body 
defense. The major function of IgA is to bind and destroy pathogenic substances, 
preventing antigens from entering human circulatory system. More complicated 
structures and glycosylation patterns, compared to IgG, have been identified for IgA 
molecules. 
1.3.1. Basic Structure 
1.3.1.1. Chain Composition and Molecular Weight 
The basic composition of IgA is same as other Ig antibodies, including two identical 
polypeptide heavy chains (~55 kDa each) and another two identical polypeptide light 
chains (~25 kDa each), as shown in Figure 3. There are four defined regions for the heavy 
chain including VRHR, CRHR1, CRHR2, and CRHR3. As for the light chain, two domains are described 
containing VRLR and CRLR. Similar to IgG molecules, IgA also has inter-chain and intro-chain 
disulfide bonds by cysteine residues to connect the polypeptide chains and rigidify the 
overall structure. The antigen binding sites on IgA are also located at the variable regions, 
including three CDRs at each VRHR and VRLR domain. A tailpiece at the C-terminal of heavy 
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chain is a particular highly conserved polypeptide for IgA (and IgM), which plays important 
roles in IgA dimerization or even polymerization (Figure 3). The cysteine residue on the 
tailpiece section of the heavy chain make it possible to form disulfide bond to another IgA 
component, joint chain or J chain,39 which is a ~16 kDa cysteine-rich glycoprotein present 
in dimeric IgA (dIgA) or secretory IgA (sIgA) structures. Two disulfide bonds formed with 
tailpieces of two IgA monomers connect Fc domains to form a dimeric structure. Higher-
order oligomer formation of IgA is thus essentially due to the presence of J chain. 
Moreover, another important polypeptide chain, as shown in Figure 3 for sIgAs, is the 
secretory component (SC), a highly glycosylated ligand-binding protein coming from 
polymeric immunoglobulin receptor (pIgR). There are five Ig-like domains for the SC (~80 
kDa) chain, including D1 to D5 from the N-terminus. In an unbound state, SC prefers to 
form a structure that curves back upon itself.40 By forming disulfide bonds with Fc part of 
IgA, SC wraps around two Fc regions of two IgA monomers, functioning to stabilize IgA 
antibodies, especially the Fc domain. However, SC only binds to polymeric IgA, primarily 
sIgA, when IgA undergoes transcytosis from epithelial cells to form sIgA in secretion 
process. The binding of SC and dimeric IgA has critical functions of increasing sIgA 
resistance to proteolysis.41 It has been reported that SC delays the digestion of sIgA, 
slowing down the conversion of sIgA to a potential digestion product F(ab’)R2 R(an antigen-
binding active protein).42  
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Figure 3. Schematic structure of IgA, including monomeric IgA1, IgA2, and dimeric IgA1, 
such as dIgA1 and sIgA1 (more details of IgA subclasses will be described in 1.3.3. 
section). N-linked glycosylation is shown in dark blue, and O-linked glycosylation is 
presented in green circle.43 (Figure reprinted) 
1.3.1.2. Glycosylation 
In comparison to IgG, IgA has notably higher carbohydrates (18-22% w/w), 
including N-linked glycosylations as well as O-linked glycosylations.25,26,39,41,44 There are 
two conserved N-glycosylation sites within the Fc domain, while IgA1 has five O-linked 
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glycosylation sites on its elongated hinge region (formed by five serine residues). For 
IgA2, two or three more conserved N-glycosylation sites have been identified in CRHR1 and 
CRHR2 domains, depending on the allotype of IgA2m(1) and IgA2m(2), respectively. More 
than 90% of N-glycans in IgA1 are in sialylated structure, while IgG has less than 10% N-
glycans with sialic acids. The N-linked glycosylation of IgA consists of a family of 
structures with a mannosyl chitobiose as the N-glycan core. High heterogeneity of IgA N-
glycans comes from the type and number of terminal sugars, such as galactose and sialic 
acid.39,45,46 Moreover, the biantennary glycans are predominant in IgA CRHR2 domain, while 
N-glycan on the tailpiece has mostly triantennary structure. For sIgAs, both J chain and 
SC chain are also highly glycosylated. J chain has a single N-glycosylation site, showing 
a carbohydrate content of ~8% w/w.41 In terms of the SC chain, up to seven N-
glycosylation sites are on different domains, and thus possessing a high amount of 
carbohydrates (~22% w/w).41 The N-glycosylation on SC chain promotes the stability 
profile of sIgAs.41 Moreover, the N-glycosylation on the heavy chain of IgA has been 
proposed to enhance antigen binding and clearance.47 Another report confirms the 
function of serum IgA glycans to bind the asialoglycoprotein receptor (ASGP-R) for 
mediating the clearance of IgA from serum.48,49 Furthermore, the O-glycosylation on IgA1 
also have many biological functions including affecting the activity of some of the 
proteases, and binding to microorganisms (to prevent the attachment of pathogens to 
epithelial cells in gut and to accelerate the excretion of such pathogens in the feces).26,50 
The one N-linked glycosylation site on J chain helps IgA form dimeric or higher-order 
structures, and also adjusts the binding affinity between IgA and pIgRs.26 As for SC chain 
glycosylation, a series of glycan epitopes could be formed due to high heterogeneity of 
21 
 
SC chain N-glycans, such as various Lewis and sialyl-Lewis epitopes.45 Competition 
binding of SC chain N-glycans with lectins or bacterial adhesins inhibits potential 
attachments or following infections on surface of epithelial cells.51,52  
1.3.2. Body Distribution and Percentage Level  
IgA, primarily in its monomeric form, is the second most abundant antibody in 
human serum, after IgG, possessing a concentration of about 1-4 mg/mL (Table 1), taking 
up of 15% of the total serum antibodies. In the mucosa compartment, however, IgA is 
primarily in its secretory dimeric form (sIgA) and is presents as the predominant antibody. 
It exists in colostrum, breastmilk, saliva, tears, and other secretions such as respiratory, 
gastrointestinal, and genitourinary tracts. In human serum, one of the IgA subclass (IgA1, 
more details will be discussed in 1.3.3. section) accounts for ~ 90% of total amount, and 
the remaining 10% are IgA2 (the second IgA subclass). However, in mucosa sites, the 
distribution of sIgA1 and sIgA2 varies a lot, ranging from 60-90% sIgA1 in male genital, 
hepatic bile, jejunal fluid, bronchial, saliva, or nasal secretions, and ~60% sIgA2 in female 
genital or colonic secretions.39 Furthermore, it has been reported that, no matter what 
age, IgA levels in serum are higher in males than in females, and the levels increase with 
age.35  
1.3.3. IgA Subclasses  
As already mentioned above, there are two major subclasses of IgA in human 
serum, including IgA1 and IgA2. Among them, IgA1 accounts for about 90% of total IgA 
in serum, while the secretory form of IgA2 (sIgA2) is the predominant form (~65%) in the 
external secretions, such as the mucosa of the airways, eyes, and the gastrointestinal 
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tract. The major difference of IgA1 and IgA2 comes from their hinge regions. Particularly, 
IgA1 features an elongated hinge region with 16 amino acids insertion, which comprises 
a repeat of 8 amino acids enriched with serine, threonine, and proline. In addition, such 
special region is usually attached with 3-5, or sometimes 6, O-linked glycans.45,47,53 IgA2, 
however, lacks of such sequence as well as O-linked glycosylation in hinge region, 
indicating a relatively shorter exposed and flexible linkage between Fab and Fc domains, 
which probably renders (s)IgA2 critical biological consequences of resisting cleavage by 
potential proteases generated by pathogenic bacteria or viruses.54 In addition, as 
aforementioned above for IgA2, there are two allotypic variants of IgA2m(1) and 
IgA2m(2).  
Besides the number of N-glycans on the heavy chain, another basic difference 
between these IgA subclasses is the nature of their disulfide bonds between their 
polypeptide chains.55,56 Specifically, IgA2m(1) does not possess disulfide bond between 
heavy and light chains, but does have disulfide bridge between two light chains, and thus 
IgA2m(1) usually appears to be heavy or light chain dimer under denaturing conditions. 
While, IgA2m(2) has same disulfide bond as IgA1 molecule between the heavy and light 
chains. Furthermore, IgA2m(1) has a hybrid composition of heavy chain constant region, 
containing a CRHR3 domain (same as IgA1 molecule), but also CRHR1 and CRHR2 domains (same 
as IgA2m(2) molecule).56 In terms of potential antigens that IgA antibodies could target, 
IgA1 mainly performs its immune responses in human serum via binding against 
essentially protein antigens, while (s)IgA2 plays crucial role in external secretions to bind 
and fight against polysaccharide and lipopolysaccaride antigens.  
1.3.4. Biological Functions 
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As the second most abundant antibody type, IgA displays its activities not only in 
serum, but more importantly in mucosal secretions. Several identified biological 
mechanisms have been described for IgAs binding to pathogenic bacteria, 
microorganisms, viruses, or toxins. Particularly, IgA prevents microbial adherence to 
epithelial surfaces and interacts with antigens on basolateral surfaces to form IgA-antigen 
complex, facilitating antigen elimination by exocytosis or phagocytosis.57 Furthermore, 
IgA can inhibit antigens penetrating across lumen epithelial surface and has functions on 
forcing salvage pathway especially at interstitial levels.58,59 There are several receptors 
that IgA can bind to perform its biological functions. Among them, FcαRI, also known as 
CD89, is a key mediator that is responsible for immune responses based on IgA-antigen 
complexes. FcαRI is a receptor located on the surface of many immune cells such as 
monocytes, eosinophils, neutrophils, and some macrophages as well as interstitial 
dendritic cells. The engagement of FcαRI with IgA-antigen complex will trigger a series of 
antigen elimination processes, including cytokine release, phagocytosis, oxygen species 
activation, calcium mobilization, degranulation, and antigen presentation, and also 
ADCC.60,61 Furthermore, another receptor, called Fcα/μR, is an immune mediator that 
binds to polymeric IgA, such as sIgA.62 Such receptor also presents at surface of various 
cells, such as macrophages, plasma cells, Paneth cells, follicular dendritic cells, and B 
cells.63,64 Although the functions of Fcα/μR have not been completely studied in humans, 
it has been discovered that mouse Fcα/μR plays a role of mediating B-cell endocytosis of 
IgM-opsonized pathogenic bacteria, and probably can trigger uptake of IgA-coated 
microorganisms.65 In addition, the pIgR on the basolateral side of mucosal epithelial cell 
performs critical roles not only in helping polymeric IgA transport cross epithelial cells to 
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gut lumen, but also in assembling polymeric IgA with SC chain as a secretory IgA 
molecule (sIgA). This process not only greatly improves the transcytosis of IgA into 
external secretions, but also enhances the physical and protease digestion stability of 
sIgA (with SC chain wrapping around Fc part of IgA molecule). In addition, it has been 
described previously that the polymeric IgA, that is undergoing pIgR-mediated 
transcytosis in epithelial cells, can neutralized intracellular pathogenic viruses, such as 
measles, Sendai, and influenza.66-68 Lastly, unlike IgG and IgM molecules, IgA lacks the 
ability of activating the classical complement pathway due to poor binding property with 
C1q. On the contrary, the complement activation can be inhibited by IgA-antigen complex, 
in a situation of limited antigen existing, due to blocking IgG- or IgM-antigen 
binding.39,65,69-71  
1.4. Formulation Development Challenges and Opportunities for IgG as 
Therapeutic mAb Candidate 
Monoclonal antibodies (mAbs), especially IgG, have been developed over the last 
30 years as successful class of therapeutic drugs. They have turned to be a well-deserved 
mainstream branch of the drug discovery and development pipelines in the 
pharmaceutical industry. All aspects of mAb pharmaceutical development has matured 
for over this time period including early R&D research, process development, clinical 
studies, and commercialization strategies. By the end of 2018, more than 80 mAb 
therapeutics have been granted marketing approvals.72 In the year of 2018, a total of 13 
therapeutic mAbs were granted first approvals in the United States or the European 
Union, reaching a record high for a single year (Figure 4).72 A significant increase of 
approved mAbs started in 2014, and after that, a steady increase has occurred each year 
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(Figure 4). A wide range of several diseases can be targeted by mAb therapies, such as 
the treatment of autoimmune, infectious, and cardiovascular diseases, cancer as well as 
inflammation. Therapeutic mAbs bring high specificity to antigen target, and thus 
potentially reduce unwanted effects during therapy. Also, relative prolonged half-life of 
mAbs substantially reduces dosage frequency.  
 
Figure 4. Number of antibody therapeutics approval in the USA or Europe.73,74 (This 
website was accessed on January 10th, 2019) 
1.4.1. Administration to Patients 
Therapeutic mAbs have been predominantly developed and administered 
intravenously (IV). Nevertheless, an increasing number of mAbs currently are designed, 
formulated and injected subcutaneously (SC).75 Based on the approved antibody drugs 
in 2018, 10 out of 13 mAbs approved were recommended to be administrated by SC 
dosing,73 including Ravulizumab, Erenumab, Fremanezumab, Galcanezumab, 
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Burosumab, Lanadelumab, Caplacizumab, Cemiplimab, Tildrakizumab, and 
Emapalumab, demonstrating the increasing popularity for antibody drugs to be 
parenterally administered by the SC route. 
1.4.1.1. Intravenous Injection 
After first introduction of mAb administration by intravenous injection (IV) in the 
1980s, it has been the preferred route for mAb therapy.76 Compared to intramuscular (IM) 
route, which was the first administration pathway attempted for mAb therapy, IV provides 
a sufficient amount of antibodies upon administration to reach therapeutic window, and 
greatly reduces injection pain for patients. In addition, ~100% bioavailability is usually 
obtained by IV injections. However, patients need to go to hospitals or clinics for IV-based 
mAb therapy, which is time-consuming, costly and inconvenient. A fairly high rate of 
adverse effects have been observed in some cases, because physiological barriers and 
systemic distribution substantially reduce the actual mAb concentration obtained in target 
organs or tissues.77 Currently, although IV administration is still an important 
administration route for mAb therapy, other potential parenteral routes are typically 
evaluated such as the SC or IM administration pathways.  
1.4.1.2. Subcutaneous Injection 
The subcutaneous route of administration for mAb therapy was first introduced in 
the 1980s, but it has been considered only as the second choice (vs. IV) for many years.76 
Due to systemic severe side effects of IV administration in certain cases, more and more 
attention was taken to utilize alternative administration pathways, such as the SC route. 
SC brings a lot of benefits for patients such as saving time, reducing cost, more 
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convenience, and self-administration. For example, SC administration has improved 
patient compliance by self-administration using pre-filled syringes, especially for 
treatment of chronic diseases.75 However, a high concentration mAb solution is usually 
required for SC administration because of the maximum volume of injection is usually 
restricted to 1-2 mL.78-81 Higher injection volume can cause a lot of pains for patients, 
which is commonly not acceptable (except using tissue-modification enzymes, such as 
use of hyaluronidase for Herceptin82). Therefore, a concentration of >100 mg/mL is often 
required for SC products.81 Many challenges exist when formulating such a high 
concentration mAb solution, such as high viscosity and turbidity, aggregation, and even 
phase separation, which are essentially due to intermolecular non-covalent protein-
protein interactions (PPIs) between mAb molecules in high concentration solutions. 
1.4.2. Reversible Self-Association of mAbs Induced by High-Concentration Protein 
Solutions 
A major formulation problem that can be encountered by high-concentration mAb 
solution is called reversible self-association (RSA), which is a phenomenon of reversible, 
non-covalent, concentration and temperature dependent non-native intermolecular 
interactions of mAb molecules to form oligomeric species of native protein. Poor solution 
properties and reduced mAb physical stability are often detected due to RSA, influencing 
the manufacturing, storage, delivery, and even administration processes of mAb 
candidates during development into commercial products.  
1.4.2.1. Viscosity 
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As one critical indicator of PPIs of mAbs at high protein concentrations, dynamic 
solution viscosity has been widely employed to study mAbs RSA under various 
conditions. Extensive intermolecular interactions of mAb molecules result in the forming 
of high molecular weight oligomers or even interacting networks, which tightens 
connections between liquid layers, and thus elevates solution viscosity.83-85 It has been 
broadly reported in previous studies that the dynamic viscosity of RSA-mAb solutions 
increased exponentially as a function of protein concentration.81,86-89 Such dramatic 
increased of solution viscosity lead to various challenges and problems involved in 
pharmaceutical product development of SC formulations at high protein concentrations. 
Extremely high pressure will be encountered using viscous solutions during tangential 
flow filtration, or during analyses of samples, causing low filtration efficacy and frequent 
instrument maintenance, respectively.90 Also, it is usually difficult to inject viscous 
solutions employing commonly used needles for parenteral administration, and thus 
additional design and manufacturing of special needles are sometimes needed.91 In 
addition, patients may suffer pain due to time and force required when injecting high-
viscosity solutions, which significantly reduces patients’ compliance.92  
1.4.2.2. Opalescence 
PPIs play critical roles in solution opalescence especially at high protein 
concentrations. For mAb solutions, it is not necessary for them to contain particulates to 
show opalescence.80 An IgG1, as reported previously80, displays opalescence at high 
concentration, but it turns out that the antibodies were essentially monomeric in nature, 
and the opalescence primarily came from Rayleigh scattering. Normally, Rayleigh 
scattering of visible light occurs when proteins have diameters of less than 30 nm. 
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However, self-associated antibodies can lead to cloudy appearance as a result of PPIs, 
indicating solution opalescence, or solution turbidity, where protein oligomers with 
broader size distributions, exist.90 Filtration does not help to reduce solution opalescence 
since it is not due to the presence of particulates, but since PPIs are reversible, dilution 
of high concentration solution results in lower turbidity values.93 High opalescent solutions 
can lead to unacceptable appearance and may fail due to patient compliance issues 
(instructions dictate to discard dosage forms with cloudy appearance).94 Also, from a 
manufacturing perspective, high-concentration mAb solutions with high opalescence 
potentially increase systemic pressures when undergoing regular protein filtrations of 
protein solutions. Furthermore, during clinical trials, it can be challenging to match 
opalescence for clinical placebo solutions as compared to the protein containing 
formulations.90 As described below, an increase of solution turbidity may also be achieved 
as more and more large particulates (irreversible aggregates) are formed in solution.95  
1.4.2.3. Aggregation 
Reversible self-associated (RSA) mAbs complexes contain protein in their native 
structures and normally return to their monomeric forms after dilution. Such the RSA 
process, however, could also lead to instability issues such as the formation of irreversible 
aggregates. As antibody molecules get closer in solution and interact with each other due 
to RSA, it presumably enhances the opportunity for any transiently formed, partially 
unfolded proteins to interact as well via exposed hydrophobic aggregation hot-spots. This 
is the first step to potentially undergo an irreversible change to form an aggregation 
“nuclei”.96 Such nuclei follows an irreversible process to grow by combining with other 
nuclei species or complexed proteins, forming soluble and insoluble aggregates. These 
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types of irreversible aggregates are not affected by dilution of the solution. The formation 
of irreversible aggregates may result in unwanted immunogenicity, loss of mAb potency 
and/or product viability.97 Furthermore, pharmacokinetic profiles of mAb products can be 
greatly altered as protein aggregates can dramatically change overall absorption, 
distribution, and even clearance or elimination (half-life).98  
1.4.2.4. Phase Separation 
As another critical phenomenon caused by PPIs, liquid-liquid phase separation, 
has been observed and studied broadly.99-101 Phase separation of high concentration 
mAb solutions is a thermodynamic process in which two distinct liquid phases appear in 
solution. The top layer is usually the protein-poor phase, possessing protein concentration 
of <10 mg/mL, while the bottom layer is extreme viscous due to the presence of large 
amount of proteins (>200-300 mg/mL), called protein-rich phase. The ratio (v/v) of protein-
poor/protein-rich phases depends on a variety of factors including net protein 
concentrations, temperature, and solution conditions (such as pH, buffer composition, or 
additives). Phase separation is also a reversible process, which can revert back to a 
single phase by changing temperature, adjusting solution composition, or simply by just 
diluting to a lower protein concentration. In many studies,102-104 a phase diagram tool has 
been used to represent phase separation behaviour of various mAbs, where the phase 
separation is demonstrated using the binodal curve. Phase separation is occurring in 
these high concentration solutions mainly because the original protein solution is 
thermodynamic unstable, and thus it tries to equilibrate to another thermodynamic stable 
condition. The kinetics of such equilibrium process varies a lot based on properties of 
particular mAbs, solution conditions, and temperature. Phase separation usually shows 
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strong opalescence during equilibrium process and even after phase separation has 
already formed. Therefore, high opalescence and viscosity, especially in the protein-rich 
phase, brings a lot of challenges during product manufacturing and administration. 
Furthermore, irreversible aggregation may happen among protein molecules, especially 
during long-time storage. A summary of the many differences that exist between phase 
separation and aggregation has been reported (Table 3).103 
1.4.3. Strategies to Mitigate Reversible Self-Association 
Due to so many challenges and problems caused by RSA of mAbs at high protein 
concentrations, including mAb manufacturing, storage stability, and delivery to patients, 
numerous approaches or strategies to mitigate PPIs have been pursued and evaluated 
in developing high-concentration mAb formulations. Various methods to improve high-
concentration solution properties have been studied and are discussed in more detail 
below including formulation, protein engineering, lyophilization, and use of the enzyme 
hyaluronidase.  
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Table 3. Difference between aggregation and phase separation for protein solutions103 
(Table reproduced) 
1.4.3.1. Formulation 
Different solution parameters such as pH, ionic strength, and addition of excipients 
have been examined for their ability to reduce mAb PPIs at high protein concentrations 
and thus improve solution properties.100,105,106 Based on the various mechanisms of PPIs, 
different buffer conditions or excipients can be employed to modulate the extent of mAb 
RSA.87,89,91 Although formulation screening can be a time-consuming process, for 
example, sometimes many factors or effects exist at the same time with addition of 
multiple excipients, it usually gives successful results in terms of identifying conditions for 
mitigating PPIs for RSA mAbs. Furthermore, a balance between excipient effects on RSA 
must be balanced against their potential effects on protein conformational and/or colloidal 
stability. For example, excipients can disrupt the RSA of a specific mAb, but at the same 
time, conformation stability of the mAb could also be altered. Rational formulation design 
and selection of specific excipient types and corresponding concentrations are thus an 
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important consideration in formulating high-concentration protein mAb solutions. Solution 
pH is another critical factor on controlling PPIs by adjusting the net charge of mAbs.87,107 
Based on the isoelectric point (pI) of a mAb, alteration of solution pH can substantially 
increase/decrease charge repulsions between protein molecules, playing a key role in 
PPIs of certain mAbs (e.g., when RSA of a mAb is driven by either electrostatic or 
hydrophobic forces).89,107 A recent study of formulation development approach to reduce 
solution viscosity demonstrates a wealth of knowledge on excipients selection, pH 
alteration, and provides a potential formulation development platforms on charactering 
ultra-high protein concentration solutions.89 Overall, a formulation strategy is a widely 
employed and useful approach to mitigate mAb RSA of mAb candidates requiring delivery 
at high protein concentrations. 
1.4.3.2. Protein Engineering 
An alternative approach, which has also been broadly employed to weaken PPIs 
of mAbs at high protein concentrations, is protein engineering by essential point 
mutations. This is a more direct method which purposely mutates particular amino acid 
residue(s) on the RSA regions (or RSA interfaces), especially charged, aromatic, or 
hydrophobic ones. Unfortunately, mAbs may undergo dramatic property changes 
(conformational or colloidal or biological) with such “key” amino acid replacement(s). 
Different protein engineering studies regarding a series of mAbs with varying RSA 
mechanisms have been performed to examine the alteration of protein RSA propensity 
as well as solution properties.88,99,108,109 These studies demonstrate that an optimally 
engineered mAbs possessed the properties of reduced self-association propensity, 
decreased protein size and solution viscosity, and enhanced solubility, while with 
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minimum loss of antigen-binding affinity. Albeit there are many successful cases, there 
are also some limitations by using this protein engineering approach. Normally, preceding 
knowledge of interaction sites, particular amino acids, or even PPIs mechanism is 
required, which must be obtained by other approaches, such as computational or 
analytical methods such as HDX-MS, providing information on selecting specific amino 
acids for mutation analysis. Also, potential conformational alterations could happen with 
one or more amino acids substitution, which may further induce a set of adverse effects, 
such as loss of binding activity, partial denaturation, irreversible aggregation, and reduced 
thermal stability. For example, since RSA sites are often at mAb CDR regions, which are 
the critical sequences of antibody (paratope) for antigen binding, mutation of amino acid 
residues especially the charged or aromatic ones could tremendously influence antibody-
antigen binding affinity. Therefore, a number of mutations with different amino acids are 
usually needed to comprehensively determine and examine protein RSA propensity, 
physical stability, solution properties, and antigen binding affinity.88,109  
1.4.3.3. Lyophilization 
In addition to aqueous liquid solution formulations, mAbs have also been prepared 
and developed in lyophilized formulations to improve stability and minimize aggregation 
and chemical degradation pathways. Physical stability can be greatly enhanced during 
long term storage due to restricting mobility by employing a lyophilized formulation with 
suitable excipients and lyoprotectants, for example, carbohydrates such as trehalose and 
sucrose.110-112 Freeze drying can also minimize other potential hydrolytic reactions by 
removal of water.110 Several commercial mAbs are formulated as lyophilized dosage 
forms such as canakinumab, omalizumab, efalizumab, palivizumab, trastuzumab, 
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infliximab, etc.113 Some of these have a concentration above 100 mg/mL after 
reconstitution, indicating a potential possibility to formulate high-concentration protein 
solutions for SC administration.113 However, many drawbacks also exist using a 
lyophilization strategy to formulate high-concentration mAbs prone to RSA. One critical 
and unique challenge is the long reconstitution time for a lyophilized high protein 
concentration drug product, which can dramatically limit practical usage as well as 
commercial marketability.114 It has been reported previously that reconstitution time of 
high concentration (>100 mg/mL) lyophilized protein containing cakes can be as long as 
30 mins or more.114 In addition, lyophilization is a stress condition for mAbs, in which 
aggregation or partial structural unfolding might take place during freezing or sublimation 
steps of the lyophilization process. Therefore, proper selection of excipients 
(lyoprotectants), including appropriate type and amount, and an optimized lyophilization 
cycle are usually required to keep mAbs in their native state both during freeze drying, 
long term storage in the solid state, and upon reconstitution.  
1.4.3.4. Use of Recombinant Human Hyaluronidase Enzyme 
The extracellular matrix (ECM) contains a network of collageneous fibrils which 
are embedded within glycosaminoglycan- and proteoglycan-rich viscoelastic gel-like 
substances, a fundamental barrier to the effective subcutaneous delivery of antibody 
drugs and thus limiting injection volume to less than 2 mL.115 Due to such fibril networks 
in ECM, it can take up to several days for mAbs to reach maximal levels in plasma after 
SC injection.115 However, the use of recombinant human hyaluronidase enzyme 
(rHuPH20) can potentially overcome this significant barrier by depolymerization of the 
viscoelastic component of the interstitial matrix. The dispersion of locally injected mAbs 
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could be substantially enhanced by using rHuPH20 without tissue distortion. Therefore, 
this effect will allow for notable increases in injection volumes, and thus it could be 
possible to decrease protein concentrations (avoid antibody self-association) as well as 
reduce as frequently the number of dosing required via SC administration. Furthermore, 
rHuPH20 could essentially alter pharmacokinetic profiles and dramatically augment the 
absolute bioavailability of mAb therapeutics.116 More importantly, the interstitial 
viscoelastic barriers are usually restored within 24 hours of SC injection without histologic 
alteration or other potential signs of inflammation.116  
There are now several commercialized mAb drugs with rHuPH20 co-formulated 
and usually co-administered by SC injections/infusions with the active therapeutic mAbs, 
such as trastuzumab and rituximab, for the treatment of breast and lymphoma cancer, 
respectively.82,117 It has been shown that the use of rHuPH20 is safe for SC injections and 
results in similar drug plasma concentrations in comparison to intravenous injections, but 
markedly shortens the infusion times.82,118 
1.5. Formulation Development Challenges and Opportunities for sIgA as 
Therapeutic mAb Candidate 
As the most dominant antibody in the mucosal compartments, sIgAs play a critical 
role binding and protecting against pathogenic substances, such as bacteria as well as 
viruses, which enlightens the possibilities of sIgA as therapeutic mAb candidates for the 
treatment of bacteria/virus-induced diseases or infections on mucosal membranes.119,120 
However, due to the complex nature of sIgAs, combined with need to provide protection 
in the harsh conditions in gastrointestinal (GI) tract, a variety of formulation challenges 
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will be encountered upon the development of sIgA as an orally delivered therapeutic drug 
candidate.121,122 
1.5.1. High Molecular Weight Species of sIgA  
Unlike IgG, sIgA is present in the external secretions in polymeric forms, 
predominantly in a tail-to-tail dimer structure linked with J chain and SC chain by disulfide 
bonds. In addition, however, higher order oligomers such as trimers and tetramers are 
also observed for sIgA.123,124 Possessing eight cysteine residues, the J chain substantially 
increases the chances to form polymeric sIgAs by potential disulfide bonds.125,126 
Moreover, based on immunochemical studies, polymeric sIgA often has multiple J chains, 
which further enhances the possibility to form higher-order structures for sIgA 
molecule.12,127 However, it has also been found that some polymeric IgAs exist in serum 
without J chain. These IgAs cannot be transported to mucosal membranes, indicating that 
J chain might not be obligatory for IgA to form polymeric structure, but necessary for sIgA 
formation and epithelial transportation.11,128,129 In terms of biological functions, polymeric 
sIgA maintains or even possesses better activities than monomeric IgA, acting as a 
digestion-resistant, high potent molecule against pathogens.130 It has been reported that 
the polymeric forms of sIgA can potentially inhibit intracellular virus production, and have 
functions on neutralizing particular toxins or pathogenic bacteria, such as neutralizing 
proinflammatory antigens.67,131  
1.5.2. Challenges Associated with Oral Protein Delivery 
Oral delivery of small molecules as therapeutic drugs has been consistently widely 
used, given that it provides benefits in terms of less manufacturing costs, ease of 
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administration, and thus increased patient compliance. For large molecules, like proteins 
or specifically monoclonal antibodies, several significant challenges for oral delivery 
include the instability of proteins in the GI tract, and unpredictable absorption across the 
intestinal epithelial membrane to the systemic circulation in lymphatic or blood vessels, 
which probably acts as the major barriers regarding efficient oral protein drug delivery for 
systemic distribution in the body.121,132,133. As discussed below, the oral delivery of sIgA 
is potentially more promising since it not being used for systemic delivery but rather is 
being considered for local oral delivery to bind and neutralize enteric disease causing 
microorganisms found in the GI tract. 
1.5.2.1. Gastric pH 
In the human stomach, gastric fluid is an acidic in nature for digestion purposes, 
composed of hydrochloric acid (HCl), potassium chloride (KCl) and sodium chloride 
(NaCl). The pH of gastric acid is about 1.5-3.5 in the human adult stomach lumen, which 
plays a key role in digestion of ingested proteins by denaturing and unfolding them.134 
Degradation of proteins in the highly acidic condition of the stomach is believed to be 
through destabilization of the three-dimensional structural folding due to alterations of 
ionic and hydrogen bonding.135 Such low pH environment is always maintained in human 
stomach through the proton pump H+/K+ ATPase. Therefore, therapeutic proteins, such 
as mAbs, will be at least partially denatured, and thus lose some of their characteristic 
folded structures, and at the same time, some of the peptide bonds between amino acid 
residues in the polypeptide chains will be exposed at low pH to be eventually broken down 
by digestive enzymes (see Section 1.5.2.2.) 
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1.5.2.2. Proteases  
Another significant challenge associated with protein oral delivery is the presence 
of a variety of proteases in GI tract. Pepsin is one of the main digestive enzymes 
predominantly found in the human stomach. It belongs to endopeptidase class of 
enzymes which can break down proteins rather non-specifically (in terms of amino acid 
sequences) into small peptides. As the most efficient digestive enzyme, pepsin cleaves 
peptide bonds between amino acid residues in the polypeptide backbone of proteins 
between hydrophobic and especially aromatic amino acids.136 The most active state of 
pepsin is usually at low pH ranges (particularly at pH =2) and between 37 oC and 42 oC.137 
Furthermore, intestinally secreted enzymes, such as trypsin and chymotrypsin, also have 
notable functions on protein digestion. Trypsin is a serine protease formed in the small 
intestine, cleaving bonds in the polypeptide chains primarily at the carboxyl side of two 
amino acids, arginine and lysine, except under the condition that the following amino acid 
is proline. The optimal operating temperature for trypsin is about 37 oC and the optimum 
pH is at about 8.138 As for chymotrypsin, it is a digestive enzyme acting in the duodenum 
as the important component of pancreatic juice. Chymotrypsin is usually activated in the 
presence of trypsin and preferentially cleaves peptide bonds in proteins at the sites of 
aromatic amino acids, such as phenylalanine, tyrosine, and tryptophan. The optimum pH 
and temperature for chymotrypsin are approximately pH 8 and 40 oC, respectively.139 
Other enzymes in the intestine, such as elastase and brush-border membrane-bound 
enzymes carboxypeptidases A and B, can also induce hydrolysis of particular sites within 
proteins, causing protein degradation.121 
1.5.2.3. Absorption 
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Protein therapeutics, including mAbs, are mostly hydrophilic with a logP value 
below zero.140 Therefore, unlike some smaller, hydrophobic substances, therapeutic 
mAbs normally cannot follow the transcellular route of absorption via passive diffusion.140 
In terms of paracellular pathway, the dimension of such space lies a range of 10 to 50 Å, 
which can probably only fit for small hydrophilic molecules, rather than macromolecules, 
such as mAbs (diameter of 9-12 nm). 141,142 However, some studies have demonstrated 
that smaller proteins, such as insulin, can be internalized after being absorbed on the 
apical membrane by particular types of endocytosis.143 As for other potentially orally 
delivered proteins, after binding to specific receptors on the surface of epithelial cells in 
the small intestine, they could be actively transported across the epithelial lining through 
certain types of membrane-bound vesicles.144 However, most of the proteins would 
degrade and/or be structurally altered causing them to lose their biological functions by 
such active transportation pathway during the process of release at the basolateral 
membrane or secretion into the interstitial space. Therefore, it turns out that successful 
transportation across epithelial cells in human small intestine is a big hurdle for oral 
delivery of large macromolecules such as proteins (including mAbs). Since the three 
dimensional structure of mAbs is closely related to their biological activities, it is of high 
importance to keep them in their folded, intact forms through absorption process. 
Although many strategies have been studied to obtain efficient and proper strategy for 
intestinal absorption for protein-based therapeutics, such as use of permeation 
enhancement agents, employment of protease inhibitors, or modulating tight-junction 
permeability, some concerns or issues still exist in terms of widespread acceptance or 
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potential safety considerations for use of these approaches with protein drug 
candidates.145-147  
1.5.3. Mucosa Compartment as an “Ideal” Place for sIgA-based Treatments 
As the “first line” of immune defense, sIgA plays a key role in immunoprotection 
within the mucosal membranes. It is the sIgA form (especially sIgA2) that is the 
predominantly present immunoglobulin in the GI tract, especially in the intestinal phase, 
and performs critical effects on neutralizing pathogenic bacteria, viruses, and toxins. In 
addition, the multi-chain composition and polymeric property of sIgA makes it more 
protease-resistant and more stable in the harsh-environment (low pH in the gastric phase) 
as compared to less tolerant molecules such as IgG. Therefore, sIgAs could potentially 
be developed as an orally delivered drug candidate for passive immunization in the 
mucosal compartment, for treatments of diseases or infections in the GI tract. 
1.5.3.1. Diarrheal Diseases 
Diarrheal diseases continue to be the leading causes of death for children under 
5-years old, especially in the low- and mid-income countries (Figure 5). Although the 
mortality rate decreased to a large extent from 2005 to 2015, due to vaccination and 
improved sanitation, still about half million children (under five) die worldwide each year 
due to such enteric diseases.148 Some of the causes of diarrheal diseases in under-
developed or developing countries include poor quality life of children coupled with lack 
of basic sanitation, bad climatic or environmental conditions, and unavailability of medical 
treatments and health-care facilities.149-151  
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Figure 5. Diarrheal disease death rates (per 100,000), 2016152 (Figure reprinted) 
Previously, severe dehydration and significant fluid loss were the two major 
reasons that led to diarrhoea induced deaths. Currently, other potential causes, such as 
septic bacterial infections, are gradually becoming the dominant reason for diarrhoea-
associated deaths. Diarrhoea is normally a symptom of potential infections in human 
intestinal tract, which can usually be caused by various infectious agents including 
bacteria, viruses, and parasitic organisms. Rotavirus, enterotoxigenic Escherichia coli 
(ETEC), vibrio cholerae, Shigella, entamoeba histolytica, and giardia lamblia are 
important infection sources of diarrheal diseases in developing countries.153-156 Among 
them, rotavirus and ETEC are the two most common etiological agents of moderate-to-
severe diarrheal diseases in these countries.157,158 Although there are vaccines available 
for rotavirus-induced diarrhoea, their availability and efficacy is limited in the developing 
world. There is currently no vaccines approved for human use for diseases caused by 
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ETEC.158 Since these pathogens are found mainly in the intestinal tract, including 
adhesions on epithelial cells and excretions of different toxins, passive immunization 
using potential mAbs, especially sIgA, could potentially greatly enhance and contribute to 
immune responses in local regions, such as small intestine. Therefore, diarrhoea are the 
first disease targets that orally delivered sIgA can be utilized as potential drug candidate 
for corresponding binding key antigens found on the microorganisms, treatments. Other 
bacterial/virus-induced diseases or infections of the GI tract can also be potentially targets 
for sIgA treatments in the future.  
1.5.4. Possible Formulation Approaches for Oral Delivery of sIgA 
Although sIgA has a relatively high stability particularly under the conditions 
present in the GI tract, low pH conditions in stomach and the presence of a variety of 
digestive enzymes would eventually “destroy” the conformational structural integrity of 
sIgA in the gut lumen, decreasing or eliminating its biological activities. As a result, proper 
buffers or excipients as well as certain oral delivery approaches are particularly desired 
to formulate sIgA for fulfilling successful oral delivery purposes. Since the goal is to use 
this treatment approach in the developing world, low-cost approaches are also a critical 
factor in the design of sIgA formulations. And eventually, the well-formulated, stable, low 
cost sIgA candidates could be developed as a potential orally delivered drug products to 
treat different diseases or infections in human GI tract.  
1.5.4.1. Protease Inhibitors 
To alter activities of different enzymes in the GI tract, protease inhibitors could 
potentially be employed to protect therapeutic sIgA mAbs from digestion during oral 
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delivery. Several potential enzyme inhibitors have been studied previously, including 
soybean trypsin inhibitor, aprotinin, chromastatin, and camostat mesilate.159-161 However, 
it is also shown that long-term administration of these inhibitors would result in deficiency 
of such enzymes in humans.159 Therefore, selection of proper type and amount of enzyme 
inhibitors would be necessary when co-formulated along with the active sIgA antibody 
therapeutics, and the proteolytic enzymes commonly follow dose-dependent inhibitory 
effects.161 Furthermore, other potential enzyme inhibitors, such as duck and chicken 
ovomucoids, and polymer inhibitor conjugates (carboxymethyl cellulose-Elastinal), also 
showed efficient protection for insulin against trypsin or chymotrypsin, which might be 
good protease inhibitor candidates for oral mAbs delivery.143,162,163 Several major 
inhibition mechanisms have been determined and reported previously.164 The vast 
majority of enzyme inhibitors can, acting as a competitive inhibitors, preferentially bind to 
a critical portion of the protease in a substrate-like manner, which presumably blocks the 
binding between digestive enzymes and target substances. Besides, plenty of enzyme 
inhibitors have secondary binding sites outside the active site, increasing the surface area 
of protein interactions to obtain greater affinity, and improving the binding specificity of 
particular inhibitors. Last but not least, some protease inhibitors, known as suicide 
substrates, can covalently bind to proteolytic enzymes, such as Serpin (Serine protease 
inhibitor), and thus interrupts conformational structures via chemical modifications, 
thereby irreversibly inhibiting enzymatic activities.165,166  
1.5.4.2. Buffers or Reagents for Gastric pH Neutralization 
In terms of the relative low pH environment in human stomach, protein therapeutics 
are prone to undergo conformational alterations and loss of their biological activities. 
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Therefore, appropriate strategies are desired to mitigate acidic pH effects (by primarily 
neutralizing gastric fluid pH) on protein structures. Previously, it has been demonstrated 
that the use of bicarbonate buffers (as well as other buffering agents) protects orally 
delivered rotavirus vaccines from acidic denaturation by pH neutralization.167 Other 
studies also have shown that a versatile pH-responsive hydrogel, which exhibited pH-
responsive activity, and could be applied as a platform for delivery of gastric-sensitive 
protein therapeutics to the intestinal tract.168 As a result, appropriate design and use of 
pH neutralizing buffers or reagents could substantially improve mAbs stability in the GI 
tract during oral delivery. However, it is also critical to consider mAbs storage stability in 
such solution conditions. Strong basic solutions, large amount of salts, and protein-
reagent reactions might also alter protein structural integrity and stability. 
1.5.4.3. Novel Mucoadhesive Encapsulation Carrier Systems 
To enhance the stability and absorption of therapeutic proteins during oral delivery, 
encapsulation and delivery by novel carrier system could also be potentially employed. A 
variety of mucoadhesive polymers, such as poly lactic-co-glycolic acid (PLGA), chitosan, 
and thiolated polymer, have been extensively used for these purposes in laboratory and 
animal studies.169-171 These formulations could be prepared in nanoparticles or 
microspheres and encapsulate therapeutic proteins inside, providing a microenvironment 
that is less accessible to proteases or acidic pH. Encapsulation potentially then could 
effectively protect protein drug candidates from enzyme degradation during oral delivery. 
These polymers can adhere to the mucosal membranes and thus affect the concentration 
gradient of proteins, increasing bioavailability for a prolonged time.160,172 However, based 
on previous studies, the protein-containing nanoparticles or microspheres have technical 
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challenges and problems including broad size distribution with poor reproducibility.173 
Furthermore, during the preparation and storage, it is also a big challenge to keep protein 
drug candidate itself intact and stable, without losing biological activities.173 In addition, 
manufacturing of such novel carrier system for protein oral delivery will be at a 
comparatively high cost, substantially increasing burdens for patients. Therefore, 
although the application of novel mucoadhesive encapsulation carrier systems is very 
attractive approach, additional studies will be needed to produce more reliable and 
affordable orally delivered drug products with these types of formulations. 
1.5.4.4. “Decoy” Protein Protection 
A decoy substance (or pseudo-substance) typically refers to a particular protein 
additive that possesses similar structure to compete as a substrate of the proteolytic 
enzymes. This simple approach would allow the decoy protein to competitively bind to the 
proteolytic enzyme and leave the actual drug candidate intact. Such a strategy could also 
be employed for the oral delivery of therapeutic proteins such as sIgAs. A variety of 
proteins can potentially be the “decoy” substances, such as casein, other milk proteins, 
soy proteins, albumin, etc. Although some of them probably don’t have highly similar 
structures as a sIgA protein therapeutics, they are more susceptible to be digested in the 
presence of proteases, and could be added in large excess, and thus would be digested 
instead of the active proteins drug candidate. As a result, the “decoy” protein strategy, 
especially in combination with infant milk, could presumably be a suitable, low-cost 
stabilization approach for oral delivery of sIgA drug candidates to infants.  
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Chapter 2 
 
Characterization of Excipient Effects on Reversible Self-association, Backbone 
Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High 
Concentrations: Part 1 
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2.1. Introduction 
Over the past two decades, monoclonal antibodies (mAbs) have become a key 
class of therapeutic drugs used for treating a variety of diseases including cancer, 
autoimmune disease, inflammatory disease, and transplant rejection.1,2,3 To date, 
approximately 70 therapeutic mAbs have been authorized for use by the FDA in the 
United States. Among the best-selling drugs in the last several years, therapeutic mAbs 
occupy a large proportion.4-6 In antibody therapy, relatively high dosing (~1-10 mgs/kg) 
via the two major routes of parenteral administration, subcutaneous (SC) and intravenous 
(IV), is used. For many chronic diseases such as asthma, autoimmune disease, and 
certain allergic conditions, frequent administration is usually required. Therefore, self-
administration or home-based treatments are preferred.7,8 SC injections using prefilled 
syringes (with or without auto-injectors) typically require limited injection volumes (less 
than 2 mL) to optimize injection time and reduce injection pain.8,9 As a result, formulation 
of high-concentration mAb solutions is required both to reach therapeutic windows and to 
meet patient needs for SC administration.  
When formulating high-concentration mAbs, many pharmaceutical challenges are 
encountered including high solution viscosity, opalescence, decreased colloidal stability 
and high aggregation propensity.8,10-12 These effects are due to protein-protein 
interactions (PPIs) at high mAb concentrations, leading to reversible self-association 
(RSA), formation of oligomeric species within their native states by intermolecular non-
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covalent interactions.13,14 Such interactions between protein molecules can form a 
network of higher-ordered protein complexes, which greatly increase solution viscosity, 
resulting in high pressure during protein filtration (during manufacturing) and protein 
administration (e.g., syringeability). In addition, pain on injection with highly viscous 
solutions can occur in patients.13,15-17 Finally, mAb RSA might promote formation of 
structurally altered aggregation precursors (nuclei) to initiate the formation of irreversible 
aggregates, potentially leading to decreased protein bioavailability, poor pharmacokinetic 
properties and unwanted anti-drug immune responses.18,19  
Another challenge often encountered with high-concentration mAb solutions is 
liquid-liquid phase separation, a phenomenon in which two distinct liquid layers are 
formed.20-23 When phase separation occurs, most of the protein remains in the high 
density phase induced by formation of intermolecular interactions, leaving only a small 
quantity of protein in the low density phase. The actual protein concentrations in the two 
phases depends largely on the surface of the protein molecule itself, pH, secondary 
solutes and temperature.23 Uncommonly high viscosity and opalescence have been 
identified for certain phase separated mAb solutions.11,12,21,24 Also, substantially 
decreased physical stability has sometimes been reported when mAbs undergo phase 
separation.20,25,26 
Excipients are added to mAb formulations for particular purposes such as 
increasing stability and solubility, reducing viscosity, and potentially enhancing efficacy.27-
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31 Some excipients enhance the stability of mAbs by direct interaction mechanisms 
(including hydrophobic, electrostatic, and dipole-dipole forces), while others by indirect 
interactions (such as protein preferential exclusion).28,29 A variety of excipients have been 
shown to have different effects on stabilizing mAbs in therapeutic mAb formulations such 
as sugars, salts, polymers, surfactants, polyols and amino acids.28-36 Hydrogen 
exchange-mass spectrometry (HX-MS) is a well-established high-resolution technique for 
exploring protein dynamics and conformational flexibility including the effect of excipients 
on aggregation propensity and reversible self-association in low and high concentration 
mAb formulations, respectively.13,32-36 Under certain circumstances, such as RSA or 
interaction with excipients, the exchange rate can be altered in specific regions, indicating 
local alterations of backbone dynamics.13 HX-MS has been used to elucidate molecular 
effects of excipients32-37 and chemical changes (e.g., asparagine deamidation,38 
deglycosylation,35 post-translational modifications,39 and engineered point mutations40) 
on mAb conformational dynamics. We recently demonstrated that a particular IgG1 (mAb-
J) undergoes extensive RSA at high protein concentrations via electrostatic attractive 
interactions between segments of the Fab and Fc domains as determined by HX-MS 
analysis.41 In addition, we demonstrated the ability of both arginine and sodium chloride 
to disrupt mAb-J RSA in a concentration dependent manner.  
In this study, we expand those observations by examining a series of charged 
excipients possessing different abilities to disrupt specific protein-protein interactions 
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(PPI) sites for mAb-J, the same IgG1 antibody previously measured by HX-MS. We then 
correlate these results with their effects on mAb-J physical stability and solution 
properties. Specifically, the effect(s) of four charged amino acids (Arg, Lys, Asp, Glu) and 
sodium chloride on both solution properties (e.g., turbidity, viscosity) and mAb-J’s 
physical properties (hydrodynamic diameter, relative solubility, phase separation) were 
examined in a series of mAb-J protein concentrations (from 5 to 60 mg/mL). HX-MS 
analysis was then performed to obtain local information on backbone dynamics of mAb-
J (5 mg/mL and 60 mg/mL) in the presence of the selected excipients. The HX-MS 
information is then used to help better understand the mechanisms by which these 
excipients partially or more extensively disrupt RSA within specific regions of mAb-J at 
high protein concentrations.  
2.2. Materials and Methods 
2.2.1. Sample Preparation 
A highly purified IgG1 monoclonal antibody, mAb-J, was obtained from 
MedImmune LLC, Gaithersburg, MD, at a concentration of 150 mg/mL. The mAb-J stock 
solution was buffer-exchanged to a base buffer “BB” (20 mM citrate phosphate buffer 
containing 30 mM NaCl) with or without excipient (from 30 to 100 mM) by dialysis at 4oC 
and pH 6.0 for 24 hours using 3.5 kDa molecular weight cutoff membranes (Slide-A-Lyzer, 
Thermo Scientific, Rockford, IL). Excipients such as sodium chloride (NaCl), L-arginine 
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hydrochloride (Arg), L-lysine hydrochloride (Lys), L-glutamic acid monosodium salt (Glu), 
and L-aspartic acid sodium salt (Asp) were obtained from Sigma-Aldrich (St. Louis, MO). 
After dialysis into the BB buffer with excipients, 5-60 mg/mL mAb-J samples were 
prepared by diluting the dialyzed sample with corresponding dialysis buffer. 
2.2.2. Solution Appearance Study 
Dialyzed mAb-J samples were diluted with corresponding base buffers (BB with or 
without selected excipients, and at excipient concentrations ranging from 30 to 100 mM 
at pH 6.0) to prepare a series of mAb-J solutions at various concentrations ranging from 
5 to 60 mg/mL. Base buffer contained 20 mM citrate phosphate buffer with 30 mM NaCl 
at pH 6.0. Each diluted sample was filled into a 2 mL FIOLAX® clear Type 1 glass vial 
(Schott North America, Elmsford, NY) with a fill volume of 1 mL. This series of vials was 
visually assessed and photographed. 
2.2.3. Ultraviolet Absorption Spectroscopy 
A Nanodrop 2000 spectrophotometer (Thermo Scientific, Rockford, IL) was used 
to measure absorbance of mAb-J samples by ultraviolet absorption spectroscopy 
(AR280nmR). An extinction coefficient value of 1.58 mL∙mg-1∙cm-1 was calculated based on 
mAb-J primary sequence to determine protein concentrations.42 
2.2.4. Turbidity Measurements 
A series of mAb-J standard solutions was prepared in BB at various protein 
concentrations, showing different solution opalescence (turbidity). Each standard solution 
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was measured in (1) a volume of 3 mL by a HACH 2100 AN turbidimeter (HACH, 
Loveland, CO; 90-degree nephelometric detector with a wavelength of 455 nm) to obtain 
turbidity values (NTU), and (2) a volume of 160 μL SpectraMax® M5 Multi-Mode 
Microplate Reader (Molecular Devices, Inc., Sunnyvale, CA) at 500 nm to obtain 
O.D.R500nmR values (see Supplemental Figure S1). The two sets of data were correlated and 
plotted to make a linear standard curve between turbidity and O.D.R500nmR. Corning black 
96-well plates with clear bottoms (Corning Incorporated, Corning, NY) were then used to 
measure the O.D.R500nmR of all mAb-J samples (at different protein concentrations in BB 
with or without excipients) using SoftMax Pro Software (Corning Incorporated, Corning, 
NY). 
2.2.5. Dynamic Light Scattering  
Samples of mAb-J were prepared in a concentration of 10 mg/mL in the absence 
or presence of 100 mM excipients. A Wyatt DynaPro Plate Reader II dynamic light 
scattering instrument (Wyatt Technology, Santa Barbara, CA) equipped with an 830 nm 
laser was used to measure the hydrodynamic diameter of mAb-J in different buffer 
conditions using the Stokes-Einstein equation per instrument software. All mAb-J 
samples were measured by fifteen 5 second acquisitions (after centrifugation of samples 
at 2000 rpm for 2 mins). The solution viscosity of each sample was measured separately 
using an m-VROC viscometer (Rheosence, San Ramon, CA) at 25°C, and viscosity 
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correction was implemented in instrument software for calculation of corrected 
hydrodynamic diameters. 
2.2.6. Viscosity Measurements 
Dialyzed mAb-J samples were diluted with base buffer to make various excipient 
solutions at different protein concentrations from 10 to 60 mg/mL. The viscosity of mAb-
J samples in the presence of 30-100 mM excipients was measured at 25°C by an m-
VROC viscometer (RheoSense, San Ramon, CA). This was performed by injecting 
samples at a rate of 100 μL/min and at a shear rate of 1420 1/s using a 1 mL glass 
syringes (Hamilton Co, Reno, NV). 
2.2.7. Composition-Gradient Multi-Angle Light Scattering (CG-MALS) 
Samples of mAb-J at 2 and 20 mg/mL (containing 10% w/v trehalose in BB) with 
or without 100 mM excipients were prepared and filtered through a 0.22-micron size 
Millex-GV syringe filter unit (EMD Millipore, Billerica, MA) before injecting into the system. 
A CG-MALS instrument with dual syringe-pump Calypso sample preparation and delivery 
unit (Wyatt Technology, Santa Barbara, CA) was used to perform static light scattering 
analysis at room temperature. A series of association models were examined to fit light 
scattering data as a function of concentration by employing the Calypso software (Wyatt 
Technology, Santa Barbara, CA). Light scattering was measured at 90o with a series of 
mAb-J solutions (~0.2 mg/mL to 20 mg/mL) diluted by a dual syringe-pump Calypso 
sample preparation and delivery unit. Excess Rayleigh ratio (RRϴR) was then obtained and 
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plotted depending on mAb-J concentration, getting the osmotic second virial coefficient 
(BR22R), a measurement of non-ideal solution behavior resulting from two-body interactions. 
Chi2 testing was used to determine the best association model for mAb-J with or without 
excipients. The experimental details of this method have been described in detail 
elsewhere.41 
2.2.8. PEG-Induced Precipitation Study 
Stock solutions of PEG-10,000 (20% w/v PEG) were used to prepare a series of 
PEG solutions (from 0% to 20% w/v PEG) using BB with or without 100 mM excipients at 
pH 6.0. Sample-containing 96-well plates were incubated overnight at room temperature. 
After centrifugation of incubated samples at 1233 xg for 15 min, 200 μL filtrate of each 
well was transferred to another clear 96-well collection plate (Greiner Bio-One North 
America Inc., Monroe, NC) for AR280nmR absorbance measurement. A spectraMax® M5 
Multi-Mode Microplate Reader (Molecular Devices, Inc., Sunnyvale, CA) was used to 
determine the final mAb-J concentration. The %PEGRmidptR was determined by 
mathematical fitting as described previously43 using Python (x, y) version 2.7.9.0, which 
is a python-language-based open-source software. Furthermore, the relative apparent 
solubility values (or the apparent thermodynamic activity) were obtained by plotting the 
transition-area data points of the same sigmoidal curve on a log scale and extrapolating 
to 0% PEG as described previously.44  
2.2.9. Lyophilization of mAb-J Samples 
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Samples of mAb-J at 5 mg/mL and 60 mg/mL were prepared by dialysis against 
BB (containing 10% w/v trehalose). For each vial, a 2-leg, 13 mm siliconized rubber 
stopper (Wheaton Industries Inc., Millville, NJ) was used to partially stopper the vials, and 
a LyoStar II lyophilizer (SP Scientific, Warminster, PA) was then used to lyophilize all 
mAb-J samples using a freeze drying cycle previously described.13,41 Lyophilized samples 
were assessed visually and photographed to display the cake appearance. The 
concentration of post-reconstitution mAb-J samples was obtained using ultraviolet 
absorption spectroscopy (AR280nmR) after a 0.22-micron membrane filtration, and the slopes 
of optical density values from 310 nm to 395 nm was examined to evaluate the formation 
of soluble protein aggregates.  
2.2.10. Size Exclusion Chromatography (SEC) 
Analysis of mAb-J samples was performed using a SEC-HPLC system with an 
inline UV detector at 214 nm. Freeze-dried samples (5 mg/mL and 60 mg/mL) were 
diluted to 0.5 mg/mL using DR2RO, and then centrifuged at 14,000 g for 5 min prior to SEC 
analysis to eliminate any insoluble aggregates. A Shimadzu HPLC system equipped with 
a photodiode array detector was used to measure SEC eluates. Two columns, a 7.8 mm 
× 30 cm Tosoh TSK-Gel BioAssist G3SWxL and a 6.0 mm x 4 cm guard column (TOSOH 
Biosciences, King of Prussia, PA), were used for species separation. mAb-J samples 
were eluted in a mobile phase of 200 mM phosphate buffer (pH 6.8) at a flow rate of 0.7 
mL/min. mAb-J monomer, fragment, and soluble aggregates (e.g., dimer) of post-
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lyophilization samples were calculated and then compared to non-lyophilized samples 
based on chromatography peak areas. The experimental details of this method have been 
described in detail elsewhere.41 
2.2.11. Karl-Fischer Titration 
Coulometric Karl-Fischer (KF) determination of water moisture for lyophilized mAb-
J samples was conducted using a C20 Compact Karl Fischer Coulometer (Mettler-Toledo 
LLC., Columbus, OH). AQUASTAR ® CombiCoulomat (EMD Chemicals Inc., Gibbstown, 
NJ) was used as the reaction reagent for this purpose. Lyophilized mAb-J cakes were 
weighed and transferred to a reaction beaker, and final water content was obtained with 
units of ppm (part per million) using methodology described in the instrument manual.  
2.2.12. Deuteration of Excipients (Amino Acids) 
Excipients were dissolved in DR2RO to remove exchangeable hydrogen and dried in 
a Vacufuge vacuum concentrator (Eppendorf, Hauppauge, NY) at 30oC until only powder 
was remaining. This process was repeated three times and then the powder was 
reconstituted in DR2RO-based 5 mM citrate-phosphate buffer to prepare 100 mM excipients 
solutions, which were adjusted with deuterium chloride and deuterium oxide to obtain final 
pH of 6.0, without correction for the deuterium isotope effect.  
2.2.13. Hydrogen Exchange-Mass Spectrometry (HX-MS) 
The HX-MS method has been described in extensive detail previously.13,41 The 
lyophilized mAb-J samples (5 mg/mL and 60 mg/mL) and 100 mM excipient-containing 
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(excluding NaCl) deuterium buffer were equilibrated at 25oC on an Echotherm 
chilling/heating plate (Torrey Pines Scientific, Inc., Carlsbad, CA). To start deuterium 
labelling in mAb-J, 930 μL of excipient-containing DR2RO-based 5 mM citrate-phosphate 
buffer (uncorrected pH = 6.0) was transferred to the lyophilized mAb-J sample to 
reconstitute the freeze-dried protein cake. Air bubbles and insoluble aggregates were 
removed by centrifugation. The reconstituted mAb-J samples were incubated and labelled 
for 2760 seconds and then quenched by mixing 20 μL of the exchanged mAb-J sample 
with 180 μL of quench buffer (0.5 M tris(2-carboxyethyl) phosphine hydrochloride (TCEP), 
4 M guanidine hydrochloride, and 0.2 M sodium phosphate at pH 2.5 pre-equilibrated at 
1°C). 60 μL of the quenched mAb-J samples were loaded into a 100 μL sample loop by 
a LEAP H/DX PAL robot (LEAP Technologies, Carrboro, NC) into an Agilent 1260 infinity 
series LC (Agilent Technologies, Santa Clara, CA). Three columns (an immobilized 
pepsin column, a peptide desalting trap, and a C18 column) were used to digest mAb-J 
samples, desalt and concentrate the digested peptides, and finally separate them by 
gradient elution, as described previously.13,41 Peptide carryover in the immobilized pepsin 
column was minimized by washing the pepsin column with two wash solutions following 
a cleaning procedure after each injection as described previously.45 The refrigerated 
column compartment was kept at 1°C to minimize back exchange, and mobile phases 
composed of water and 90% acetonitrile/10% water, both containing 0.1% (v/v) formic 
acid, were used to separate and elute peptides into an Agilent 6530 quadrupole-time of 
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flight mass spectrometer (Agilent Technologies, Santa Clara, CA), equipped with a 
standard electrospray ionization source operated in positive mode for measuring the 
deuterium level of each peptide.  
2.2.14. HX-MS Data Processing and Analysis 
All the identified peptides were confirmed by using accurate mass (± 10 ppm) and 
tandem MS with collision induced dissociation on the quadrupole-time of flight mass 
spectrometer (Agilent 6530 QTOF MS). Three replicate sets of HX-MS data were 
analyzed using HDExaminer software (Sierra Analytics, California), including re-analysis 
of previously obtained raw data for mAb-J in BB,1 and data were also manually reviewed 
for chromatographic peak integration adjustments. A confidence interval was estimated 
by propagation of random error using the 99th percentile of the standard deviations from 
triplicate technical replicates, giving a value of ±0.43 Da for the significant differences in 
our dataset. HX-MS results were processed to compare mAb-J dynamics with and without 
excipients at both low and high protein concentrations, demonstrate excipient efficacy at 
disrupting RSA and also the intrinsic effects on mAb-J, especially at high protein 
concentrations. HX-MS results are displayed on a homology model of mAb-J created 
previously, based on crystal structures of an isolated Fc and an in-silico generated 
KOL/Padlan structure of an Fab. The results of the mAb-J homology models were 
displayed by Pymol software version 1.4.1 (Schrödinger LLC, Portland, OR). 
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2.3. Results 
2.3.1. Solution Properties of mAb-J in the Absence/Presence of Excipients 
As a first step to evaluate the effect of various additives on the solution properties 
of low to high concentrations of mAb-J, we visually examined the solutions. In Figure 1a, 
a series of mAb-J solutions show the effects of protein concentration on solution 
appearance. The clarity of mAb-J solution at 5 mg/mL was similar to protein-free buffer 
(result not shown). However, as the concentration of mAb-J increased from 10 to 60 
mg/mL, opalescence increased. When the concentration of mAb-J was close to 60 
mg/mL, an obvious phase separation phenomenon was observed with ~5 mg/mL protein 
in the low density phase and ~300 mg/mL protein in the high density phase. The five 
excipients showed varying ability to prevent mAb-J opalescence at high protein 
concentrations, as illustrated in Figure 1a-e. The addition of Arg and Lys (Figure 1b and 
c) inhibited turbidity, and even at a high protein concentration of 60 mg/mL, mAb-J 
solutions with 100 mM Arg or Lys were almost transparent and similar in appearance to 
the solution of base buffer (BB) alone. Furthermore, 30 mM Arg prevented turbidity of 60 
mg/mL mAb-J better than 30 mM Lys. Finally, Figure 1 panels a, d and e show the effect 
of NaCl, Glu, and Asp. Although NaCl, Glu, and Asp prevented mAb-J from undergoing 
phase separation, high-concentration protein solutions still exhibited opalescence, 
especially with NaCl.  
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To better quantify the opalescence, the turbidity value of each of the mAb-J 
solutions was then measured to determine the concentration-dependent effects of protein 
and excipient. As shown in Supplemental Figure S1, solution turbidity (NTU, as measured 
by a turbidimeter requiring 3 mL sample) correlated very well (R2 value of 0.99) with 
O.D.R500nmR values measured with a UV transparent cuvette (using only 160 μL sample) for 
each measurement.41 Using this standard curve, Figure 2a illustrates the measured 
O.D.R500nmR values (and corresponding turbidity values) for different concentrations of mAb-
J with and without varying concentrations of NaCl. There was one condition (60 mg/mL 
mAb-J with extra 30 mM NaCl in solution) in which mAb-J showed extremely high turbidity 
that exceeded the range of the standard curve, so no value could be obtained. For other 
conditions, however, as NaCl concentration increased and protein concentration 
decreased, the solution turbidity was reduced to a large extent. As shown in Figure 2b 
and c, mAb-J solutions in the presence of Arg or Lys not only showed no phase separation 
(see above), but also showed much lower turbidity values (below 50 NTU) for each of the 
examined protein concentrations. In contrast, Glu and Asp showed intermediate effects 
in terms of lowering turbidity values (better than NaCl, but not as effective as Arg and 
Lys), and yet, these negatively-charged amino acids did prevent phase separation under 
these conditions (Figure 2d and e).  
Solution viscosity was then evaluated to characterize the effect of these five 
excipients on the solution properties of high-concentration mAb-J solutions. Figure 3 
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shows solution viscosity as a function of both mAb-J and excipient concentrations. In BB 
alone with no added charged excipients, the viscosity of mAb-J solutions increased 
exponentially as the protein concentration increased up to 60 mg/mL (Figure 3a). 
However, in the presence of excipients, solution viscosity was lower and could be titrated. 
Solution viscosity of 60 mg/mL mAb-J solution decreased from ~18 to ~2-4 mPa•s in the 
presence of 100 mM excipient, as shown in Figure 3a-e. Positively-charged amino acids 
(Arg and Lys) had greater ability to reduce solution viscosity than the negatively-charged 
amino acids (Glu and Asp) or NaCl. 
2.3.2. Physical Properties of mAb-J in the Absence/Presence of Excipients 
The next stage of the work focused on developing a better understanding of the 
molecular nature of mAb-J interactions leading to the solution properties described in the 
preceding sections (solution turbidity, phase separation and elevated viscosity), both in 
the presence and absence of the five charged excipients. To this end, the hydrodynamic 
diameter, percentage of associated oligomers, and apparent relative solubility values of 
mAb-J in these various solutions were determined.46-50  
Table 1 summarizes the effect of these excipients on the average hydrodynamic 
diameter of mAb-J at 10 mg/mL determined by dynamic light scattering. The expected 
average hydrodynamic diameter value for an IgG1 molecule, consistent with values 
reported previously, is in the range of 9 to 12 nm.51,52 The average hydrodynamic diameter 
of mAb-J in BB, however, was 20.4 nm, larger than expected for monomeric mAb-J. With 
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excipients added to the solution, mAb-J displayed notably lowered hydrodynamic 
diameters. Furthermore, polydispersity index (PDI) values of these measurements 
displayed a trend of higher PDI values (indicating broader size distributions) for the mAb-
J samples with greater sizes.  
Concentration gradient, multi-angle light scattering (CG-MALS) was then used to 
better characterize different mAb-J oligomers and their mole percentage as a function of 
protein concentration in the absence and presence of excipients. Large negative BR22R 
values, indicating net attractive forces between proteins,53,54 have been determined 
previously for mAb-J.41 Consistent with these previous results, as shown in Figure 4a, the 
mole percentage of mAb-J monomer in base buffer decreased notably as the protein 
concentration increased, remaining only about 50% monomeric at a protein concentration 
of 20 mg/mL with a concomitant increase in oligomer species, primarily monomer-dimer-
tetramer equilibrium (based on the best model). When excipients were added (Figure 4b-
f), decreased levels of oligomer formation were observed. MAb-J remained monomeric in 
the presence of Arg up to the highest concentration examined (~23 mg/mL), suggesting 
complete disruption of attractive PPIs between mAb-J monomers. In contrast, the mole 
percentage of mAb-J oligomers still increased to varying extents at the higher protein 
concentrations (10-23 mg/mL) in the presence of the other excipients, suggesting 
differential ability to disrupt oligomer formation. A similar protective trend was observed 
in terms of formation of oligomers. For example, as shown in Figure 4e, with addition of 
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Glu, the mole percentage of oligomers displayed a similar increasing profile like that of 
the control (mAb-J in BB). The mAb-J dimer, however, was dominant in Glu-containing 
solution, while tetramer was the major species in BB.  
Finally, the relative apparent solubility (thermodynamic activity) of mAb-J was also 
affected by addition of excipients. PEG-induced precipitation, a widely used method for 
measuring relative protein solubility,43,55-57 was employed to determine the effects of 
excipients on altering mAb-J apparent solubility. Figure 5a illustrates the concentration of 
mAb-J as a function of %PEG (w/v) in BB with and without additives, showing sigmoidal 
curves under different buffer conditions. To compare the effect of different excipients on 
mAb-J, the relative solubility, the amount of PEG required to precipitate 50% of protein 
(%PEGRmidptR), was determined (Figure 5b). While 3.5% of PEG was needed to precipitate 
half of all mAb-J in BB, the %PEGRmidptR values increased in the presence of the additives. 
To estimate apparent solubility (thermodynamic activity), data points in the transition 
region of the sigmoidal curves were replotted on a logarithmic scale so that the apparent 
solubility values of mAb-J at zero PEG concentration could be obtained by extrapolation 
(Figure 5c). Apparent solubility of ~10 mg/mL was observed for mAb-J in BB. In 
comparison, higher apparent solubility values (30-50 mg/mL) were determined for mAb-
J in presence of negatively charged amino acids (Glu and Asp) and NaCl, while much 
larger values (~670 mg/mL and ~170 mg/mL) were found for mAb-J in the presence of 
positively-charged amino acids (Arg and Lys). 
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To better summarize and compare the results obtained from these diverse 
biophysical methods, radar chart arrays58 were generated to visualize and better describe 
the effects of excipients on solution properties of mAb-J, as shown in Figure 6. In this 
figure, each corner of the individual radar chart refers to solution conditions (BB buffer 
either with or without excipients) and their effect on mAb-J solutions at the specific 
concentration tested by each technique. It can be seen in Figure 6, at the top position of 
each radar chart, mAb-J in BB buffer alone, undergoes extensive RSA displaying high 
turbidity, larger hydrodynamic diameter, elevated viscosity, notably high mole percentage 
of oligomers, and lower relative apparent solubility. When excipients are added to the 
solution, mAb-J has less extensive RSA along with improved solution properties (e.g., 
lower turbidity, viscosity, improved relative solubility) with a consistent trend in the relative 
ability of the amino acid excipients to affect the physical properties of mAb-J solutions as 
follows: Arg > Lys > Asp > Glu. For NaCl, it is consistently less effective than the 
positively-charged amino acids for disrupting RSA, but it demonstrates sometimes more 
beneficial effects on mAb-J than the negatively-charged amino acids, depending on the 
solution property.  
2.3.3. HX-MS Reveals the Effects of Excipients on RSA Disruption and Changes of 
Local Dynamics for mAb-J 
 
To obtain localized structural information on how the backbone dynamics of mAb-
J is affected by these excipients, HX-MS was performed as described previously (for 
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mAb-J).41 As a first step to provide a DR2RO environment for mAb-J at high protein 
concentrations (preceding hydrogen exchange), we generated a lyophilized sample of 
mAb-J with each excipient as described previously.41 mAb-J was lyophilized at two 
concentrations (5 mg/mL and 60 mg/mL) in BB containing 10% (w/v) trehalose (as a 
lyoprotectant). The lyophilized mAb-J cakes are shown in Supplemental Figure S2a, 
indicating good cake appearance with minimal cracks at the edge. Karl Fischer titration 
was used to determine the moisture content of the lyophilized cakes, which is often an 
important parameter for quality assessment.59 Supplemental Figure S2b shows the 
lyophilized samples had moisture content within a range of 1.5% to 2.5%, with an average 
moisture of about 2% for both mAb-J concentrations, which is more than acceptable for 
HX-MS analysis. The effect of lyophilization on the mAb-J protein itself was evaluated 
using UV-Visible spectroscopy and SEC by reconstituting the lyophilized cakes with DR2RO 
(see Supplemental Table S1). Overall, a similar slope of ODR320-350nmR was obtained after 
lyophilization and reconstitution, indicating no significant aggregation happened during 
lyophilization. Also, the protein was found to be 98.4-99.7% monomeric based on SEC 
(with ~99% protein recovery), with small amounts of aggregates (~1%) that could be 
removed by centrifugation, and was therefore suitable for use in HX-MS experiments.  
To evaluate the effects of the charged amino acids on mAb-J at the molecular 
level, HX-MS was performed to investigate changes in backbone dynamics and flexibility 
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at both low and high protein concentrations. In this study, re-analysis of the data acquired 
in our earlier work using an updated peptide list (see Supplemental Table S2) was 
performed to define mAb-J RSA interfaces (Figure 7a).41 Here, we focus on the effects of 
the charged excipients on disruption and alterations of RSA interfaces. Lyophilized mAb-
J samples (5 mg/mL and 60 mg/mL) were reconstituted in excipient-containing (100 mM) 
DR2RO-buffer to trigger protein amide-hydrogen labeling. Following a 2760s interval of 
hydrogen exchange, the reaction was quenched, the mAb was then digested with 
immobilized pepsin and the uptake of deuterium in each peptide was determined by LC-
MS as described in Supporting Information. A total of 182 peptides were confirmed (see 
Supplemental Table S2) leading to 94% percent sequence coverage in both the heavy 
chain and light chain. Each of the confirmed peptides was analyzed to determine mass 
difference between two different protein concentration conditions in each of the 
buffer/excipient conditions. The negative and positive values of mass difference showed 
protected and de-protected regions in mAb-J at 60 mg/mL, and a significance criterion 
(±0.43 Da) was applied for determining the degree of excipient effects at different mAb-J 
regions.  
The HX-MS results for each of the peptides, with and without excipients, at both 
low and high protein concentrations were evaluated. To this end, we compared 
deuterium-uptake profiles of mAb-J peptides at low (5 mg/mL) vs high protein 
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concentration (60 mg/mL) with and without excipients, indicating RSA interfaces and 
effects of excipients on RSA. Figure 7 shows the difference plots, i.e., HX Difference = 
HX (60 mg/mL) – HX (5 mg/mL), of the deuterium uptake results, in the absence of 
additives (panel a) and in the presence of four selected excipients (Arg, Lys, Glu, and 
Asp; panels b-e, respectively). As shown in Figure 7a, three protected regions were 
identified in mAb-J at 60 mg/mL at the RSA interfaces, which are located in the variable 
heavy chain (VRHR), variable light chain (VRLR), and constant domain of the heavy chain (CRHR3) 
of the antibody, defining the RSA interface as being heavy chain (HC) 92-116 (CDR H3), 
light chain (LC) 39-76 (CDR L2), and HC 381-408 (CRHR3), respectively, consistent with our 
earlier work.41 
When 100 mM Arg was present in solution at a mAb-J protein concentration of 5 
and 60 mg/mL (Figure 7b), two of the three high concentration protected regions in mAb-
J due to RSA were eliminated, with only weaker protection at the CDR L2 region still 
remaining. There was, however, one region (CDR L2) showing slower hydrogen 
exchange at 60 vs 5 mg/mL, possibly because 100 mM Arg could not fully disrupt the 
mAb-J PPIs at the protein concentration of 60 mg/mL, especially the CDR L2 regions. 
Similar effects were observed with Lys (Figure 7c). More details on interpreting HX-MS 
protection on CDR L2 region are discussed below. 
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For the negatively-charged amino acids (Glu and Asp), different effects on different 
regions of mAb-J were observed including less efficiency in disrupting mAb-J RSA 
interfaces (Figure 7d and e). For the addition of Glu, similar to the effects of Arg and Lys, 
there is no increased HX protection at 60 mg/mL in the CDR H3 and CRHR3 regions 
indicating that the addition of Glu disrupted the same two RSA interfaces in CDR H3 and 
CRHR3 regions. Moreover, it seems that the RSA interface on CDR L2 was also disrupted 
by Glu, which in fact was not the case, as indicated by biophysical analysis (see 
Discussion section). Furthermore, other regions in mAb-J were also affected by the 
addition of Glu, displaying increased flexibility in primarily four regions of HC, containing 
VRHR HC 124-138 (TKGPSVFPLAPSSKS), CRHR1 HC 208-218 (HKPSNTKVDKK), CRHR2 HC 
340-352 (ISKAKGQPREPQV), and CRHR3 HC 430-450 (SVMHEALHNHYTQKSLSLSPG). 
Multiple positively-charged amino acids, based on our mAb-J homology model, are 
exposed on each of the Glu responsive regions, giving +2, +4, +2, and +3 net charges on 
the increased-flexibility regions of VRHR, CRHR1, CRHR2, CRHR3, respectively. Therefore, it is 
possible that, at high protein concentrations, Glu interacted with the positively-charged 
amino acids in these regions, and thus affected local dynamics of mAb-J, thereby 
increasing HX at 60 mg/mL. For the addition of Asp, this additive also had a comparatively 
poorer ability to disrupt RSA interfaces for mAb-J in comparison to Arg and Lys, and 
showed similar results to Glu. In addition to the peptide segments in the HC showing 
increased flexibility at 60 mg/mL (probably also due to charge interactions between Asp 
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and local regions of mAb-J), protein segments in CDR L2 showed slowed HX at 60 
mg/mL, which is similar to the observations with Arg or Lys, suggesting incomplete 
disruption of this RSA interface with Asp addition (see Discussion section).  
To visualize these effects, homology models of mAb-J were utilized and regions of 
mAb-J that are affected in terms of changes in local flexibility at high vs low protein 
concentrations are shown in Figure 8a. The effects of mAb-J concentration in the 
presence of different excipients are highlighted in color (Figure 8b-e) where regions of 
mAb-J which showed significant increase or decrease in hydrogen exchange in the 
presence of excipients. Collectively, the HX-MS observations suggest that significant 
interactions involving both the Fab and Fc are the major driving force for mAb-J to 
undergo RSA at high protein concentrations, mainly through electrostatic attractive 
interactions (net positive charges on the interfaces of the CDR H3 and CDR L2 regions 
and net negative charges on the interface in CRHR3 region). Interaction with charged amino 
acids weakens mAb-J PPIs and thus disrupts RSA at high protein concentrations. 
However, weak interactions through CDR L2 region appear to still exist at high protein 
concentration to varying extents in the presence of different excipients.  
2.4. Discussion 
Formulating monoclonal antibodies at high protein concentrations is usually 
required for SC administration to both reach the therapeutic window and increase patient 
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compliance.7,8 However, high concentrations of some antibodies can lead to solution 
opalescence, high viscosity, and even phase separation through intermolecular reversible 
self-association.15-17 Many strategies have already been tested to reduce mAb RSA, such 
as engineering antibodies by mutating specific amino acids,60 or optimizing antibody 
formulations by adding excipients, altering pH and ionic strength.61-63 Herein, we have 
studied different excipients to identify their ability to disrupt RSA of a specific human 
immunoglobulin G1 (mAb-J) at both the solution and the molecular levels, to elucidate an 
improved understanding of how the excipients affect the RSA of this particular mAb.  
In this work, the effects of two positively-charged amino acids (Arg and Lys), two 
negatively-charged amino acids (Glu and Asp), and NaCl on disrupting known sites of 
PPIs for mAb-J were evaluated. These effects were then correlated with solution 
properties of mAb-J as a function of increasing protein concentration as well its physical 
properties. Each of the five charged excipients showed RSA-disrupting effects of mAb-J, 
albeit to different extents, consistent with electrostatic interactions as probably the 
dominating driving force for reversible self-association of mAb-J molecules (as reported 
previously from HX-MS analysis of mAb-J41). In that previous work we found that, mAb-J 
at pH 6.0 (pI ~7.3) contains a region of net +2 charge in each of the two Fab-CDR regions: 
CDR L2 (LC 39-76, YQQLPGTAPKLLIYDNFNRPSGVPDRFSGSKSGTSASL) and CDR 
H3 (HC 92-116, AVYYCATVMGKWIKGGYDYWGRGTL). Another charged region 
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involved in the RSA interfaces of mAb-J at the same pH is located in the Fc domain, 
containing net -4 charge peptide segment (HC 381-408, 
IAVEWESNGQPENNYKTTPPVLDSDGSF). Because electrostatic attractive interactions 
are likely the dominant force for mAb-J to form high-order oligomers due to RSA, it was 
of interest to assess how different charged excipients might modulate and improve the 
physical properties of mAb-J as well as associated solution properties at high protein 
concentrations.  
2.4.1. Effect of Five Excipients on Solution Properties of mAb-J 
For mAb-J in the base buffer (BB) at pH 6.0, increasing the protein concentration 
led to formation of increasing amounts of mAb-J oligomers in solution as demonstrated 
by both dynamic light scattering and CG-MALS analysis.41 This RSA increased turbidity, 
elevated viscosity and decreased relative apparent solubility as summarized in the radar 
chart in Figure 6. In addition, as shown in Figure 1, mAb-J in BB not only showed a greater 
propensity to form more turbid solutions, but to eventually undergo phase separation at 
higher protein concentrations. The addition of these five charged excipients, however, did 
improve the mAb-J solution properties, again to varying extents, that overall correlated 
well with the remaining RSA between mAb-J molecules (as measured by DLS and CG-
MALS) and specific Fab-Fc contact sites between mAb-J molecules (at 60 vs 5 mg/mL 
as measured by HX-MS).  
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In general, the addition of the five additives clarified the mAb-J solutions based 
both on their visual appearance and decreased turbidity at high protein concentrations. 
Our results suggest that, albeit to different extents, all charged excipients we used in this 
study can disrupt the RSA interface sites of mAb-J by a charge shielding effect, which 
can be explained by DLVO (Derjaguin-Landau-Verwey-Overbeek) theory.64 For example, 
a trend of decreasing the effective charge of mAb-J by increasing the solution ionic 
strength results in a shorter Debye screening length caused by electrostatic charge 
screening, and thus electrostatic attractive interactions can be mitigated or even 
eliminated by the less effective surface charge on mAb-J.65,66 This charge shielding effect, 
as observed by the concentration-dependent excipient efficiency of disrupting RSA of 
mAb-J, was observed to affect solution properties. As increasing levels of the excipients 
were added to BB (from 30 mM to 100 mM), not only the opalescence of mAb-J solutions 
dramatically decreased, but phase separation at high protein concentrations was inhibited 
(Figure 1). Similar results were also seen in by more quantitative measurements including 
turbidity and viscosity values, where the excipients exhibited concentration-dependent 
profiles for the reduction of solution turbidity and viscosity. In this work, we examined 
excipient effects in the concentration range from 30 mM to 100 mM (a range over which 
Debye–Hückel charge shielding is dominant), because higher excipient concentrations 
(e.g., 0.2-2 M range) could complicate data interpretation due to competing physical 
effects on the mAb-J molecules (e.g., salting out effects).  
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2.4.2. HX-MS Analysis of Effect of Five Excipients on Sites of RSA in mAb-J 
For HX-MS analysis, interpretation of HX differences in the presence of various 
excipients requires correction for the effects on the chemical exchange rate.67 In our 
current work, we were unable to incorporate a reporter peptide to compensate for 
potential chemical exchange effects. Thus, we focused only on differences in hydrogen 
exchange between high and low protein concentrations in the presence of each individual 
additive. Three RSA interfaces (CDR L2, CDR H3, and CRHR3) were identified in BB 
between 60 mg/mL and 5 mg/mL based on slowed HX. More highly oligomerized mAb-J 
with interacting networks probably formed at 60 mg/mL and thus multiple regions on mAb-
J are involved in RSA in BB condition. Based on CG-MALS analysis, which showed a 
small fraction of lower-order oligomers in solution, PPIs were still present for mAb-J in BB 
at 5 mg/mL. But due to the relatively higher oligomerized state of mAb-J at higher protein 
concentration, HX protection could be observed between 60 and 5 mg/mL samples.  
The addition of 100 mM of any of these five excipients was sufficient to eliminate 
the high concentration HX protections particularly in the CDR H3 and CRHR3 regions, 
suggesting that the RSA association in these regions is a signature of the highly 
oligomerized form. The presence of Arg or Lys in solution mitigated mAb-J RSA to a larger 
extent, but probably not completely, dissociating high-order mAb-J oligomer to perhaps a 
dimeric form as probed by CG-MALS. Therefore in HX analysis, there was still a 
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protection at the CDR L2 region. These results suggest that mAb-J at 60 mg/mL in the 
presence of Arg or Lys is more dimeric than that at 5 mg/mL. Such HX protection in CDR 
L2 is probably a signature of the difference between the monomeric and dimeric mAb-J 
forms. The negatively-charged Glu and Asp were not as effective as Arg or Lys in terms 
of RSA disruption for mAb-J according to biophysical analysis, but could still eliminate HX 
protections in CDR H3 and CRHR3 regions. However, the protection of the CDR L2 region 
was only observed for Asp, and not for Glu, which is probably due to their different RSA 
disruption efficiency, especially in the CDR L2 region. The absence of HX protection for 
Glu probably indicates a similar extent of dimerization at both high and low protein 
concentrations. Greater RSA inhibition effects on the CDR L2 region was observed by 
Asp addition, resulting in a detectable HX difference between the two protein 
concentrations.  
Therefore, PPIs on potentially mAb-J dimer formation were still detected in the 
CDR L2 region (LC 39-76, YQQLPGTAPKLLIYDNFNRPSGVPDRFSGSKSGTSASL) 
even in the presence of excipients. In addition to the net +2 charges in this region, there 
are also two negatively-charged and three aromatic amino acids, which might induce 
further Fab-Fab interactions based on the CDR L2 region (possibly electrostatic or 
hydrophobic interactions).68 It is also possible that these Fab-Fab interactions were 
present even in the absence of excipients, forming low-order oligomers, such as dimers. 
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More extensive associations, involving multiple regions on mAb-J as discussed above, 
occurred by Fab-Fc electrostatic attractions to form high-order oligomers, transient 
networks, or even phase separation.41 As reported in a recent paper69, Arg and Lys could 
increase the surface aromatic hydrophobicity, and Arg was reported more effective than 
Lys, which might improve the Fab-Fab hydrophobic attractions. Also, as the positively-
charged side chains of Arg and Lys are relatively more chaotropic69, the surface tension 
of water decreases, and thus the conformational structure of mAb-J might become 
altered, exposing some buried amino acid residues. Therefore, Fab-Fab interactions of 
mAb-J with hydrophobic forces might replace the original Fab-Fc interactions in the 
presence of Arg or Lys at high protein concentrations. In terms of electrostatic 
interactions, albeit there is a net +2 charge on CDR L2 interface, it does have two 
negatively-charged amino acids in this region, which might also be responsible for weak 
Fab-Fab interactions by charge attraction (even in the presence of excipients at high 
protein concentrations). 
2.4.3. Effect of Five Excipients on Properties of mAb-J 
The addition of NaCl also had the ability to decrease PPIs of mAb-J solutions, but 
the extent of its effectiveness (in the concentration range examined) was less than the 
charged amino acids. As shown in Figures 1 and 2, at high mAb-J concentrations, the 
solutions with NaCl still appeared opalescent and had higher turbidity even in the 
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presence of relatively high concentration of NaCl. Beyond being charged, the amino acids 
also possess a positively-charged primary amine group and a negatively-charged 
carboxylate group, leading to zwitterionic properties. Furthermore, amino acids have 
larger surface area (due to their non-polar side chains) than the sodium ion, which likely 
enhances their ability to interact more sites on proteins via other non-covalent 
mechanisms.70 Also, NaCl at low concentrations does not have an ability to modify 
hydrophobic interactions71,72. In summary, there are more possible non-covalent 
interactions between the mAb-J and charged amino acids than between mAb-J and NaCl, 
and thus charged amino acids more effectively disrupted RSA at high protein 
concentrations. 
As for Glu and Asp, they probably have additional effects on the mAb-J including 
interaction via other non-covalent mechanisms (e.g., hydrogen bonding or specific 
interactions) as well as potentially weak preferential exclusion effects.73,74 Additional 
interactions with mAb-J were confirmed in HX-MS results (Figures 7 and 8) where it was 
demonstrated that there were regions of both increased and decreased backbone 
flexibility in mAb-J in the presence of Glu and Asp at high protein concentrations. These 
include Fab interaction sites in CDR L2 as described above. Moreover, a combination of 
different interactions and effects on mAb-J are present for Glu and Asp, which is 
consistent with their lower ability to improve solution properties due to competing 
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interactions vs solely interacting at the RSA interfaces of mAb-J molecules. This might 
include forming hydrogen bonds with the protein, resulting in changes in protein structure, 
local pH microenvironments and backbone flexibility.28,75 The increase of backbone 
flexibility on mAb-J in the presence of Glu or Asp at high concentration was again not 
necessarily involved with mAb-J RSA.  
In this work, Arg-containing mAb-J solutions consistently displayed the best 
solution properties and the largest fraction of protein monomers, even compared to 
another positively-charged amino acid, Lys. As discussed above, although electrostatic 
attractions are the dominant force for formation of mAb-J RSA networks, additional 
contributions by other non-covalent interactions are also important. For example, Arg can 
favorably interact with aromatic residues in proteins, by forming cation-π interactions.76-
78 Furthermore, although Arg has a guanidinium group, the carboxylate group in Arg has 
been shown to limit the interaction of the guanidinium group, weakening Arg’s interaction 
with proteins so that it can no longer extensively alter structure.78 Also, Arg has a relatively 
larger surface area than Lys, which contributes more steric repulsion, leading to fewer 
surface-exposed attraction sites on mAb-J and thus might reduce the chance for protein 
interactions.71 Other studies also indicate Arg can increase protein solubility, increase 
second osmotic virial coefficient (BR22R, with increasing positive values indicating repulsive 
effects), and suppress formation of protein dimers, which are consistent with our results 
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(Figure 4 and 5).79-81 Moreover for the HX-MS results, mAb-J still demonstrated weak 
protection in the CDR L2 region even with Arg or Lys in solution. Therefore, it is possible 
that positively-charged amino acids localize and act primarily on CRHR3 domain RSA 
interfaces rather than CDR L2 and that other potential interactions may occur with the 
CDR L2 region when the original electrostatic interactions involving Fab and Fc sites are 
broken at high protein concentrations.68 So it is likely that disruption of a combination of 
different non-covalent forces which induce the apparent RSA interfaces in the mAb-J 
molecule, and Arg is most able to outcompete for all of these non-covalent sites of 
interactions. Similar observations have been reported that Arg has a higher ability than 
sodium to disrupt PPIs, decrease viscosity, and increase solubility by not only a charge 
shielding effect, but also cation-π interaction.69,82,83 Although high concentrations of Arg 
promoted protein aggregation in some reported cases, low concentrations induce 
significant effects by decreasing dynamic viscosity and increasing colloidal stability, 
without strongly influencing protein conformational stability and aggregation propensity.82 
In our work, as shown in Figure 1b, Arg also effectively prevented phase separation by 
disrupting PPIs even at low excipient concentrations.  
2.4.4. Comparative Results in Companion Paper with Different IgG1 mAb 
This work is part one of two studies examining the inter-relationships of 
pharmaceutical excipients, solution properties and molecular interactions in high 
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concentration mAb solutions. In the companion paper (Part II), we performed a similar 
series of studies with a second IgG1 mAb (mAb-C) which has been previously shown to 
undergo a different predominant mechanism of RSA at high protein concentrations. For 
mAb-c, hydrophobic attractions mediated by Fab-Fab interactions in the CDR regions 
have been shown to be the dominant driving force in intermolecular associations.13 
Therefore, a different set of excipients were employed with varying ability to affect 
hydrophobic interactions in mAb-C. Taken together, using two different mAbs (mAb-J and 
mAb-C) that display RSA by different mechanisms, these studies demonstrate the rational 
design of high concentration mAb formulations with specific additives by (1) elucidating 
the ability of additives to disrupt specific intermolecular interactions leading to RSA a mAb 
by HX-MS, and then (2) correlating these findings with their effects in a concentration-
dependent manner on both the solution properties (opalescence, phase separation and 
viscosity) and molecular physical properties (average size and relative solubility) of the 
mAb at high protein concentrations. 
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2.6. Figures and Tables 
 
Table 2.1. Excipient effects on the hydrodynamic diameter of mAb-J as measured by 
dynamic light scattering. All measurements were taken at 25°C with a protein 
concentration of 10 mg/mL at pH 6.0. All excipients have a concentration of 100 mM in 
solution in base buffer (BB). Triplicate measurements were performed for this study. SD 
denotes the sample standard deviation. 
 
 
 
 
 
 
 
Cond
ition 
Hydrodynamic Dimeter (nm) Polydispersity Index 
Mean SD Mean SD 
BB 20.4  0.8 0.125  0.019 
NaCl 14.3  0.1 0.107  0.013 
Arg 12.15  0.02 0.057  0.018 
Lys 12.7  0.1 0.075  0.018 
Glu 15.22  0.03 0.103  0.014 
Asp 14.9  0.1 0.104  0.025 
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Figure 2.1. Excipient effects on mAb-J solution opalescence and phase separation based 
on solution appearance. Excipients are (A) NaCl, (B) Arg, (C) Lys, (D) Glu, and (E) Asp. 
Column I represents mAb-J was in BB + 100 mM excipients (except (A) row, which in BB 
only), but as the protein concentration varied from 5 to 60 mg/mL. Column II shows mAb-
J was at 60 mg/mL. In addition to BB, extra amount of excipient was in solution. 
Representative samples shown were photographed at room temperature. 
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Figure 2.2. Turbidity values of mAb-J solutions as a function of both protein and excipient 
concentrations. Turbidity was calculated from a linear standard curve in Supplemental 
Figure S1 based on the relationship between O.D.R500nmR and turbidity. Blue bars indicate 
the turbidity of mAb-J solution in the presence of (A) NaCl, (B) Arg, (C) Lys, (D) Glu, and 
(E) Asp, while the original measured O.D.R500nmR values are shown in black circle symbol. 
All data are presented as mean ± standard deviation; n = 3. 
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Figure 2.3. Excipient effects on solution viscosity profile of mAb-J vs. protein 
concentration at 25oC in the presence (A) NaCl,1 (B) Arg,1 (C) Lys, (D) Glu, and (E) Asp. 
Dynamic viscosity was measured in a range of protein concentrations (from 0 to 60 
mg/mL) at indicated excipient concentrations in BB containing 20 mM citrate phosphate 
with 30 mM NaCl at pH 6.0. The viscosity curves for mAb-J alone and in the presence of 
NaCl and Arg have been published previously and are shown again here comparison to 
the other additives.1 All data are presented as mean ± standard deviation; n = 3. 
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Figure 2.4. Excipient effects on self-association of mAb-J as measured and analyzed by 
static light scattering, showing mole percentage of three mAb-J species (monomer, dimer, 
and tetramer) in (A) BB,1 (B) NaCl,1 (C) Arg,1 (D) Lys, (E) Glu, and (F) Asp. A 
concentration of 100 mM was applied for all excipients. Samples of mAb-J were 
measured by CG-MALS instrument at room temperature. All data are presented as mean 
± standard deviation; n = 3. 
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Figure 2.5. Relative apparent solubility (thermodynamic activity) of mAb-J as measured 
by %PEGR10,000R precipitation assay. (A) Change of mAb-J concentration as a function of 
%PEGR10,000R with and without excipients. (B) %PEGRmidptR values indicate the amount of 
PEGR10,000R that precipitated half of the total protein out of solution. (C) Apparent solubility 
values of mAb-J were obtained from Y-axis extrapolation of transition-area data points in 
each sigmoidal curve of (A). (D) Comparison of mAb-J apparent solubility values in both 
absence and presence of various excipients. All data are presented as mean ± standard 
deviation; n = 3. 
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Figure 2.6. 
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Figure 2.6. Radar chart array analysis to evaluate effects of excipient on mAb-J RSA and 
solution properties summarizing results from Figures 2-5 and from Table 1. Excipients in 
BB have a concentration of 100 mM. The radar charts indices indicate (A) turbidity at the 
concentration of 60 mg/mL (The asterisk on BB condition indicates unmeasurable 
turbidity value due to phase separation), (B) hydrodynamic diameter at 10 mg/mL, (C) 
viscosity solution at 60 mg/mL, (D) oligomerized mAb-J (%) at 15 mg/mL, and (E) 
apparent solubility values. The perimeter of the outermost polygon displays the mean 
morphology parameter; the perimeter of the polygon-labeled “mean - standard deviation” 
displays the value of mean minus one standard deviation; and the distance between the 
perimeters of the two polygons (along an axis) is one standard deviation. Triplicate 
measurements were performed. 
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Figure 2.7. 
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Figure 2.7. HX difference plot to show effect of excipients on local region flexibility of 
mAb-J as measured by HX-MS. (A) shows the mass difference of each peptide between 
60 mg/mL and 5 mg/mL of mAb-J concentrations in the absence of excipients, which was 
obtained by re-analysis of data acquired earlier in our lab using an updated peptide list 
(see Supplemental Table S2) for comparisons of the excipient disruption effects on the 
RSA interfaces of mAb-J.1 Other panels also represent the mass difference between two 
protein concentrations, but in the presence of 100 mM excipients, including (B) Arg, (C) 
Lys, (D) Glu, and (E) Asp. Peptides are indexed in order from the N-to-C termini of the 
heavy chain followed by the light chain of mAb-J (see Supplemental Table S2 for the 
locations and sequences of the peptides). HX difference in Da is shown along with vertical 
axis between different solution situations. Positive and negative values imply increased 
or decreased HX by mAb-J, respectively at 60 mg/mL. The mAb domain boundaries are 
approximate because several peptides span two domains. The dashed horizontal lines 
denote the limit for significant HX differences as detailed in the Supplemental Information. 
Three independent HX measurements was performed. 
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Figure 2.8. Excipient effects on local flexibility of mAb-J as measured by HX-MS plotted 
on mAb-J homology models. (A) mAb-J RSA interfaces in purple color, which was also 
published in a previous article.1 Excipient effect on mAb-J RSA is demonstrated in the 
following panels, including (B) Arg, (C) Lys, (D) Glu, and (E) Asp. Flexibility change of 
specific region in the presence of excipients is shown in orange and blue, representing 
increased and decreased flexibility, respectively. Changes in flexibility of particular 
peptide segments were derived from the differential exchange data in Figure 7. 
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Supplemental Figure 2.1. Standard curve between nephelometric turbidity (NTU) and 
O.D.R500nmR values for various high concentration mAb-J solutions (see Figures 1 and 2 of 
manuscript). Linear regression was performed to fit equation y = a + b*x, where “a” is 
equal to -3.4 and “b” is equal to 581.2, with the R-Square value of 0.99. All data are 
presented as mean ± SD; n = 3. 
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Supplemental Figure 2.2. Description of lyophilized cakes of mAb-J. (A) Appearance 
and (B) moisture determination of lyophilized mAb-J samples at both low and high protein 
concentrations. Formulation contains 20 mM citrate phosphate with 30 mM NaCl and 10% 
w/v trehalose at pH 6.0. Moisture data are presented as mean ± SD; n = 6. 
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Supplemental Table 2.1. Characterization of pre-lyophilization and post-lyophilization 
(and reconstitution) samples of mAb-J at low and high protein concentrations using UV-
visible spectroscopy and size exclusion chromatography. All data are presented as mean 
± sample standard deviation; n = 3. 
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Supplemental Table 2.2. Peptide list of mAb-J from pepsin digestion during HX-MS 
analysis with their corresponding peptide locations. 
Peptide 
Number Location 
Peptide 
Number Location 
Peptide 
Number Location 
1 Heavy 1‐10 (VH) 36 Heavy 117‐121 (CH1) 71 Heavy 246‐255 (CH2) 
2 Heavy 1‐17 (VH) 37 Heavy 150‐159 (CH1) 72 Heavy 246‐256 (CH2) 
3 Heavy 2‐10 (VH) 38 Heavy 160‐167 (CH1) 73 Heavy 257‐264 (CH2) 
4 Heavy 4‐10 (VH) 39 Heavy 163‐178 (CH1) 74 Heavy 257‐265 (CH2) 
5 Heavy 11‐22 (VH) 40 Heavy 167‐178 (CH1) 75 Heavy 266‐281 (CH2) 
6 Heavy 17‐32 (VH) 41 Heavy 168‐178 (CH1) 76 Heavy 267‐281 (CH2) 
7 Heavy 29‐35 (VH) 42 Heavy 172‐178 (CH1) 77 Heavy 270‐281 (CH2) 
8 Heavy 30‐35 (VH) 43 Heavy 179‐183 (CH1) 78 Heavy 282‐290 (CH2) 
9 Heavy 33‐49 (VH) 44 Heavy 184‐188 (CH1) 79 Heavy 304‐310 (CH2) 
10 Heavy 34‐49 (VH) 45 Heavy 184‐189 (CH1) 80 Heavy 305‐309 (CH2) 
11 Heavy 35‐49 (VH) 46 Heavy 184‐197 (CH1) 81 Heavy 305‐310 (CH2) 
12 Heavy 36‐44 (VH) 47 Heavy 184‐201 (CH1) 82 Heavy 310‐317 (CH2) 
13 Heavy 36‐49 (VH) 48 Heavy 185‐194 (CH1) 83 Heavy 313‐323 (CH2) 
14 Heavy 37‐50 (VH) 49 Heavy 187‐201 (CH1) 84 Heavy 317‐329 (CH2) 
15 Heavy 45‐49 (VH) 50 Heavy 188‐201 (CH1) 85 Heavy 320‐324 (CH2) 
16 Heavy 47‐50 (VH) 51 Heavy 189‐197 (CH1) 86 Heavy 328‐338 (CH2) 
17 Heavy 48‐50 (VH) 52 Heavy 189‐201 (CH1) 87 Heavy 329‐335 (CH2) 
18 Heavy 50‐58 (VH) 53 Heavy 189‐203 (CH1) 88 Heavy 338‐352 (CH2) 
19 Heavy 50‐60 (VH) 54 Heavy 190‐201 (CH1) 89 Heavy 340‐352 (CH2) 
20 Heavy 51‐59 (VH) 55 Heavy 190‐202 (CH1) 90 Heavy 353‐362 (CH2) 
21 Heavy 60‐66 (VH) 56 Heavy 201‐212 (CH1) 91 Heavy 353‐368 (CH2) 
22 Heavy 71‐79 (VH) 57 Heavy 202‐213 (CH1) 92 Heavy 353‐369 (CH2) 
23 Heavy 71‐80 (VH) 58 Heavy 203‐217 (CH1) 93 Heavy 361‐369 (CH2) 
24 Heavy 81‐86 (VH) 59 Heavy 203‐219 (CH1) 94 Heavy 363‐369 (CH2) 
25 Heavy 82‐86 (VH) 60 Heavy 204‐210 (CH1) 95 Heavy 363‐370 (CH2) 
26 Heavy 84‐91 (VH) 61 Heavy 208‐216 (CH2) 96 Heavy 370‐372 (CH2) 
27 Heavy 84‐92 (VH) 62 Heavy 229‐245 (CH2) 97 Heavy 370‐384 (CH2) 
28 Heavy 87‐93 (VH) 63 Heavy 231‐240 (CH2) 98 Heavy 372‐380 (CH3) 
29 Heavy 92‐108 (VH) 64 Heavy 231‐242 (CH2) 99 Heavy 373‐380 (CH3) 
30 Heavy 97‐111 (VH) 65 Heavy 235‐238 (CH2) 100 Heavy 373‐382 (CH3) 
31 Heavy 101‐116 (VH) 66 Heavy 239‐244 (CH2) 101 Heavy 373‐384 (CH3) 
32 Heavy 104‐116 (VH) 67 Heavy 239‐246 (CH2) 102 Heavy 381‐383 (CH3) 
33 Heavy 109‐116 (VH) 68 Heavy 239‐245 (CH2) 103 Heavy 381‐384 (CH3) 
34 Heavy 110‐116 (VH) 69 Heavy 245‐255 (CH2) 104 Heavy 381‐394 (CH3) 
35 Heavy 111‐116 (VH) 70 Heavy 245‐256 (CH2) 105 Heavy 381‐402 (CH3) 
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106 Heavy 383‐402 (CH3) 132 Heavy 489‐499 (CH3) 158 Light 580‐588 (CL) 
107 Heavy 384‐402 (CH3) 133 Heavy 489‐500 (CH3) 159 Light 580‐590 (CL) 
108 Heavy 385‐394 (CH3) 134 Heavy 489‐501 (CH3) 160 Light 581‐588 (CL) 
109 Heavy 385‐402 (CH3) 135 Light 489‐505 (VL) 161 Light 582‐588 (CL) 
110 Heavy 385‐408 (CH3) 136 Light 500‐505 (VL) 162 Light 584‐590 (CL) 
111 Heavy 395‐402 (CH3) 137 Light 500‐526 (VL) 163 Light 589‐591 (CL) 
112 Heavy 396‐402 (CH3) 138 Light 502‐526 (VL) 164 Light 589‐601 (CL) 
113 Heavy 403‐408 (CH3) 139 Light 516‐526 (VL) 165 Light 592‐595 (CL) 
114 Heavy 408‐410 (CH3) 140 Light 526‐531 (VL) 166 Light 592‐601 (CL) 
115 Heavy 409‐414 (CH3) 141 Light 526‐533 (VL) 167 Light 592‐603 (CL) 
116 Heavy 410‐413 (CH3) 142 Light 527‐531 (VL) 168 Light 594‐601 (CL) 
117 Heavy 410‐414 (CH3) 143 Light 527‐532 (VL) 169 Light 595‐601 (CL) 
118 Heavy 411‐414 (CH3) 144 Light 527‐533 (VL) 170 Light 614‐633 (CL) 
119 Heavy 415‐426 (CH3) 145 Light 527‐534 (VL) 171 Light 617‐633 (CL) 
120 Heavy 415‐427 (CH3) 146 Light 527‐535 (VL) 172 Light 634‐640 (CL) 
121 Heavy 428‐450 (CH3) 147 Light 527‐538 (VL) 173 Light 634‐641 (CL) 
122 Heavy 430‐450 (CH3) 148 Light 527‐539 (VL) 174 Light 634‐650 (CL) 
123 Heavy 433‐451 (CH3) 149 Light 534‐539 (VL) 175 Light 635‐640 (CL) 
124 Heavy 437‐450 (CH3) 150 Light 539‐543 (VL) 176 Light 641‐650 (CL) 
125 Heavy 445‐450 (CH3) 151 Light 544‐559 (VL) 177 Light 650‐659 (CL) 
126 Heavy 456‐484 (CH3) 152 Light 550‐559 (VL) 178 Light 658‐666 (CL) 
127 Heavy 474‐488 (CH3) 153 Light 560‐572 (VL) 179 Light 658‐667 (CL) 
128 Heavy 484‐488 (CH3) 154 Light 560‐573 (VL) 180 Light 658‐668 (CL) 
129 Heavy 484‐499 (CH3) 155 Light 560‐579 (VL) 181 Light 660‐666 (CL) 
130 Heavy 485‐488 (CH3) 156 Light 560‐581 (VL) 182 Light 660‐668 (CL) 
131 Heavy 485‐501 (CH3) 157 Light 579‐581 (VL)   
 
1. Arora J, Hu Y, Esfandiary R, Sathish HA, Bishop SM, Joshi SB, Middaugh CR, Volkin DB, Weis DD 
2016. Charge‐mediated Fab‐Fc interactions in an IgG1 antibody induce reversible self‐association, cluster 
formation, and elevated viscosity. MAbs 8(8):1561‐1574. 
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Chapter 3 
 
Characterization of Excipient Effects on Reversible Self-association, Backbone 
Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High 
Concentrations: Part 2 
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3.1. Introduction 
Monoclonal antibodies (mAbs) are parenterally administered to patients as 
biotherapeutic drugs primarily by intravenous (IV) or subcutaneous (SC) injection.1 The 
latter route offers the potential of reducing costs, saving time, and increasing patient 
compliance by having patients self-administer.1,2,25 As outlined in detail in the Part 1 
companion paper,3 successful formulation of mAbs as high concentration protein dosage 
forms is a challenge in terms of both protein instability (e.g., aggregation and reversible 
self-association) and pharmaceutical solution properties (e.g., high viscosity).  
One of the challenges of formulating mAbs at high concentrations is caused by 
reversible self-association (RSA), a phenomenon in which native proteins undergo 
specific, non-covalent, concentration- and temperature- dependent, reversible protein-
protein interactions (PPIs).1,4-11 Formation of intermolecular protein complexes by RSA 
can dramatically increase solution viscosity, resulting in pharmaceutical development 
challenges including high pressure during processing (e.g., sterile filtration) and clinical 
administration (injection via syringe).12 In addition, aggregation nuclei might form, 
potentially leading to the creation of aggregates of varying size (i.e., small soluble 
aggregates, subvisible particles and larger visible particulates). Such aggregates might 
not only reduce antibody therapeutic potency, but could also potentially generate 
unwanted immune responses.13,14 Moreover, high opalescence and even phase 
separation can occur in high concentration mAb solutions.5,6 For patients, injection of 
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highly viscous or turbid mAb solutions should be avoided due to potential pain on injection 
and an inability to view the solution for the presence of particulates.2 Based on these 
considerations, various strategies to mitigate RSA in high concentration mAb solutions 
are often required. 
The two major approaches taken to reduce RSA in mAb candidates during their 
development are point mutations through protein engineering15-17 and formulation 
development including the addition of excipients.18,19 Both strategies are mAb-specific 
and require systematic work for each individual mAb. For example, protein engineering 
approaches require site-specific information in the regions that initiate mAb-mAb 
interactions. Although point mutations can work well to reduce RSA, the binding affinity 
between the mAb and its antigen can potentially also be altered (i.e., increased or 
decreased), and the physicochemical stability profile of the mAb can also be affected. In 
addition, it is usually too late for a mAb molecule to be re-engineered once it enters clinical 
development since it will likely be considered a new molecular entity. Alternatively, 
formulation approaches focus on optimizing the environment around mAb molecules, 
rather than altering the mAb molecule itself. Although additives can be identified that 
reduce RSA, their effect(s) on mAb stability (i.e., conformational, colloidal and chemical 
degradation pathways) and relative solubility in solution must be evaluated. 
The companion paper in this issue describes an IgG1 mAb referred to as mAb-J, 
which finds electrostatic interactions to be the dominant force that drives RSA. This work 
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(part two) examines the effect of a series of additives on the RSA of a different human 
monoclonal IgG1 (mAb-C) that has been previously shown to undergo RSA by an apolar 
mechanism. As reported previously, high solution viscosity was observed for mAb-C at 
relatively high protein concentrations, and potential PPI sites on mAb-C as well as 
potential dominant interaction forces were identified,20,21 as being increasingly driven by 
specific hydrophobic interactions as the solution pH increased from 6 to 8 (approaching 
the mAb-C isoelectric point (pI) range of 9.1–9.4).22 Using HX-MS differential analysis of 
high vs. low concentrations of mAb-C at pH 7.0, it was demonstrated that Fab-Fab 
interactions, including specific CDR regions, rich in hydrophobic and aromatic amino acid 
residues, plays a crucial role in the RSA of mAb-C.22  
It has also been demonstrated that point mutation of specific hydrophobic amino 
acid residues in the mAb-C RSA regions manifested improved solution properties 
(reduced extent of PPIs).15 Concomitantly, however, antigen binding affinity of mAb-C 
decreased significantly (by ~200-400 fold).15 Therefore, modulating mAb-C RSA by 
employing different additives (i.e., evaluating and better understanding the effect of these 
additives) at high protein concentrations was the major goal of this work. We therefore 
evaluated both solution and molecular behavior as well as backbone flexibility alterations 
of mAb-C at various protein concentrations in the absence/ presence of five additives 
known to affect protein hydrophobic interactions to varying extents. 
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Based on previous work showing that certain regions within specific CDRs in mAb-
C (containing many hydrophobic and aromatic amino acid residues) were the dominant 
sites of interaction for mAb-C RSA,20 we selected a series of additives to compare their 
RSA-disrupting properties including a chaotropic salt (guanidine hydrochloride, GdnHCl), 
a hydrophobic salt (trimethylphenylammonium iodide, TMPAI), an aromatic amino acid 
derivative (tryptophan amide hydrochloride, TrpNHR2RHCl), a kosmotropic salt (sodium 
sulfate, NaR2RSOR4R), and a less polar solvent (ethanol). A variety of biophysical techniques 
were employed to examine mAb-C solution properties as well as protein molecular 
behavior in the presence of the excipients. Hydrogen exchange-mass spectrometry (HX-
MS) was also used to better understand the effect of these additives on particular regions 
of mAb-C known to be involved in the RSA of mAb-C. 
3.2. Materials and Methods 
3.2.1. Materials  
MedImmune LLC (Gaithersburg, MD) provided a highly purified IgG1 antibody 
(mAb-C) in a stock solution at 10 mg/mL. A base buffer (BB) solution, selected as the 
baseline condition to examine mAb-C reversible self-association (RSA), contained 40 mM 
potassium phosphate at pH 7.5. The stock solution of mAb-C was first concentrated to 70 
mg/mL and then buffer exchanged into the desired BB solution (with and without various 
additives). Dialysis was performed using 3.5 kDa molecular weight cutoff membranes 
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(Slide-A-Lyzer, Thermo Scientific, Rockford, IL) at 4 oC overnight against BB or BB with 
various additives (including 0.5 M guanidine hydrochloride (GdnHCl); 150 mM sodium 
sulfate (NaR2RSOR4R); 150 mM trimethylphenylammonium iodide (TMPAI); 150 mM 
tryptophan amide hydrochloride (TrpNHR2RHCl), 150 mM phenylalanine amide 
hydrochloride (PheNHR2RHCl), and 15% ethanol). Different excipient concentrations were 
used based on their relative hydrophobicity. For example, TMPAI, TrpNHR2RHCl, 
PheNHR2RHCl and NaR2RSOR4R were examined at a concentration of 150 mM due to these 
molecules possessing aromatic groups and/or displaying salting-out effects at higher 
concentrations. Because of lack of these properties, elevated amounts of GdnHCl were 
used (0.5 M). Finally, as a co-solvent, 15% v/v ethanol was used, and even at this 
concentration, protein precipitation was noted in some experiments (see Results section). 
These additives were obtained from Sigma-Aldrich (St. Louis, MO) or Chem-Impex 
International (“CII”) (Wood Dale, IL).  
3.2.2. Ultraviolet Absorption Spectroscopy 
Protein concentration was measured by ultraviolet absorption spectroscopy 
(AR280nmR) obtained by a Nanodrop 2000 spectrophotometer (Thermo Scientific, Rockford, 
IL) based on the ER1cmR0.1% value of 1.54 mL∙mg-1∙cm-1 which was calculated by the following 
equations.23 
 ε (M−1 ∙ cm−1)  =  (5500𝑛𝑛W)  +  (1490𝑛𝑛Y)  +  (125𝑛𝑛C) (Eq.1) 
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 ε (mL ∙ mg−1 ∙ cm−1)  = ε (M
−1∙cm−1)
MW(g∙mol−1)
 (Eq.2) 
in which, ε is the absorbance extinction coefficient, MW is the molecular weight, 𝑛𝑛W, 𝑛𝑛Y, 
and 𝑛𝑛C are the total numbers of tryptophan, tyrosine, and cysteine residues in mAb-C, 
respectively. 
3.2.3. Viscosity Measurements 
Dynamic viscosity of dialyzed mAb-C sample was measured with and without 
additives at different protein concentrations, from 5 mg/mL up to 60 mg/mL. An m-VROC 
viscometer (Rheosence, San Ramon, CA) along with a temperature control system was 
used for determining mAb-C viscosity at both 4°C and 25°C. The mAb-C sample was 
injected at a constant flow rate through a sensor chip channel, in which four pressure 
sensors monitored the pressure drop from the inlet to the outlet.  
3.2.4. Hydrodynamic Diameter Measurements by Dynamic Light Scattering (DLS) 
To measure mAb-C hydrodynamic diameter, a concentration of 10 mg/mL was 
used with and without additives. A Wyatt DynaPro Plate Reader II dynamic light scattering 
instrument (Wyatt Technology, Santa Barbara, CA) equipped with a 830 nm laser was 
utilized to determine the size of mAb-C in different buffer conditions, based on the Stokes-
Einstein equation: 
 𝐷𝐷H  =
𝑘𝑘∙𝑇𝑇
3∙π∙η∙𝐷𝐷m
 (Eq.3) 
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in which, DRHR is hydrodynamic diameter, k is the Boltzmann constant, T is absolute 
temperature, DRmR is mutual-diffusion coefficient, π is a mathematical constant, and η is the 
solution viscosity. A 20 μL mAb-C sample was pipetted into the well of a 384-well plate, 
and triplicate measurements were performed. Viscosity values were obtained separately 
from a m-VROC viscometer (Rheosence, San Ramon, CA) at 25°C, and automatic 
viscosity correction was implemented in the operating software for calculating the 
corrected hydrodynamic diameter. 
3.2.5. Protein Interaction Parameter (kRD2R) by Dynamic Light Scattering (DLS) 
The kRD2R parameter was obtained to determine RSA propensity of mAb-C in solution 
using DLS.24-28 For solutions containing proteins with high-interaction propensity, the 
mutual-diffusion coefficient (DRmR) is concentration-dependent, and proportional to self-
diffusion coefficient (DRsR), as shown in equation 4 below. 
 𝐷𝐷𝑚𝑚 = 𝐷𝐷𝑠𝑠(1 + 𝑘𝑘𝐷𝐷 ∙ c) (Eq.4) 
where kRDR is the overall protein interaction parameter, and c is the protein concentration. 
The kRDR expansion equation contains more specific parameters as shown below. 
 k𝐷𝐷 = k𝐷𝐷2 + k𝐷𝐷3 ∙ c + k𝐷𝐷4 ∙ c2 … … (Eq.5) 
The second, third, fourth… interaction sub-parameters will appear more notable 
as the protein concentration goes higher and higher. Usually within a certain protein 
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concentration range, one specific interaction sub-parameter will be dominant, reflecting 
the major interaction force from PPIs. In this study, a protein concentration range of 1-10 
mg/mL mAb was used to determine protein interaction parameter for mAb-C, and 
according to the experimental results, kRD2R was the major factor influencing mAb-C PPIs, 
so other sub-parameters will be much smaller than kRD2R, and didn’t contribute significantly 
to kRDR. Based on the Taylor expansion (Eq.6) and expanded DLS equation (Eq.7), a final 
equation to determine the kRD2R parameter was obtained (Eq.8) as shown below. 
 1 + x + 𝑥𝑥2 + 𝑥𝑥3 + ⋯ = 1
1+𝑥𝑥
 (Eq.6) 
 D𝑚𝑚 = D𝑠𝑠(1 + k𝐷𝐷2 ∙ c + k𝐷𝐷3 ∙ c2 + k𝐷𝐷4 ∙ c3 … … ) (Eq.7) 
 1
Dm
= 1
Ds
− c ∙ kD2
Ds
 (Eq.8) 
Therefore, there is a linear relationship between 1/DRmR and c, with 1/DRsR as the 
intercept, and kRD2R/DRsR as the slope. A negative value of kRD2R means attractive interactions 
between mAb molecules, and a positive value of kRD2R shows repulsive interactions. In 
addition, the larger the absolute value, the stronger protein interactions present in 
solution.29-32 The kRD2R and DRsR values were obtained in the units of L/kg and m2/s, 
respectively. 
3.2.6. Composition-Gradient Multi-Angle Light Scattering (CG-MALS) 
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To identify and quantify various oligomeric mAb-C species in solution, CG-MALS 
was used, where CG (a dual syringe-pump Calypso sample preparation and delivery unit 
from Wyatt Technology, Santa Barbara, CA) is a solution pump used to prepare a series 
of mAb-C solutions at different concentrations, and MALS is a system for detecting static 
light scattering signals and analysis (at room temperature). For each solution condition 
with or without additives, samples of two mAb-C (2 and 20 mg/mL) were prepared in a 
volume of about 5 mL and filtered through a 0.22-micron Millex-GV syringe filter unit (EMD 
Millipore, Billerica, MA) before loading onto the CG pump system. Different 
concentrations of mAb-C in a range of 0.2-20 mg/mL were sequentially prepared for 
analysis. To correlate the scattering signal induced by the protein to its molecular 
properties, the excess scattering intensity was normalized per unit volume as well as solid 
angle depending on the incident intensity. Finally, a series of association models were 
evaluated by fitting light scattering data points at different mAb concentrations by using 
the Calypso software (Wyatt Technology, Santa Barbara, CA).33 A data fitting model with 
Chi2 (χ2) testing was used to determine the best association/dissociation model for mAb-
C with or without various additives.33 Data were plotted as each oligomer fraction as a 
function or mAb-C concentration. 
3.2.7. PEG-Induced Precipitation Assay  
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The relative apparent solubility (thermodynamic activity) values of mAbs can be an 
important property to monitor, especially when high-protein-concentration mAb solutions 
need to be manufactured.34 Samples of mAb-C prepared in base buffer (BB, 40 mM 
potassium phosphate buffer at pH 7.5) with or without additives were prepared with a 
stock solution of PEGR10,000 R(20% w/v PEG) to obtain a series of PEG solutions (from 0% 
to 20% w/v PEG). Protein solutions with varying concentrations of %PEG were 
transferred to a UV-transparent 96-well plate (Greiner Bio-One North America Inc., 
Monroe, NC) for concentration measurement by AR280nmR values using a spectraMax® M5 
Multi-Mode Microplate Reader (Molecular Devices, Inc., Sunnyvale, CA). However, 
A280nm could not be obtained for all solutions including the ones containing TMPAI, 
TrpNHR2RHCl, or PheNHR2RHCl. For these mAb solutions, alternative methods were utilized 
for mAb-C concentration determination including a BCA assay kit (Thermo Fisher 
Scientific, Waltham, MA) or size exclusion chromatography (SEC) (as described below). 
Standard curves were established for these two methods, shown in Supplemental Figure 
S1. Determination of mAb-C concentration in the PEG precipitation assay was obtained 
using the same procedure and calculated via standard curve. 
A standard 4-parameter, modified Hill-slope sigmoidal curve equation35 was used to fit 
PEG assay data using Origin software. 
 𝑦𝑦 = b + t−b
1+𝑒𝑒𝑠𝑠(𝑚𝑚𝑚𝑚𝑚𝑚−𝑥𝑥)
 (Eq.9) 
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in which, mid is x-axis midpoint, t is the top plateau, b is the bottom plateau, and s is the 
slope. Furthermore, by the replotting of the transition-region data points (from fitted 
sigmoidal curve) into Y axis log scale, the relative apparent solubility can be determined 
at 0% PEG solution by performing an extrapolation based on the following equation.36 
 LogS = LogS0 − β ∙ [PEG] (Eq.10) 
where SR0R is the apparent solubility of mAb-C in PEG-free buffer, S is the observed 
apparent solubility of mAb-C in PEG-containing buffers, and [PEG] is the concentration 
of PEGR10,000R. 
3.2.8. Lyophilization of mAb-C Samples 
Both 5 mg/mL and 60 mg/mL of mAb-C in 20 mM potassium phosphate buffer at 
pH 7.5 were prepared with 10% w/v trehalose for lyophilization. FIOLAX® clear 1 mL glass 
vials (Schott North America, Elmsford, NY) were used to hold the mAb-C samples (0.5 
mL), and were partially stoppered by 2-leg, 13 mm siliconized rubber stoppers (Wheaton 
Industries Inc., Millville, NJ). Lyophilization was performed using a LyoStar II lyophilizer 
(SP Scientific, Warminster, PA) employing a conservative freeze drying cycle over ~3 
days as described previously.20 Cake appearance was determined visually and recorded 
in photos of the post-lyophilization samples. After filtration with 0.22-micron membrane, 
reconstituted mAb-C samples were measured to determine their protein concentration 
using AR280nm Rvalues as described above. 
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3.2.9. Size Exclusion Chromatography (SEC) 
A SEC-HPLC system with an inline UV absorbance detector at 214 nm was used 
to measure species for post-lyophilization mAb-C samples as described in detail 
elsewhere.33 Two analytical columns (a 7.8 mm × 30 cm Tosoh TSK-Gel BioAssist 
G3SWxL and a 6.0 mm x 4 cm guard column [TOSOH Biosciences, King of Prussia, PA]) 
were utilized to separate varying species. A mobile phase of 200 mM phosphate buffer 
(pH 6.8) at a flow rate of 0.7 mL/min was used to elute mAb-C samples. Monomer, 
fragment, and soluble aggregates (e.g., dimer) of post-lyophilization mAb-C samples 
were determined and then compared to non-lyophilized samples based on peak areas at 
5 and 60 mg/mL protein concentrations. The amount of insoluble aggregates were 
calculated by the difference between the total areas of the SEC chromatograms of the 
lyophilized and non-lyophilized mAb-C samples. 
3.2.10. Karl-Fischer Titration 
The moisture content of lyophilized mAb-C samples was measured by Coulometric 
Karl-Fischer (KF) titration following vendor instructions and as described in detail 
elsewhere.37 Water content of lyophilized mAb-C freeze-dried cakes was obtained with 
units of ppm (parts per million). The following is the standard reaction equation (Eq. 11) 
for the KF reaction to determine water content of samples. 
ROH + SO2 + 3RN + I2 + H2O → (RNH) ∙ SO4R + 2(RNH)I (Eq.11) 
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3.2.11. Circular Dichroism (CD) 
In order to confirm the native structure of mAb-C after lyophilization, a Chirascan 
Plus Circular Dichroism Spectrometer (Applied Photophysics Ltd., Leatherhead, UK) was 
used to determine any secondary structure alterations before and after lyophilization as 
described in detail elsewhere.20 Far-ultraviolet (UV) CD spectra of lyophilized and non-
lyophilized mAb-C samples (0.2 mg/mL) were collected from 200 nm to 260 nm using 0.1 
cm path length quartz cuvettes. 
3.2.12. Excipients Deuteration 
To provide a low H environment and minimize their effects on hydrogen exchange, 
each of the additives used in this study were put into pure DR2RO to remove all 
exchangeable H and replaced by D, except ethanol, which was directly purchased in 
deuterated form as ethanol-dR6 R(Sigma-Aldrich, Inc., St. Louis, MO). Additive-containing 
DR2RO was dried in a VacufugeTM vacuum concentrator (Eppendorf, Hauppauge, NY) at 
30oC overnight until only excipient crystals remained. After repeating this procedure 3 
times, exchangeable H in excipients should be essentially fully replaced by D. Then the 
excipient crystals were reconstituted in a DR2RO-based 20 mM potassium phosphate buffer 
at pH 7.5. Finally, DR2RO buffers were re-adjusted with deuterium oxide and/or deuterium 
chloride to obtain a final solution pH of 7.5, without further correction for the deuterium 
isotope effect.  
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3.2.13. Hydrogen Exchange-Mass Spectrometry (HX-MS) 
Labeling was initiated for both 5 and 60 mg/mL lyophilized mAb-C samples when 
they were reconstituted with DR2RO-based buffers (containing deuterated excipients). The 
reconstituted mAb-C samples were centrifuged to remove air bubbles and any potential 
insoluble aggregates, and then equilibrated at 25oC on an Echotherm chilling/heating 
plate (Torrey Pines Scientific, Inc., Carlsbad, CA). The labeling reaction was for 3600 sec 
which was then quenched by a volume ratio of 1 to 9 mixing with a quench buffer (0.5 M 
tris (2-carboxyethyl) phosphine hydrochloride (TCEP), 4 M guanidine hydrochloride, and 
0.2 M sodium phosphate at pH 2.5 pre-equilibrated at 1°C). A LEAP H/DX PAL (LEAP 
Technologies, Carrboro, NC), with a refrigerated column compartment (containing an 
immobilized pepsin column, desalting trap column, and C18 column)20,33, and an Agilent 
1260 infinity series LC (Agilent Technologies, Santa Clara, CA) were used for sample 
injection, online protein digestion, desalting, peptide concentration and separation. The 
pepsin column was cleaned by two washes after each injection to minimize peptide 
carryover,38 and double gradients with mobile phases composed of water or 90% 
acetonitrile, both containing 0.1% (v/v) formic acid, were performed to firstly separate 
peptides and secondly clean the system. From quenching, samples were kept at 1°C to 
minimize back exchange until introduced into an Agilent 6530 quadrupole-time of flight 
mass spectrometer (Q-TOF Agilent Technologies, Santa Clara, CA). Peptide ionization 
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was produced by a standard electrospray ionization source operated in positive mode, 
and different m/z signals of each peptide were distinguished by a TOF analyzer. More 
details concerning this hydrogen exchange methodology have been published 
previously.33 
3.2.14. HX-MS Data Processing and Analysis 
Pepsin digested peptides were identified by peptide mapping with a mass accuracy 
range of ± 10 ppm. Tandem MS with collision induced dissociation on the quadrupole-
time of flight mass spectrometer (Agilent 6530 QTOF MS) was applied to confirm 
identified peptides. HDExaminer software (Sierra Analytics, California) was employed to 
analyze three replicate sets of HX data. Manual inspection was also performed to 
minimize bias from the automatic analysis by HDExaminer. Deuterium uptake plots with 
average deuterium uptake values as well as standard deviations were obtained based on 
three replicates. The 99th percentile of the standard deviations based on triplicate 
measurements was obtained (±0.67 Da) as the critical criteria in our dataset,20 indicating 
a threshold for the significant differences.  
3.2.15. Homology Modeling and Protein-Additive Docking 
A mAb-C homology model, built previously to demonstrate potential RSA regions 
at high protein concentrations,39 was based on the mAb-C primary sequence, and crystal 
structures of an isolated Fc and an in-silico generated KOL/Padlan structure of an 
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Fab.40,41 The homology model was then prepared, charged, and minimized via a 
Molecular Operating Environment (MOE 2016 of Chemical Computing Group ULC).42 The 
complementarity determining regions (CDRs) of mAb-C were identified by MOE software 
based on sequence analysis of the variable regions. Hydrophobic patches of 170 Å2 of 
solvent-accessible surface area were also identified in MOE. Simple local rigid body 
docking between mAb-C RSA interfaces and selected excipients were modelled using 
MOE software based on a combination of energetics and shape complementarity. 
Docking to model the excipients-mAb interface used 100 runs for each compound and a 
triangle marcher technique for placement stage, affinity dG for rescoring and forcefield 
method for refining. Potential docking locations and lowest-energy poses (less than -7 
kcal/mol) were demonstrated using a mAb-C homology model. 
3.3. Results 
3.3.1. Additive Effects on Solution Properties of mAb-C 
The viscosity of mAb-C solutions of increasing protein concentration was 
measured in base buffer (BB) alone and in the presence of five additives at two 
temperatures, 4oC and 25oC. As shown in Figure 1, the dynamic viscosity values 
increased exponentially as a function of protein concentration. For example, values of 
12.8 and 3.5 centipoise (Cp) are seen at a protein concentration of 60 mg/mL in BB alone 
at 4oC and 25oC, respectively. The addition of the different additives to mAb-C solutions 
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perturbed the solution dynamic viscosity at all temperatures. GdnHCl had the largest 
effect on reducing the viscosity of mAb-C solutions, showing values of 4.7 and 2.1 Cp at 
a protein concentration of 60 mg/mL at 4oC and 25oC, respectively. Similarly, both TMPAI 
and TrpNHR2RHCl also decreased the solution viscosity of mAb-C with TMPAI showing 
comparatively greater effect. Since solution viscosity is related to PPIs, especially at high 
mAb-C concentrations, the ability of these three excipients to reduce viscosity is probably 
due to their RSA-disrupting properties.2,7,19 Interestingly, NaR2RSOR4R had the opposite effect, 
resulting in increased mAb-C solution viscosity. For example, at a protein centration of 60 
mg/mL, a viscosity value of 16.5 Cp was observed at 4oC in BB containing NaR2RSOR4R 
compared to 12.8 Cp in BB alone. Due to varying amounts of precipitation observed with 
some of the mAb-C solutions at 4oC, dynamic viscosity measurements for mAb-C were 
not performed in 15% (v/v) ethanol.  
3.3.2. Additive Effects on Molecular Behavior of mAb-C 
The relative apparent solubility (thermodynamic activity) as determined by 
PEGR10,000 Rinduced precipitation assay is not only an indicator of PPIs,43 but also provides 
a practical rank ordering of excipient effects on relative protein solubility. Sigmoidal curves 
of mAb-C protein concentration as a function of the amount of %PEGR10,000R were obtained 
in the absence and presence of additives as shown in Figure 2A. The %PEGRmidptR values 
(the amount of PEGR10,000R needed to precipitate half of the total protein in solution) 
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obtained for mAb-C in the presence of each additive are shown in Figure 2b. In BB alone, 
a %PEGRmidptR value of 4.0% was obtained, while in the presence of the additives, this value 
changed in different directions and varying magnitudes. For example, GdnHCl, TMPAI, 
and TrpNHR2RHCl showed increased %PEGRmidptR values of 7.4, 5.8, 5.3% respectively, 
indicating higher relative solubility of mAb-C in comparison to that in BB. With ethanol, 
however, the relative solubility of mAb-C decreased showing a %PEGRmidptR value of 2.0%. 
Moreover, in the presence of NaR2RSOR4R, mAb-C showed higher relative solubility 
(%PEGRmidptR value of 5.0%) at an excipient concentration of 150 mM, but lower relative 
solubility (%PEGRmidptR value of 2.5%) in 0.5 M NaR2RSOR4R. Finally, the apparent solubility 
values in the absence of PEGR10,000R in solution were estimated by extrapolation of the 
linear portion of data in Figure 2a as plotted in Figure 2c and displayed in Figure 2d. The 
results are overall consistent with the trend of excipient effects on the relative solubility of 
mAb-C as reflected by the %PEGRmidptR values.  
The effect of these five additives on the average size of mAb-C complexes in 
solution were determined by dynamic light scattering (DLS) as shown in Figures 3. In 
general, the hydrodynamic diameter of an antibody molecule is around 9-12 nm.44 In 
contrast, DLS measurements showed a hydrodynamic diameter of 22 nm for mAb-C in 
the base buffer at 10 mg/mL indicating mAb-C molecules are prone to form larger-size 
complexes. In the presence of GdnHCl, mAb-C showed a diameter value of 12 nm 
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(consistent with monomer) indicating a disruption of the complexes. Similarly, TMPAI, 
TrpNHR2RHCl, and ethanol also possessed some ability to reduce mAb-C hydrodynamic 
diameter by disrupting PPIs, displaying values of approximately 13 nm, 15 nm, and 18 
nm, respectively. The addition of NaR2RSOR4R resulted in the opposite effect, increasing the 
hydrodynamic diameter of mAb-C to 31 nm, a result consistent with NaR2RSOR4 Reffects on 
mAb-C solution viscosity (indicating an ability to promote intermolecular interactions 
among mAb-C molecules). Polydispersity index values between ~10-20% were observed 
for all samples.  
The protein interaction parameter, kRD2,R for mAb-C was also measured by DLS in 
the presence and absence of the five additives. Positive and negative values for kRD2R 
indicate repulsive and attractive interactions between mAb-C molecules, respectively. As 
shown in Figure 3b, a kRD2R value of -81 mL/g was measured for mAb-C in BB, indicating 
extensive attractive interactions between mAb-C molecules. Values of kRD2R of -11, -35, -
44, or -50 mL/g in the presence of GdnHCl, TMPAI, TrpNHR2RHCl, or ethanol, respectively, 
were observed indicating their ability to weaken mAb-C PPIs. NaR2RSOR4R resulted in a kRD2R 
value of -161 mL/g consistent with stronger attractive interactions for mAb-C. In summary, 
the values of both hydrodynamic diameter and protein interaction parameter (kRD2R) as 
measured by DLS showed similar trends of excipient effects on RSA of mAb-C. 
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The size and nature of mAb-C complexes in solution were further examined by 
static light scattering using CG-MALS as shown in Figure 4. The fraction of each species 
was calculated based on curve-fitted the scattering signal as a function of protein 
concentration. For example, as displayed in Figure 4a, the monomeric fraction of mAb-C 
in the base buffer decreased as protein concentration increased. Concomitantly, 
multimers of mAb-C including dimer, trimer and hexamer increased. In the presence of 
0.5 M GdnHCl, the distribution of species vs protein concentration was dramatically 
altered. As shown in Figure 4b, >95% of mAb-C remained monomeric across the 
concentration range examined. In Figure 4c and d, it can be seen that the addition of 
0.15M TMPAI and TrpNHR2RHCl reduced the extent of complex formation for mAb-C, but 
to a lesser extent than GdnHCl, protecting monomeric mAb-C from becoming oligomeric 
species. In contrast, mAb-C in a 15% ethanol-containing solution showed a similar 
speciation profile, but comparatively different multimer pattern, compared to BB alone 
(Figure 4e). Finally, as shown in Figure 4f, a rapid decrease of monomeric mAb-C along 
with a rapid increase of hexamers were observed in mAb-C solution in the presence of 
0.15M NaR2RSOR4R as the mAb-C concentration was increased. 
To better compare and visualize these additive effects on mAb-C solution and 
molecular properties, the preceding results can be displayed as radar charts (Figure 5). 
Comparative results for dynamic viscosity values (at a protein concentration of 60 mg/mL 
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at 4oC), apparent solubility values, fraction of monomeric mAb-C from CG-MALS (at 20 
mg/mL), and protein interaction kRD2R values are displayed in Figure 5a-d, respectively. 
Each corner of the individual radar chart represents a solution condition (BB, BB with 
GdnHCl, TMPAI, TrpNHR2RHCl, ethanol, and NaR2RSOR4R clockwise from the top corner). By 
summarizing the data together, differential effects of the five different additives on mAb-
C can be more easily assessed. Three additives show consistent RSA-disruption effects 
with a ranking order of GdnHCl > TMPAI > TrpNHR2RHCl. In contrast, although ethanol 
demonstrates and ability to disrupt PPIs of mAb-C, it had detrimental effects on relative 
solubility. Finally, NaR2RSOR4R consistently shows RSA-promotion effects on mAb-C across 
the different measurements at high concentrations. 
3.3.3. Alteration of mAb-C RSA Propensity by Excipients as Measured by HX-MS 
To better understand backbone flexibility alterations of mAb-C in the presence of 
these five additives at high vs. low protein concentrations, hydrogen exchange-mass 
spectrometry (HX-MS) was employed. The deuterium environment of mAb-C was 
provided by a lyophilization-reconstitution method at 5 and 60 mg/mL, as described 
previously.20 Briefly, mAb-C was first lyophilized and then reconstituted with excipient-
containing DR2RO. To confirm the integrity of lyophilized mAb-C samples, analytical 
characterization of reconstituted mAb-C was performed, as shown in Supplemental 
Figure S2 and Supplemental Table S1. As shown by a combination of visual inspection 
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(acceptable cake integrity), moisture content (0.5-2.0% water by Karl Fischer titration), 
overall secondary structure (similar CD spectra), and absence of aggregation (~99% 
protein recovery with 98-99% monomer as determined by UV spectroscopy and SEC 
analysis, respectively), lyophilized mAb-C samples retained their integrity after 
lyophilization and reconstitution. Thus these samples are suitable for use in HX-MS 
analysis. 
After reconstitution with DR2RO buffer to trigger mAb-C amide-hydrogen labeling in 
the presence or absence of the five additives, a 3600 seconds incubation was performed 
before quenching the HX reaction. Peptides were obtained by immobilized pepsin 
digestion and analyzed by LC-MS as described in the Supporting Information. A total of 
200 peptides were confirmed (see Supplemental Table S2), with 98% and 100% 
sequence coverage of the heavy chain and light chain, respectively. The mass difference 
for each peptide was obtained based on 5 and 60 mg/mL protein concentrations, both 
with and without excipients. A value of 0.67 Da, representing a 99% confidence interval 
significance criteria for peptide mass differences was used to identify significantly different 
HX between 60 and 5 mg/mL. As shown in Figure 6, HX differences for each peptide are 
plotted in the absence and presence of excipients. For panel a, ∆HX = HX (BB, 60 mg/mL) 
– HX (BB, 5 mg/mL); and for panels b-f: ∆HX = HX (BB + excipient, 60 mg/mL) – HX (BB 
+ excipient, 5 mg/mL).  
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Although RSA sites were determined previously for mAb-C at 60 mg/mL at pH 
7.0,20 additional regions of mAb-C might be involved in PPIs at pH 7.5, used here to 
deliberately increase mAb-C RSA propensity. Five significant protection regions of mAb-
C at pH 7.5 were observed, as shown in Figure 6a. As reported previously, the CDR L2 
region was the primary RSA site for mAb-C at pH 7.0, where it showed strong protection 
at high protein concentration.20 The CDR H2 was also observed to have increased 
protection at high protein concentrations, especially at shorter labeling times.20 In this 
study (Figure 6a), consistent with these previous results, significant protection was 
observed in the CDR L2 region (sequence YR504RVASSLQSR511R, peptide 156-161), however 
HX differences in the CDR H2 region did not exceed the significance limit at the single 
HX time point examined. Additional regions of mAb-C showed protection at pH 7.5 
covering CDR H1 (sequence GR11RYTFTGYYMHWVR22R, peptide 3-11), the beginning region 
of CRHR1 (sequence VR123RSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTR163, 
Rpeptide 61-69), and the end region of CRHR3 (sequence AR439RLHNHYTQKSLSLSPGR454, 
Rpeptide 140-145), and CDR L3 (sequence FR538RATYYCQQANSFPWTR552, Rpeptide 171-
176), indicating extensive, multi-region intermolecular interactions. 
Different additives were examined for their ability to either promote or disrupt 
regions of RSA within mAb-C. Consistent with the biophysical results, the most efficient 
solute in terms of disrupting RSA interaction sites within mAb-C was GdnHCl (Figure 6b) 
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where essentially all of the RSA sites were diminished except for the one located in the 
CRHR3 region. As shown in Figure 6c and d, TMPAI and TrpNHR2RHCl also had the ability to 
disrupt RSA between mAb-C molecules, especially in the CDR H1, CDR H2, CDR L2, 
and CDR L3 regions, although some weak protection still exists. For other regions of RSA, 
however, these two additives did not affect mAb-C RSA-induced protection. As for ethanol 
effects (Figure 6e), only the RSA regions on the light chain variable regions of mAb-C 
were disrupted, and little effect was seen on the other RSA sites. In contrast, as shown 
in Figure 6f, NaR2RSOR4R promoted protection during deuterium exchange of mAb-C, 
especially within the RSA regions.  
To better visualize these specific RSA regions on mAb-C at pH 7.5, the HX-defined 
RSA interface is shown mapped onto a mAb-C homology model shown in Figure 7. 
Molecular modeling using MOE software (see Methods section) was utilized to examine 
additive binding as shown in Figure 8. The colored structures highlight the CDR regions 
while the remaining regions of the mAb are shown in white. The RSA interaction sites, 
based on HX-MS results, are highlighted in the space-filling representation as shown on 
the left-side panel in Figure 7. This shows that the variable regions of both the heavy and 
light chains are primarily responsible for mAb-C RSA, with a small hydrophobic site at the 
end of CRHR3 domain also contributing to RSA. As an additional analysis, hydrophobic 
patches, shown in green areas on the right-side panel homology model in Figure 7 were 
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identified in the homology model. Interestingly, some of the top-ranked hydrophobic 
patches (greater than 200 Å2 solvent-accessible surface area) overlap with the RSA sites. 
Modeling based on local rigid docking was then performed at the major RSA rites in the 
CDR regions of both heavy and light chains of mAb-C with three of the additives, GdnH+, 
TMPA+, and TrpNHR2RH+. Interactions stronger than -7 kcal/mol are shown on the Fab 
homology model of mAb-C in Figure 8. Five locations were found for GdnH+ to interact 
with these mAb-C CDR regions, while only three locations were detected for TMPA+ and 
TrpNHR2RH+. 
3.4. Discussion 
Although protein engineering approaches have been shown in some cases to 
mitigate mAb intermolecular protein-protein interactions (and thus optimizing solution 
properties at high mAb concentrations),15,16,45,46 a more straight-forward strategy (that 
does alter the molecule itself) is excipient addition to improve the solution properties of 
mAbs at high concentrations. This can be pursued by either an excipient screening 
approach to semi-empirically identify stabilizers,47 or by a more rational additive selection 
process based on a mechanistic understanding of RSA interactions for a particular mAb 
(as outlined in the companion paper in this issue with mAb-J). In this work, we continue 
to examine the latter, more targeted approach to excipient selection by using HX-MS to 
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identify regions of mAb-C (and associated molecular mechanisms) resulting in a more 
rational selection of additives to disrupt specific RSA interactions within a mAb.  
As reported previously, a major RSA site on mAb-C was CDR L2 at pH 7.0. This 
involved regions containing hydrophobic and aromatic amino acid residues that appeared 
to result in protein-protein interactions among mAb-C molecules.20 In this work, as we 
increased solution pH from 7.0 to 7.5, not only the CDR L2 region, but additional regions 
within mAb-C showed protection from deuterium exchange when comparing high vs. low 
protein concentrations by HX-MS (Figure 6). This indicates more PPI sites mediated in 
RSA of mAb-C under these conditions. Since mAb-C has an isoelectric point (pI) ranging 
from 9.1-9.4 (data not shown), the protein will have less net positive charge, and thus 
weaker charge repulsion, presumably allowing mAb-C molecules to more easily self-
associate at pH 7.5 (vs. pH 7.0). Computational mapping of hydrophobic patches on mAb-
C, as shown in Figure 7, is in general agreement with the protected surfaces identified by 
HX-MS, consistent with apolar interactions being a major force that drives mAb-C RSA. 
It is quite possible, however, that additional cross-interactions (e.g., Fab-Fab, Fab-Fc) 
sites between mAb-C molecules under these conditions (base buffer at pH 7.5) form 
leading to additional interaction networks.18,20,33,48,49 Hydrophobic interactions between 
mAb-C molecules at high protein concentrations are probably not the only source that 
induce PPIs. Other weak intermolecular forces, such as dipole-dipole coupling, hydrogen 
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bonding, or even electrostatic interactions, could also contribute to mAb-C RSA to some 
extent.20  
Similar to the HX-MS analysis described in the companion paper with mAb-J, 
potential chemical exchange rate differences in mAb-C formulated with the various 
additives prevent direct comparisons between HX kinetics in the different formulations.50 
Thus, we focused on HX difference between high and low protein concentrations of mAb-
C in the presence of each additive separately. PPIs of mAb-C in base buffer were not 
only observed at the high concentration (60 mg/mL), but also detected, albeit to a much 
lower extent, at the low protein concentration (5 mg/mL). For example, this was seen by 
CG-MALS analysis examining the size distribution of mAb-C at ~1-20 mg/mL. HX-MS 
analysis was primarily based on the difference of RSA extent between high and low 
protein concentrations. Thus, we are comparing conditions with more vs less RSA rather 
than complete vs no RSA. Such HX-MS analysis shows that several specific regions of 
mAb-C undergo PPI resulting in protection of these regions from hydrogen exchange 
(Figure 6a).  
3.4.1. Effects of Hydrophobic (TMPAI and TrpNHR2RHCl) and Chaotropic (GdnHCl) 
Salts on RSA of mAb-C 
In the presence of the additives either with hydrophobic apolar character, including 
TMPAI (I- is also a stronger chaotrope than Cl-) and TrpNHR2RHCl (both at 0.15M), or with 
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properties attributed to chaotropes, including GdnHCl (at 0.5M), HX-MS analysis shows 
several RSA regions within mAb-C had diminished protection from hydrogen exchange, 
especially at CDR H1, CDR H2, CDR L2, and CDR L3 (Figure 6b-d). Beyond the CDRs, 
there were a few additional regions of mAb-C that show protection at high concentration. 
For example, the end of CRHR3 region in the presence of GdnHCl, and both the beginning 
of CRHR1 and the end of CRHR3 in the presence of TMPAI and TrpNHR2RHCl manifest protection. 
Such phenomena probably indicates that these three excipients could dissociate higher-
order oligomeric mAb-C complexes to smaller dimeric or trimeric forms (consistent with 
CG-MALS studies). Thus, the remaining interactions at CRHR1 and/or CRHR3 regions are 
possibly a signature of difference between dimeric/trimeric complexes of mAb-C.  
Combining these HX-MS results with the biophysical and solution measurements, 
it can be seen that GdnHCl, TMPAI, and TrpNHR2RHCl all displayed an ability to disrupt 
RSA interactions within mAb-C with a rank ordering of effectiveness of GdnHCl > TMPAI > 
TrpNHR2RHCl. Presumably, the major effects of these additives are mediated by the cations: 
GdnH+, TMPA+, and TrpNHR3R+. Several types of protein-excipient interactions (hydrogen 
bonding, preferential hydration, electrostatic interactions, dispersive interactions, cation–
π interactions) could each effectively disrupt the PPIs within proteins.51,52 Although 
TMPAI and TrpNHR2RHCl have the potential for π–π interactions (via their aromatic rings 
interacting with aromatic rings in amino acid residues in mAb-C), GdnHCl, as a chaotropic 
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salt,53 was more effective in terms of diminishing PPIs for mAb-C.54 Preferential 
interactions of GdnHCl with mAb-C might more effectively compete PPIs.52 However, 
comparisons are complicated because I- from TMPAI is a stronger chaotrope than Cl-.55 
Therefore, albeit similar properties exist between cations of TMPAI and TrpNHR2RHCl, the 
anions of these two additives, including I- and Cl-, may play roles that differentiate their 
RSA-disrupting efficiency.56,57 Furthermore, the size of the cations may also be a 
determining factor since their rank order by size is GdnH+<TMPA+<TrpNHR2RH+ which 
reverses the rank order of their effectiveness in disrupting RSA. Therefore, steric 
hindrance might decrease the tendency for larger excipients to interact with the surface 
of mAb-C; it may be easier for smaller excipients to access shallow pockets on the mAb-
C surface. Consistent with this hypothesis, we found in protein-excipient docking analysis 
that there were more potential interaction sites for GdnH+ than for the other two excipients 
(Figure 7). Although GdnHCl showed greater ability to disrupt PPIs compared to the other 
two hydrophobic salts, the concentration used in this study was higher, and guanidine 
decreased the conformational stability of mAb-C, as indicated by lower thermal melting 
temperature values (data not shown). 
3.4.2. Effects of Ethanol on RSA of mAb-C 
In the case of the HX-MS results for mAb-C in the presence of 15% ethanol, 
several unique trends were observed. For example, many of the RSA regions within mAb-
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C were retained, except for the CDR L2 and CDR L3 regions, thus resulting in either a 
diminished RSA of mAb-C at 60 mg/mL or promotion of RSA at 5 mg/ml, but to a lesser 
extent than observed in the presence of either GdnHCl, TMPAI, and TrpNHR2RHCl, or 
NaR2RSOR4R, respectively. In comparison to mAb-C in BB alone, there was also one region 
(middle of CRLR1) that shows increased protection at high protein concentration in the 
presence of ethanol (Figure 6e).  
Ethanol, as a less polar solvent, was used to determine its effects on mAb-C PPIs. 
As shown in Figures 2, 3, 4 and 6, the results of relative solubility, DLS, CG-MALS and 
HX-MS demonstrated a contradictory trend on the extent of RSA for mAb-C in the 
presence of ethanol. Moreover, the conformation of mAb-C was also easily perturbed as 
a function of temperature with ethanol in solution (data not shown). It has been broadly 
reported that ethanol could alter both intramolecular and intermolecular interactions by 
preferentially interacting with hydrophobic residues,58-60 but it also, depending on the 
temperature, decreases protein solubility to different extents.60-63 In fact, due to lower 
protein solubility in ethanol,64,65 the addition of ethanol led to the precipitation of mAb-C 
in high concentration solutions during viscosity measurements especially at lower 
temperatures. Finally, addition of ethanol could alter original solution hydrogen bonding 
networks, surface tension, and density, which may further perturb the molecular behavior 
of mAb-C.66,67 As a result, multiple effects of ethanol on mAb-C created diverse 
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observations based on different biophysical or HX techniques, requiring more systemic 
studies to better understand its complicated effects on mAb-C.  
3.4.3. Effects of NaR2RSOR4R on RSA of mAb-C  
 In the presence of 0.15M NaR2RSOR4R, elevated levels of PPIs within mAb-C were 
detected by HX-MS, showing overall an even more extensive extent of protection within 
the mAb-C RSA regions (Figure 6f). NaR2RSOR4 Rwas the only additive examined in this work 
that promoted mAb-C RSA, as observed in all biophysical and HX analysis. This resulted 
in relatively higher solution dynamic viscosity as well as a larger hydrodynamic size (and 
a larger protein interaction parameter) of mAb-C complexes as measured by DLS. As a 
kosmotropic salt, NaR2RSOR4 Ris excluded from surfaces of mAb-C molecules, and at the 
same time increases surface tension of bulk water, which likely contributes to mAb-C 
molecules forming relatively larger higher-order oligomeric species (as shown in CG-
MALS studies in Figure 4).68,69 In comparison to mAb-C in BB alone, 150 mM of NaR2RSOR4 
Radded to BB shows increased relative solubility of mAb-C, while 0.5 M of NaR2RSOR4R 
reduced its solubility. At relatively low concentrations (150 mM) of NaR2RSOR4R, salting-in 
(charge-shielding) effects are probably the dominant factor that increases mAb-C 
solubility as described by Debye-Huckel theory.70 Essentially, mAb-C molecules are 
surrounded by salt counterions, screening their charges, which will decrease the 
electrostatic free energy of mAb-C molecules and increase solvent activity, and finally 
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lead to higher relative solubility.70 At higher salt concentrations (0.5 M), however, salting-
out effects begin to dominant as the major influence. Here water molecules are attracted 
by salt ions, and a decreased number of water molecules interacting with mAb-C, leading 
to protein dehydration, and thus stronger PPIs among mAb-C molecules and ultimately 
protein precipitation.71 
3.5. Conclusions 
In this work (Part II) with mAb-C, along with a companion paper (Part I) in this issue 
with mAb-J, we examined the role of additives and excipients in disrupting and enhancing 
specific protein-protein interactions that lead to the RSA of two different IgG1 mAbs at 
high protein concentrations. In this work, the solution properties, molecular features and 
backbone flexibility (at specific sites known to facilitate RSA) were evaluated for a human 
monoclonal IgG1 antibody (mAb-C), previously demonstrated to undergo RSA via Fab-
Fab interactions (at specific peptide segments within the CDR regions of mAb-C rich in 
hydrophobic amino acids). These parameters were evaluated in the presence a 
chaotropic salt (GdnHCl), hydrophobic salt (TMPAI), aromatic amino acid derivative 
(TrpNHR2RHCl), kosmotropic salt (NaR2RSOR4R), and a less polar solvent (ethanol). The ability 
of these additives to disrupt RSA and improve the solution properties of mAb-C at high 
protein concentrations was demonstrated and ranked ordered (GdnHCl > TMPAI > 
TrpNHR2RHCl). Contradictory results were observed for ethanol probably due to 
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coexistence of multiple effects of the less polar solvent on mAb-C. NaR2RSOR4R, on the other 
hand,R Rshowed the opposite effect and promoted the RSA of mAb-C and resulted in less 
desirable solution properties.  
In a companion paper (Part I), similar experiments were performed with a different 
human IgG1 mAb (mAb-J) that displays RSA at high protein concentration primarily 
through a different molecular mechanism (charge interactions between Fab-FC regions 
of the antibody).13 A series of charged excipients were then employed in the companion 
paper to determine their effects on the solution properties, molecular attributes and 
backbone flexibility. By examining two different human IgG1 mAbs (mAb-J and mAb-C) 
that undergo RSA by different molecular mechanisms, these two studies demonstrate a 
rational approach to the development of high concentration mAb formulations by (1) 
determining the molecular mechanism of RSA by HX-MS analysis, (2) selecting specific 
additives expected to disrupt these known intermolecular interactions and rank-order their 
ability to do so by HX-MS, and then (3) evaluating the effects of these specific additives 
on the solution properties (e.g., viscosity) and molecular attributes (e.g., size and relative 
solubility) of the mAb at high protein concentrations. 
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3.7. Figures and Tables 
 
 
 
 
 
 
 
Figure 3.1. Effect of additives on dynamic viscosity of mAb-C solutions at varying protein 
concentrations at (A) 4oC and (B) 25oC. Excipients were at 150 mM, except GdnHCl (0.5 
M) and ethanol (15% v/v) in base buffer (BB). Data are presented as mean ± standard 
deviation; n = 3. 
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Figure 3.2. 
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Figure 3.2. Relative apparent solubility (thermodynamic activity) of mAb-C as measured 
by PEGR10,000R induced precipitation assay. (A) Change of mAb-C concentration as a 
function of %PEGR10,000R added to solution (data fit by sigmoidal curves). (B) %PEGRmidptR 
values are shown in a bar chart, indicating the amount of PEGR10,000R that was needed to 
precipitate half of total protein out of solution. (C) Apparent solubility values were obtained 
from Y-axis extrapolation of data points in the transition range shown in panel A. (D) 
Comparison of the apparent solubility values obtained for mAb-C in the 
absence/presence of various additives. Two concentrations of sodium sulfate (150 mM 
for “NaR2RSOR4R” and 0.5 M for “NaR2RSOR4R*”) were used for this study. Other excipient solutions 
had a concentration of 150 mM, except GdnHCl (0.5 M) and ethanol (15% v/v) in BB. 
Multiple methods were employed to determine protein concentration, including UVR280nmR 
for mAb-C in BB, and BB in the presence of GdnHCl, ethanol, and NaR2RSOR4R; BCA assay 
for mAb-C solution in the presence of TMPAI (Supplemental Figure S1a), and SEC 
method for mAb-C solution in the presence of TrpNHR2RHCl (Supplemental Figure S1b). 
Data are presented as mean ± standard deviation; n = 3. 
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Figure 3.3. Effect of additives on mAb-C hydrodynamic diameter and protein interaction 
parameter (kRD2R) as determined by dynamic light scattering. (A) Hydrodynamic diameter 
(bars, left axis) and polydispersity values (squares, right axis) were determined at a 
protein concentration of 10 mg/mL, and (B) kRD2R values were calculated from a series of 
mAb-C hydrodynamic diameter measurements from 1-10 mg/mL protein concentrations 
at 25oC. Additives concentration was 150 mM, except GdnHCl (0.5 M) and ethanol (15% 
v/v) in BB. DLS cumulative data was weighted by intensity. Data are presented as mean 
± standard deviation; n = 3. 
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Figure 3.4. 
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Figure 3.4. Effect of additives on the self-association induced complexes of mAb-C as 
determined by static light scattering from CG-MALS analysis. Fraction of various species 
was determined as a function of protein concentration in the absence/presence of 
different additives in base buffer (BB) containing (A) BB alone, or BB with (B) GdnHCl, 
(C) TMPAI, (D) TrpNHR2RHCl, (E) ethanol, and (F) NaR2RSOR4R. Concentration of excipients 
was 150 mM, except GdnHCl (0.5 M) and ethanol (15% v/v). Measurements were 
performed at room temperature. All data are presented as mean ± standard deviation; n 
= 3. 
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Figure 3.5. Radar chart array analysis to better visualize excipient effects on mAb-C 
solution and molecular properties. Except for GdnHCl (0.5 M) and ethanol (15% v/v), all 
other additive solutions have a concentration of 150 mM. Specifically, (A) dynamic 
viscosity values at protein concentration of 60 mg/mL, (B) mAb-C apparent solubility 
values in log scale, (C) the fraction of mAb-C monomer at the concentration of 20 mg/mL 
as measured by CG-MALS, and (D) the values of protein interaction parameter (kRD2R). The 
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distance between the perimeters of the two polygons (along an axis) is one standard 
deviation. Triplicate measurements were performed. 
Figure 3.6. 
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Figure 3.6. Effect of additives on mAb-C RSA and backbone flexibility by mass difference 
plot from HX-MS. (A) Mass difference of each peptide between 60 mg/mL and 5 mg/mL 
of mAb-C in BB. Panels (B) GdnHCl (0.5 M), (C) TMPAI (150 mM), (D) TrpNHR2RHCl (150 
mM), (E) ethanol (15% v/v), and (F) NaR2RSOR4 R(150 mM) shows effects of different 
excipients on alteration of protein interactions as well as local peptide flexibility. Alternate 
backgrounds indicate antibody domain boundaries. The number of peptides is ordered 
from the N-to-C termini of the heavy chain followed by the light chain of mAb-C. Positive 
values imply increased backbone flexibility, while negative values mean the opposite. The 
dashed horizontal lines are the 99% confidence criteria. Three independent HX 
measurements was performed. 
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Figure 3.7. RSA interfaces defined and hydrophobic patches visualized on mAb-C. RSA 
interfaces of mAb-C, as defined by HX protection, are shown on the left in space-filling 
representation. Brown, red, and purple colors denote CDR H1, H2, H3, and CDR L1, L2, 
and L3, respectively. Hydrophobic patches (> 200 Å2, and are displayed in green) 
predicted by homology modeling using Molecular Operating Environment (MOE) are 
shown on the right side.  
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Figure 3.8. Local rigid docking of excipients to identify favorable locations for binding on 
the Fab RSA sites of mAb-C at pH 7.5 calculated using MOE. Top-ranking candidates 
(below -7 kcal/mol) are shown on the Fab domain of the mAb-C homology model. For 
additive molecules, blue, yellow, red, green, and dark red represent nitrogen, carbon, 
oxygen, chloride, and iodide respectively. 
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Supplemental Figure 3.1. Standard curves of BCA and SEC using known concentrations 
of mAb-C to determine protein concentration of mAb-C for PEGR10,000R induced precipitation 
assay (see Figure 4 of manuscript). (A) Fitting of BCA assay results between O.D.R562nmR 
and protein concentration, which was based on an equation y = (a ∙ b + c ∙ x𝑑𝑑)/(b + x𝑑𝑑), 
where “a”=1.6 x10-2, “b”=3.4x107, “c”=2.8x107, and “d”=1.2. (B) Linear regression 
between SEC absorbance values at 214 nm and protein concentration, with an equation 
of y = a ∙ x + b, in which “a”=3.8x107, “b”=1.7x105. Data are presented as mean ± 
standard deviation; n = 3. 
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Supplemental Figure 3.2. Lyophilization of mAb-C solutions. (A) Representative vials 
displaying cake appearance post freeze-drying, (B) moisture content of lyophilized cakes 
determined by Karl Fischer titration, and (C) CD spectra of mAb-C pre- and post-
lyophilization samples (after reconstitution) at both low and high protein concentrations. 
Solutions contains 20 mM potassium phosphate with 10% trehalose (w/v) at pH 7.5 with 
indicated concentration of mAb-C. Data are presented as mean ± standard deviation; n = 
6 for moisture measurements; n = 3 for CD measurements. 
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Supplemental Table 3.1. Analytical characterization of pre-lyophilization and post-
lyophilization (and reconstitution) samples of mAb-C as measured by UV-Vis 
spectroscopy and SEC. The protein concentration and percent aggregate formation were 
determined for reconstituted mAb-C samples lyophilized at low and high protein 
concentrations. Data are presented as mean ± standard deviation; n = 3.  
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Supplemental Table 3.2. Peptide list of mAb-C from pepsin digestion during HX-MS 
analysis with their corresponding peptide locations. 
Peptide 
Number Location 
Peptide 
Number Location 
Peptide 
Number Location 
1 Heavy 1‐4 (VH) 36 Heavy 67‐80 (VH) 71 Heavy 164‐187 (CH1) 
2 Heavy 1‐10 (VH) 37 Heavy 71‐78 (VH) 72 Heavy 167‐182 (CH1) 
3 Heavy 1‐17 (VH) 38 Heavy 71‐79 (VH) 73 Heavy 171‐182 (CH1) 
4 Heavy 1‐22 (VH) 39 Heavy 71‐80 (VH) 74 Heavy 172‐182 (CH1) 
5 Heavy 1‐32 (VH) 40 Heavy 74‐79 (VH) 75 Heavy 183‐187 (CH1) 
6 Heavy 5‐17 (VH) 41 Heavy 79‐83 (VH) 76 Heavy 188‐193 (CH1) 
7 Heavy 5‐22 (VH) 42 Heavy 80‐83 (VH) 77 Heavy 188‐201 (CH1) 
8 Heavy 5‐32 (VH) 43 Heavy 81‐86 (VH) 78 Heavy 188‐205 (CH1) 
9 Heavy 11‐22 (VH) 44 Heavy 83‐93 (VH) 79 Heavy 193‐201 (CH1) 
10 Heavy 11‐32 (VH) 45 Heavy 84‐93 (VH) 80 Heavy 193‐205 (CH1) 
11 Heavy 18‐22 (VH) 46 Heavy 84‐94 (VH) 81 Heavy 194‐205 (CH1) 
12 Heavy 18‐32 (VH) 47 Heavy 84‐95 (VH) 82 Heavy 206‐217 (CH1) 
13 Heavy 33‐36 (VH) 48 Heavy 87‐93 (VH) 83 Heavy 243‐248 (CH2) 
14 Heavy 33‐44 (VH) 49 Heavy 87‐94 (VH) 84 Heavy 243‐259 (CH2) 
15 Heavy 33‐45 (VH) 50 Heavy 94‐99 (VH) 85 Heavy 243‐260 (CH2) 
16 Heavy 33‐46 (VH) 51 Heavy 94‐101 (VH) 86 Heavy 249‐259 (CH2) 
17 Heavy 33‐47 (VH) 52 Heavy 95‐99 (VH) 87 Heavy 249‐260 (CH2) 
18 Heavy 33‐48 (VH) 53 Heavy 95‐101 (VH) 88 Heavy 250‐259 (CH2) 
19 Heavy 33‐49 (VH) 54 Heavy 96‐101 (VH) 89 Heavy 250‐260 (CH2) 
20 Heavy 33‐59 (VH) 55 Heavy 100‐112 (VH) 90 Heavy 260‐268 (CH2) 
21 Heavy 35‐48 (VH) 56 Heavy 102‐112 (VH) 91 Heavy 260‐269 (CH2) 
22 Heavy 37‐59 (VH) 57 Heavy 107‐112 (VH) 92 Heavy 261‐268 (CH2) 
23 Heavy 45‐48 (VH) 58 Heavy 108‐112 (VH) 93 Heavy 261‐269 (CH2) 
24 Heavy 45‐49 (VH) 59 Heavy 113‐120 (VH) 94 Heavy 261‐270 (CH2) 
25 Heavy 49‐59 (VH) 60 Heavy 113‐122 (VH) 95 Heavy 269‐285 (CH2) 
26 Heavy 50‐59 (VH) 61 Heavy 121‐150 (CH1) 96 Heavy 270‐273 (CH2) 
27 Heavy 50‐60 (VH) 62 Heavy 121‐152 (CH1) 97 Heavy 270‐285 (CH2) 
28 Heavy 50‐70 (VH) 63 Heavy 121‐153 (CH1) 98 Heavy 271‐285 (CH2) 
29 Heavy 60‐66 (VH) 64 Heavy 123‐150 (CH1) 99 Heavy 274‐285 (CH2) 
30 Heavy 60‐70 (VH) 65 Heavy 123‐153 (CH1) 100 Heavy 308‐314 (CH2) 
31 Heavy 60‐79 (VH) 66 Heavy 153‐163 (CH1) 101 Heavy 309‐313 (CH2) 
32 Heavy 61‐70 (VH) 67 Heavy 153‐182 (CH1) 102 Heavy 309‐314 (CH2) 
33 Heavy 67‐70 (VH) 68 Heavy 154‐163 (CH1) 103 Heavy 314‐317 (CH2) 
34 Heavy 67‐78 (VH) 69 Heavy 154‐182 (CH1) 104 Heavy 315‐326 (CH2) 
35 Heavy 67‐79 (VH) 70 Heavy 164‐182 (CH1) 105 Heavy 315‐329 (CH2) 
166 
 
106 Heavy 315‐341 (CH2) 137 Heavy 414‐418 (CH3) 169 Light 537‐540 (VL) 
107 Heavy 327‐341 (CH2) 138 Heavy 419‐454 (CH3) 170 Light 537‐546 (VL) 
108 Heavy 342‐356 (CH2) 139 Heavy 432‐454 (CH3) 171 Light 538‐569 (VL) 
109 Heavy 342‐364 (CH3) 140 Heavy 434‐454 (CH3) 172 Light 540‐552 (VL) 
110 Heavy 342‐373 (CH3) 141 Heavy 435‐454 (CH3) 173 Light 540‐570 (VL) 
111 Heavy 357‐364 (CH3) 142 Heavy 436‐454 (CH3) 174 Light 541‐569 (VL) 
112 Heavy 357‐373 (CH3) 143 Heavy 437‐454 (CH3) 175 Light 541‐570 (VL) 
113 Heavy 357‐375 (CH3) 144 Heavy 439‐454 (CH3) 176 Light 542‐570 (VL) 
114 Heavy 365‐373 (CH3) 145 Heavy 449‐454 (CH3) 177 Light 559‐569 (VL) 
115 Heavy 365‐374 (CH3) 146 Light 455‐476 (VL) 178 Light 560‐569 (VL) 
116 Heavy 365‐375 (CH3) 147 Light 455‐486 (VL) 179 Light 570‐579 (CL) 
117 Heavy 365‐376 (CH3) 148 Light 459‐486 (VL) 180 Light 570‐586 (CL) 
118 Heavy 367‐373 (CH3) 149 Light 478‐486 (VL) 181 Light 571‐579 (CL) 
119 Heavy 374‐376 (CH3) 150 Light 487‐489 (VL) 182 Light 571‐586 (CL) 
120 Heavy 374‐384 (CH3) 151 Light 487‐500 (VL) 183 Light 578‐586 (CL) 
121 Heavy 375‐384 (CH3) 152 Light 487‐501 (VL) 184 Light 580‐588 (CL) 
122 Heavy 376‐384 (CH3) 153 Light 487‐502 (VL) 185 Light 580‐597 (CL) 
123 Heavy 376‐387 (CH3) 154 Light 490‐500 (VL) 186 Light 587‐589 (CL) 
124 Heavy 377‐384 (CH3) 155 Light 501‐503 (VL) 187 Light 590‐597 (CL) 
125 Heavy 377‐386 (CH3) 156 Light 501‐508 (VL) 188 Light 590‐602 (CL) 
126 Heavy 385‐387 (CH3) 157 Light 501‐516 (VL) 189 Light 590‐608 (CL) 
127 Heavy 385‐388 (CH3) 158 Light 501‐524 (VL) 190 Light 590‐615 (CL) 
128 Heavy 385‐398 (CH3) 159 Light 501‐525 (VL) 191 Light 598‐615 (CL) 
129 Heavy 385‐406 (CH3) 160 Light 503‐524 (VL) 192 Light 603‐615 (CL) 
130 Heavy 385‐412 (CH3) 161 Light 504‐508 (VL) 193 Light 616‐626 (CL) 
131 Heavy 389‐406 (CH3) 162 Light 509‐516 (VL) 194 Light 616‐632 (CL) 
132 Heavy 399‐406 (CH3) 163 Light 509‐524 (VL) 195 Light 627‐632 (CL) 
133 Heavy 400‐406 (CH3) 164 Light 525‐528 (VL) 196 Light 633‐646 (CL) 
134 Heavy 407‐412 (CH3) 165 Light 525‐536 (VL) 197 Light 634‐649 (CL) 
135 Heavy 413‐418 (CH3) 166 Light 525‐537 (VL) 198 Light 636‐649 (CL) 
136 Heavy 413‐431 (CH3) 167 Light 526‐536 (VL) 199 Light 639‐649 (CL) 
137 Heavy 414‐417 (CH3) 168 Light 526‐537 (VL) 200 Light 650‐668 (CL) 
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Chapter 4 
 
Structure Characterization and Stability Assessments of Secretory IgA 
Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral 
Administration 
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4.1. Introduction 
Diarrheal diseases are the second leading cause of death in developing countries, 
especially in Sub-Saharan Africa and South Asia,1-3 with ~0.6 million children under 5 
years of age dying each year due to complications caused by severe diarrhea.4-6 A major 
cause of diarrhea is from drinking water contaminated by pathogenic bacteria, viruses, or 
parasites.4 Enterotoxigenic Escherichia coli (ETEC) is the most common bacterial cause 
of diarrhea-associated mortality, which leads to approximately one quarter of all diarrheal 
episodes for infants and children less than 5-years of age.7-10 To further complicate these 
problems, enhanced antibiotic resistance has been found in many ETEC strains.11-13 
Thus, the development of an ETEC vaccine is considered the most effective and feasible 
strategy to prevent diarrheal diseases among children in developing countries,14,15 and 
has become a high priority for the World Health Organization.16 Currently, no ETEC 
vaccines are commercially available and numerous challenges impede ETEC vaccine 
development including heterogeneity of potential target antigens (e.g., virulence factors 
such as enterotoxins and colonization factors),4 poor mucosal immunogenicity, potential 
safety issues of such antigens, and cost hurdles to develop, manufacture and 
commercialize such prophylactic vaccines.8,17  
Due to these challenges, there is growing interest in the use of passive 
immunization strategies to treat ETEC-induced diarrheal diseases in targeted populations 
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by oral delivery of neutralizing immunoglobulins. For example, local delivery of antibodies 
that bind and neutralize ETEC in the gut could be utilized to prevent infection. Multiple 
virulence factors from ETEC have been recognized as potential antigens for passive 
immunity,11,18 including secretion heat-labile enterotoxin (LT) which directly induces 
diarrhea by prompting solute retention and loss of water absorption in the intestinal lumen. 
LT is a heterohexameric A-B subunit toxin comprised of a catalytically active A subunit 
and five B subunits.18 Subunit A has ADP-ribosylation activity, which covalently modifies 
the subunit of the GTP-binding protein (Gs), leading to the constitutive activation of 
adenylate cyclase and production of 3’,5’-cyclic AMP (cAMP).19 Consequently, 
continuous release of chloride and water into intestinal lumen causes watery diarrhea 
while the five B subunits mediate LT binding to glycolipid and glycoprotein receptors on 
host cells.19 Thus, antibody-induced neutralization of LT enzymatic activity and inhibition 
of adhesion could potentially be effective in controlling ETEC infection.  
 Secretory IgA (sIgA) antibodies are of particular interest for passive immunization 
during oral administration due to its natural abundance in secretions and mucosal 
surfaces.20 As the most abundant isotype of immunoglobulins in mucosal membranes, 
secretory IgAs (sIgAs) play crucial roles in protecting gut mucosal surfaces from 
pathogens and toxins.21-23 Secretory IgAs functions to promote clearance of pathogens, 
maintenance of intestinal homeostasis, direct neutralization of bacterial virulence factors 
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(e.g., enterotoxins), and modulation of proinflammatory responses.21-24 sIgA antibodies 
consist of dimeric IgG-like molecules, linked by a joining chain (J-chain), and complexed 
with a secretory component (SC) chain25 (see results section). The SC protein is acquired 
as the polymeric immunoglobulin receptor cleaves upon transport across epithelial cells 
into mucosal surfaces and secretions. sIgA antibodies are inherently more resistant to 
proteolysis by digestive enzymes when compared to IgG in the gastrointestinal tract.26,27 
In this work, three anti-LT isotype variants of the same mAb (sIgA1, sIgA2 and 
IgG1) were expressed and purified from CHO cells in quantities of 5-10 mg. A series of 
physiochemical methods were developed (to accommodate limited availability of 
material) and utilized to characterize the anti-LT sIgA1, sIgA2, and IgG1 mAbs in terms 
of primary structure, post-translational modifications (i.e., N-linked glycosylation), 
molecular weight and size heterogeneity, physicochemical stability, aggregation 
propensity, and relative solubility. In addition, we examined the stability of the three mAbs 
under conditions that mimic the gastric phase of oral delivery using simulated gastric 
fluids in a modified in vitro gastric digestive model. The results are evaluated in terms of 
relative rank-ordering of the pharmaceutical stability of these molecules from the point of 
view of future formulation development work to optimize storage stability as well as 
stability during oral delivery.  
4.2. Materials and Methods 
171 
 
4.2.1. Sample Preparation 
The three anti-heat labile toxin (LT) immunoglobulins (sIgA1, sIgA2, and IgG1) 
were expressed in CHO cells and purified by MassBiologics (University of Massachusetts 
Medical School, Boston, MA). The antibodies were prepared in 10 mM sodium phosphate, 
150 mM NaCl, pH 7.2 (phosphate-buffered saline, PBS) and stored at 2-8°C. Protein 
concentration was determined by ELISA using known concentrations of sIgA1, sIgA2 or 
IgG1 as standards. The protein concentration was confirmed by HPLC. When protein 
concentration was determined by UV-visible spectroscopy, extinction coefficients were 
calculated based on the primary sequences28 as 1.49, 1.49, 1.64 mL∙mg-1∙cm-1 for sIgA1 
sIgA2 and IgG1, respectively.  
4.2.2. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Twenty µL of each 0.2 mg/mL Ig sample was mixed with or without 1 µL of PNGase 
F (New England BioLabs, Ipswich, MA) and incubated overnight at 37oC. Both 
deglycosylated and glycosylated Ig samples were reduced with 50 mM dithiothreitol (DTT, 
Invitrogen, Carlsbad, CA) at 70oC for 30 min. Reduced and non-reduced samples were 
then mixed with 4X LDS loading dye (Life Technologies, Grand Island, NY) containing 
100 mM iodoacetamide (IAM, Life Technologies), and incubated at 100oC for 5 min. 
Samples were cooled to room temperature (RT) and separated by SDS-PAGE using 
NuPAGE 10% Bis-tris gels (Life Technologies) and MOPS running buffer (Life 
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Technologies) at 150 V for 75 min. Gels were stained with Coomassie Blue R-250 
(Teknova, Hollister, CA) and destained with 40% methanol 10% acetic acid. Gels were 
digitized using an AlphaImager (Protein Simple, Santa Clara, CA) gel imaging system. 
4.2.3. Size Exclusion Chromatography (SEC)  
A Shimadzu Prominence ultra-fast liquid chromatography HPLC system equipped 
with a diode array detector (with absorbance detection at 214 nm) was utilized. The 
system was equilibrated at 0.5 mL/min flow rate in 0.2 M sodium phosphate buffer at pH 
6.8 for at least 2 hours. Ten µL of each Ig (10 µg total protein per injection) was injected 
and separated by a TOSOH TSKgel G4000SWXL column (8 µm particle size, 7.8 mm ID 
× 30 cm) for sIgA or a TOSOH TSK-Gel BioAssist G3SWxl column (5 µm size, 7.8 mm 
ID × 30 cm) for IgG1 with a corresponding guard column operated at ambient temperature 
(Tosoh Biosciences) using a 30-minute run time. Gel filtration molecular weight standards 
(Bio-Rad, Hercules, CA) were injected before and after the Ig sample sets to ensure 
integrity of the column and HPLC system. Potential presence of larger aggregates were 
determined by running Ig samples with and without the SEC column (i.e., protein 
percentage recovery). Greater than 95% protein recovery was obtained for each of the 
three mAbs by SE-HPLC, indicating minimal loss of protein (e.g., larger aggregates) by 
using optimized SE-HPLC conditions for sIgA vs IgG1. Data were analyzed using LC-
Solution software (Shimadzu, Kyoto, Japan). 
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4.2.4. Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) 
SV-AUC was performed using a Proteome Lab XL-I (Beckman Coulter) analytical 
ultracentrifuge equipped with a scanning ultraviolet-visible optical system. Samples were 
diluted to 0.2 mg/mL in PBS pH 7.2 and transferred into Beckman charcoal-epon two 
sector cells with a 12 mm centerpiece and sapphire windows. All experiments were 
performed at 20oC after at least 1 hour of equilibration after the rotor reached 20oC. SV-
AUC was performed at a rotor speed of 40,000 RPM and with detection at 280 nm. The 
data were analyzed using Sedfit (Dr. Peter Schuck, NIH). The partial specific volume was 
calculated using Sednterp (software provided by Professor Thomas Laue, University of 
New Hampshire and BITC) based on the primary sequence. The buffer density and 
viscosity used in the analysis were also calculated using Sednterp based on the 
composition of the buffer. The density and viscosity of PBS were calculated to be 1.0059 
g/mL and 0.01021 Poise, respectively. A continuous c(s) distribution model was applied 
with a range from 0 to 15 svedbergs, with a resolution of 300 points per distribution and 
a confidence level of 0.95. Baseline, radial independent noise, and time independent 
noise were fit parameters, while the meniscus and bottom positions were set manually.  
4.2.5. LC-MS Peptide Mapping 
Ninety μl of 0.5 mg/mL Ig samples were reduced with 3 μl of 0.5 M DTT for 30 min 
at 80oC and alkylated with 6 μl of 0.5 M IAM for 30 min at 37oC in the dark. The samples 
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were then incubated overnight at 37oC with 12 μg of trypsin or chymotrypsin (~1:25 
enzyme:Ig ratio). The following day, the samples were heated to 98oC for 5 min to inactive 
the enzyme. After cooling down, samples were treated with PNGase F (New England 
BioLabs, Ipswich, MA) as described above to remove N-linked oligosaccharides. Before 
LC-MS injections, 0.05% (v/v) trifluoroacetic acid was added, and samples were 
centrifuged for 5 min at 14,000 xg. The peptides from the digested protein solution were 
then separated by reversed phase UHPLC (Thermo Scientific) using a C18 column 
(1.7µm, 2.1 x 150 mm, Waters Corporation) and a 85 min 0-30% B gradient (A: HR2RO and 
0.05% trifluoroacetic acid; B: ACN and 0.05% trifluoroacetic acid; 200 μl/min flow rate). 
MS was performed using a LTQ-XL ion trap (Thermo Scientific) and Xcalibur v2.0 
software (Thermo Scientific). The instrument was tuned using a standard calibration 
peptide (Angiotensin II, Sigma) for maximal sensitivity prior to running any experiments. 
The mass spectra were acquired in the LTQ over a mass range of m/z 400-1900 using 
an ion selection threshold of 40,000 counts and a dynamic exclusion duration of 5 sec. 
Raw experimental files were processed using PepFinder 2.0 software (Thermo Scientific). 
The database used for this experiment consisted of the primary sequences of all Ig 
molecules. Potential Cys carbamidomethylation, Asn deamidation, and Met oxidation 
were included in the analysis. Peptide assignments of MS/MS spectra were validated 
using a confidence score of > 95%. 
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4.2.6. Total Carbohydrate Analysis 
A glycoprotein carbohydrate estimation kit (Thermo-Fisher #23260) was used to 
determine the total carbohydrate content (both N- and O-linked glycosylation) in Ig 
samples as a percentage of total protein mass. Prior to experiments, proteins were buffer 
exchanged into PBS pH 7.2 using 30 kD MWCO filters (EMD Millipore, Billerica, MA) to 
remove trace of detergent and a final concentration of 0.25 mg/mL Ig was used in each 
reaction. The recommended procedure by the manufacturer was used. Absorbance at 
550 nm was read using a SpectraMax M5 microtiter plate reader (Molecular Devices). 
Lysozyme, BSA, ovalbumin, Apo-transferrin, fetuin, and α1-acid were used as 
glycoprotein standards to construct a standard curve.  
4.2.7. N-Glycan Oligosaccharide Analysis 
A GlycoWorks RapiFluor-MS N-Glycan Kit (Waters Corporation, Milford, MA) was 
used to identify and quantify all N-linked glycans following the manufacturer instructions. 
Briefly, Ig samples were centrifuged at 10,000 rpm for 5 mins, 7.5 µL of 2 mg/mL Igs were 
mixed with 15.3 µL ultrapure water and 6 µL Rapi-surfactant and heated at 90oC for 3 
min. After cooling to ambient temperature, 1.2 µL of Rapi-PNGase F was added and 
samples were incubated at 50oC for 5 min to release N-linked glycans. Labeling was 
performed by combining oligosaccharide samples with 12 µL RapiFluor-MS reagent for 5 
min. The reaction was diluted in 358 µL of acetonitrile and the reaction products purified 
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using a HILIC µElution plate. The plate was washed three times in wash buffer (1% formic 
acid, 90% acetonitrile) and eluted in 90 µL of elution buffer. The samples were further 
diluted in 310 µL of diluent buffer. Fluor-MS N-glycan analysis was performed using an 
Agilent 1260 Infinity II HPLC system equipped with a 1260 FLD detector (Agilent, Santa 
Clara, CA) and an Agilent 6230 electrospray ionization Time-of-Flight mass spectrometer 
(Agilent, Santa Clara, CA). A HILIC AdvanceBio Glycan Mapping column (120 Å, 2.1 x 
150 mm, 2.7 µm), that was operated at 45oC, was used to separate various N-glycans. 
Fifty µL of prepared samples was injected into LC-MS system, with a flow rate of 0.6 
mg/mL and a gradient run time of 55 min. Fluorescence was obtained using excitation 
and emission wavelengths of 265 and 425 nm, respectively. MS was acquired 
simultaneously from 400 to 2000 m/z at a constant scan rate of one spectrum per second. 
N-glycans were assigned based on m/z values using a N-glycan database,29 and N-
glycan quantification was calculated on integration of the fluorescence chromatogram. 
4.2.8. Conformational Stability Assessments 
Thermal unfolding experiments were performed with Ig samples diluted in either 
PBS pH 7.2 or buffer exchanged into a simulated gastric fluid (SGF, 94mM NaCl, 13mM 
KCl) with 10 mM citrate phosphate (CP) buffer at pH 3.030. Samples were then diluted in 
the corresponding buffer to a final concentration of 0.2 mg/mL. A fluorescence plate 
reader equipped with a charge-coupled device (CCD) detector (Fluorescence 
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Innovations, Minneapolis, MN) was used to obtain intrinsic tryptophan fluorescence 
spectra. Twenty µL of each sample were loaded into a 384-well plate (Hard-Shell 384- 
well PCR plates), and overlaid with 2 µL of silicon oil (ThermoFisher Scientific, Waltham, 
MA). Samples were excited at 295 nm (>95% tryptophan emission) and the emission 
spectra were recorded from 300 to 450 nm with an integration time of 100 ms. 
Temperature ramps were programed from 10 to 100oC with an increment of 2.5oC per 
step. The mean center of spectra mass (MSM) peak algorithm was used to analyze the 
data to determine the shift in fluorescence peak position as a function of temperature.  
Denaturant unfolding experiments were performed using 8 M stocks of GdnHCl 
prepared in either PBS pH 7.2 or SGF containing 10 mM CP buffer at pH 3.0. Ig samples 
were buffer exchanged and diluted to final Ig concentration of 0.2 mg/mL, with a series of 
GdnHCl concentrations from 0 to 5.5 M. Ten µL of each Ig sample was transferred to a 
384-well plate (Hard-Shell 384-well PCR plates) and incubated at 4oC overnight before 
performing fluorescence measurements as above, but without the silicone oil overlay and 
at a fixed temperature (10oC). Data analysis was performed as described above. 
4.2.9. Relative Protein Solubility (Polyethylene Glycol Precipitation Assay) 
Relative solubility of Igs was performed by adapting the method by Gibson et al.31 
and Toprani et al.32 using smaller volumes. Briefly, 384-well polystyrene filter plates 
(Corning Life Sciences, Corning, NY) were used. Thirty percent w/v PEGR10,000 Rstock 
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solutions were prepared in either PBS pH 7.2 or SGF containing 10 mM CP buffer pH 
3.0. Various concentrations of PEGR10,000R solutions ranging from 0 to 25% w/v were 
prepared with Ig concentration of 0.2 mg/mL in both buffer conditions. Samples were 
incubated overnight at RT in dark. The next day, plates were centrifuged at 1,233 × g for 
15 min and directly eluted into a clean 384-well plate. Relative protein concentration in 
each well was determined using a SpectraMax M5 plate reader (Molecular Devices) using 
detection at 214 nm. %PEGRmidptR values were then calculated as described previously.31 
4.2.10. In vitro Model of Gastric Digestion  
To determine the stability of the proteins under simulated gastric conditions, each 
Ig was diluted in simulated gastric fluid (SGF), which was composed of 94 mM NaCl, 13 
mM KCl), 0.15 mM CaClR2R, along with 10 mM citrate-phosphate buffer pH 3.5 (added to 
maintain pH). Proteins were either diluted directly into SGF/CP buffer alone or SGF/CP 
buffer with added bicarbonate buffer (9:1 ratio of the digestion solution and a bicarbonate 
neutralization buffer containing 0.03 M trisodium citrate and 0.3 M sodium bicarbonate at 
pH 8.533) at a final protein concentration of 0.2 mg/mL. The reaction was started when 
the pepsin (2000 U/mL pepsin, Sigma)30 was added to the solution and samples were 
incubated at 37oC for varying amounts of time. The reaction was quenched by the addition 
of 400 mM NaOH to adjust to neutral pH. Samples were then analyzed by SDS-PAGE 
and ELISA. For ELISA analysis, samples were diluted in ELISA blocking buffer (0.1% 
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BSA in PBS) at 40 µg/mL and 1 µg/mL of sIgAs and IgG1 digested samples based on the 
starting concentration, respectively and stored at -20oC until analysis. 
4.2.11. Immobilized Pepsin Digestion 
Igs samples were diluted in SGF/CP buffer (see composition above) at a final 
concentration of 0.2 mg/mL. Immobilized pepsin-agarose (Thermo-Fisher) was washed 
three times in SGF by centrifugation at 12,000 x g prior to addition to the diluted Ig mixture 
to a final pepsin concentration of 2000 U/mL. Samples were incubated at 37°C with end 
over end rotation to keep the beads in suspension. Beads were removed by centrifugation 
at 12,000 x g for 1 min upon completion of the desired incubation times, and the 
supernatant was removed. Samples were then neutralized by addition of 400mM NaOH 
prior to analysis by SE-HPLC. SE-HPLC was performed as described above, but with an 
injection volume of 25 µl.  
4.2.12. Enzyme-Linked Immunosorbent Assay (ELISA) 
96-well affinity immunoassay plates (Thermal Scientific, Rochester, NY) were 
coated with 1.0 µg/mL Heat-Labile Enterotoxin, B subunit (LTB) from E. coli (Sigma 
E8656) in PBS pH 7.2 and incubated overnight at 4oC. The following day, after removing 
coating solution, 96-well plates were filled with 200 µL of ELISA blocking buffer (0.1% 
BSA in PBS) for 2 hours at room temperature. After flicking out blocking buffer, digested 
Ig samples were loaded 1:1 with blocking buffer and 1:1 serial dilutions were performed 
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using blocking buffer as the diluent. Samples were incubated for 30 mins at room 
temperature. Plates were washed three times with 0.05% Tween-20 in PBS, then 50 
µL/well of HRP conjugated Goat anti-human Ig protein (Fisher, Southern Biotechnology 
Associates) diluted in blocking buffer (1:15,000 was added and incubated for 30 mins at 
room temperature. Plates were washed as before, and 100 µL/well TMB substrate 
solution (3,3',5,5'-Tetramethylbenzidine (TMB)) was added and incubated for 5 min at 
room temperature in the dark. The reaction was quenched with 100 µL/well 1 M 
phosphoric acid. Optical density (OD) was recorded using a SpectraMax M5 microtiter 
plate reader (Molecular Devices) at 450 nm. 
4.3. Results 
4.3.1. Characterization of Purity, Primary Structure and Post-translational 
Modifications of sIgA vs. IgG mAbs 
As shown schematically in Figure 1A, sIgA antibodies are composed of two IgG-
like molecules which are disulfide linked by a ~16 kDa joining chain (termed the J-chain), 
and also a ~70 kDa secretory component (SC) chain that is complexed via the heavy 
chains in the Fc domains.25 The combined molecular weight of sIgA polypeptide chains 
is ~400 kDa which increases to ~460-480 kDa due to 15-20% N-linked and O-linked 
glycosylation depending upon the sIgA subclass (see below). In comparison to sIgAs, IgG 
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antibodies are less structurally complex and smaller (~150 kDa with 1-2% N-linked 
glycosylation). There are two main subclasses of sIgAs (sIgA1 and sIgA2) which 
structurally differ primarily in their hinge regions (e.g., length of hinge region, disulfide-
bonding pattern, and the type and number of attached glycosylation sites)34 as depicted 
schematically in Figure 1A. Two and three conserved N-linked glycans are found on each 
Fc domain of sIgA1 and sIgA2, respectively, while sIgA2 also possesses one or two 
additional N-linked glycans on the CRHR1 domain. Another key structural difference is sIgA1 
contains multiple O-glycans on its elongated hinge region, while sIgA2 possesses a 
shorter hinge region that lacks such glycosylation.35 Both subclasses contain several N-
linked glycosylation sites on the J-chain and SC.36  
SDS-PAGE analysis was performed under non-reducing and reducing conditions, 
both with and without PNGase F treatment to remove N-glycans, as shown in Figure 1B. 
Under non-reduced conditions, both sIgA1 and sIgA2 mAbs displayed smear bands with 
a composition of monomer, dimer, and higher molecular weight (MW) species (i.e., 
migrating near the top of gel) when compared to IgG1 (~150 kDa), which is consistent 
with the composition of sIgA antibodies (Figure 1A). The sIgA1 and sIgA2 samples had 
multiple high molecular weight bands that are primarily covalently cross-linked disulfide 
bonded species upon comparison to the reduced samples (and consistent with previous 
reports).37-39 Conversely, IgG1 showed relatively higher purity in the non-reduced sample 
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with primarily a single band. Under reducing conditions, three major components were 
identified for the sIgA mAb samples: the SC (~70 kDa), heavy chain (~50 kDa), and light 
chain (~25 kDa). Note, the J-chain (~16 kDa) was not observed by SDS-PAGE 
(consistent with literature results; see discussion). Specifically for sIgA2, we also 
observed two bands at relatively lower molecular weights (~17 kDa and ~40 kDa), which 
could represent sIgA2 fragments rather than J chain (for the former) due to their 
disappearance after reduction. The heavy and light chains of the PNGase F-treated, 
reduced sIgAs migrated at slightly lower MW on the gel, indicating deglycosylation of 
these molecules. As expected, no migration differences were observed for the light chain 
bands independent of PNGase F treatment. In contrast, in the reduced IgG1 sample, both 
heavy (~50 kDa) and light (~25 kDa) chains were observed, and small amount of 
fragments (~17 kDa) were also seen. Since the IgG1 heavy chain is N-glycosylated (see 
below), it also displayed lower MW migration after PNGase F treatment.  
To confirm the primary sequence and identify potential post-translational 
modifications (PTMs), LC-MS peptide mapping was performed on the three mAbs. Due 
to the PNGase F treatment required for successful chromatographic resolution (data not 
shown), contributions of the N-glycans were not detected, and this PTM was examined 
separately (see below). Due to the sequence similarity (>97%) of sIgA1 and sIgA2, 
including both the variable and constant regions, many peptides were similar in terms of 
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elution profile (Figure 2A). At the same time, some differences in peptide elution profiles 
were also observed thus demonstrating a unique profile for each sIgA. For IgG1, the base 
peak chromatogram was significantly different when compared to the sIgAs, indicating a 
distinct digestion profile. Therefore, “fingerprint” chromatograms were obtained for each 
of the three mAbs. The sequence coverage obtained for each of the polypeptide chains 
is shown in Figure 2B. Overall, >85% coverage was obtained for each polypeptide chain 
for each mAbs. The light chain displayed the best coverage (97-100%), the heavy chain 
coverage was from 83% to 97%, and SC and J chain displayed 86-87% and 83-96% 
sequence coverage, respectively. In terms of PTMs, no notable chemical modifications 
on sIgA1 and sIgA2 mAbs were observed. For IgG1, N-terminal pyroglutamic acid 
formation and C-terminal lysine residual truncation were identified in the heavy chain, 
which are commonly observed PTMs with IgG1 mAbs.40,41 
  Glycosylation of antibodies plays an important role in functional activity (effector 
function and potentially antigen binding) as well as physical properties such as solubility 
and stability.42-45 A combination of total carbohydrate content as well the identification and 
quantification of the N-glycan profile was determined for each of the three anti-LT mAbs. 
As shown in Figure 3A, a substantial difference in the total carbohydrate content between 
sIgAs mAbs (18.7% and 18.5% for sIgA1 and sIgA2, respectively), and IgG1 (1.2%) was 
observed. This result is consistent with the known structure and post-translational 
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modifications of each mAb (Figure 1A). Further analysis was performed to identify specific 
N-glycan type and relative quantification was performed by removal and derivatization of 
the N-glycans followed by chromatographic separation with detection by a combination 
of MS analysis and fluorescence measurements (see methods). Twenty-four and twenty-
three different N-glycans for sIgA1 (Figure 3B) and sIgA2 (Figure 3C) were identified, with 
G2+NANA and G2F+NANA as the most dominant glycan types, respectively. In contrast, 
as shown in Figure 3D, the IgG1 mAb displayed a much simpler N-glycan profile, with 5 
major N-glycan oligosaccharides, in which glycan G0F was the most dominant type 
(>80%). Each N-glycan type and corresponding percent composition found in each anti-
LT mAb are summarized in Figure 4. It can be seen that the N-linked oligosaccharide 
composition and distribution greatly differs between the sIgA and IgG1 mAbs, as well as 
between the sIgA1 and sIgA2 mAbs. 
4.3.2. Characterization of Size and Aggregation Profile of sIgA vs IgG mAbs 
In addition to size analysis under denaturing conditions by SDS-PAGE (see Figure 
1B), size distribution profile under non-denaturing conditions was determined for each of 
the three mAbs using two orthogonal methods, SV-AUC and SE-HPLC, as shown in 
Figure 5A and 5B, respectively. Two size categories (monomeric sIgA and higher 
molecular weight (HMW) species) were used to classify the species distribution of each 
sample. For sIgA1 and sIgA2 samples, multiple peaks were identified by both SV-AUC 
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and SE-HPLC, with SV-AUC displaying superior peak resolution, especially for larger MW 
species. For IgG1, a more homogeneous peak distribution was observed (it should be 
noted that to optimize separation of different species and percent recovery, different SEC 
columns were employed for the sIgA vs. IgG1 samples, and thus the IgG1 eluted at an 
earlier retention time; see methods). Overall, similar species distribution results were 
achieved in comparing SV-AUC and SE-HPLC results after peak area integration (Figure 
5C). Both sIgA1 and sIgA2 samples displayed a relatively high amount of HMW species 
in solution, representing ~50% and ~80% of total protein, respectively. On the other hand, 
<10% of total protein was in the form of HMW species in the IgG1 sample. For each of 
the observed species, the molecular weight values were estimated, based on 
sedimentation coefficient values and comparison to the gel filtration standards for SV-
AUC and SE-HPLC, respectively, as shown in Supplemental Table S1. 
4.3.3. Conformational Stability and Relative Solubility Assessment of sIgA vs IgG 
mAbs  
 The sIgA1, sIgA2 and IgG1 mAbs were then compared in terms of their 
conformational stability and relative solubility profiles under two different pH solution 
conditions including pH 7.2 (to evaluate stability/relative solubility under storage 
conditions at neutral pH) and pH 3.0 (to evaluate stability/relative solubility under gastric 
conditions at acidic pH). First, the conformational stability of the mAbs was examined as 
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a function of temperature. As shown in Figure 6A, solution pH effects the overall tertiary 
structure of the mAbs as a function of increasing temperature as determined by intrinsic 
Trp fluorescence spectroscopy. One major transition was observed to begin at 60-70oC 
at pH 7.2 for each of the mAbs. When the solution pH was decreased to 3.0, however, 
multiple transitions were detected across the entire temperature range, and a red shift 
was observed at 10oC. These results suggest that the overall tertiary structure of each 
mAb is partially altered under acidic pH solution conditions. Second, the conformational 
stability of the three mAbs was examined by the addition of increasing amounts of the 
chemical denaturant guanidine hydrochloride (GdnHCl), by monitoring changes in overall 
tertiary structure of the mAbs by fluorescence spectroscopy as shown in Figure 6B. The 
sIgA1 and sIgA2 mAbs showed one broad transition as the GdnHCl concentration was 
increased with a midpoint of ~3M at pH 7.2. At pH 3.0, both sIgA mAbs showed lower 
conformational stability. Two distinct transitions were observed for IgG1 at pH 7.2, with 
midpoints of ~2 and ~4M GdnHCl. Lower conformational stability was also noted at pH 
3.0 for the IgG1 mAb. 
Interestingly, in terms of relative apparent solubility as measured by PEG-10,000 
precipitation assay, a higher concentration of PEG-10,000 was required at pH 3.0 to 
precipitate each of the three mAbs compared to pH 7.2 in the relative rank order of sIgA1 > 
sIgA2 > IgG1 (Figure 6C). In fact, the sIgA1 remained soluble and failed to precipitate 
187 
 
despite addition of the highest concentration PEG-10,000 (25%, w/v) when the solution 
pH was 3.0. Thus, higher relative apparent solubility was observed for each of three 
mAbs, albeit to various extents, by decreasing the solution pH from 7.2 to 3.0 (see 
Discussion section). 
4.3.4. Examination of sIgA vs IgG Stability in an In Vitro Gastric Digestion Model to 
Mimic Oral Administration  
To investigate and compare stability profiles of each of the mAbs under conditions 
that mimic oral delivery, we adapted an in vitro digestion model that focused on the gastric 
phase using simulated adult conditions for food digestion.33 In this adapted model, we 
scaled down the volume requirements and determined the most crucial variables on mAb 
digestion rates including solution pH, digestion time, and pepsin concentration (data not 
shown). We fixed the solution pH to 3.5 (using a low concentration of citrate phosphate 
buffer), optimized the pepsin concentration to 2000 U/mL, and monitored digestion in 1 
mL solution as a function of time at 37°C (see methods section). Three analytical 
techniques (ELISA, non-reducing SDS-PAGE, SE-HPLC) were used to assess the 
antigen binding activity, purity and size of each the mAbs (and/or their degradation 
products) vs. incubation time, respectively.  
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First, the LT-antigen binding activity of each mAb was assessed by ELISA as a 
function of incubation time in the in vitro digestion model. The ELISA binding activity 
correlated well with antibody activities in functional assays (data not shown). At time zero, 
the sIgA1, sIgA2 and IgG1 mAbs bound the antigen in a concentration dependent manner 
with a midpoint between 0.01 to 0.1 mg/mL mAb (Figure 7A, 7B and 7C, respectively). 
During incubation, a decreased signal (indicating decreasing amounts of mAb binding to 
the LT antigen) was observed for both sIgA1 and sIgA2. Nonetheless, no shift in the 
midpoint was noted and some antigen binding was still observed even after overnight 
digestion (Figure 7 A, B). In contrast, IgG1 lost its LT binding ability to a much greater 
extent (shift in the midpoint values as well as decreased total signal), and much more 
rapidly, when compared to the sIgAs (Figure 7C). The majority of the binding capacity of 
IgG1 sample was lost after 5-10 minutes of digestion. To better compare these results 
across the three anti-LT mAbs, the percent loss of binding signal was calculated and the 
relative loss rates were then compared (Figure 7D). For IgG1, the loss of mAb binding to 
LT antigen was rapid versus the significantly slower rates observed for both of the sIgAs. 
The co-addition of sodium bicarbonate buffer, which neutralizes the acidic pH leading to 
irreversible inactivation of pepsin,46,47 resulted in ~100% retention of LT binding even after 
overnight incubation in the in vitro gastric digestion model as shown in Figure 7D. 
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Second, non-reducing SDS-PAGE was performed on the same sIgA1, sIgA2 and 
IgG1 samples incubated in the in vitro gastric digestion model (Figure 8). The sIgA1 mAb 
gradually digested, and a series of digestion byproducts were observed including a major 
species ~100 kDa, which presumably corresponds to the F(ab’)R2R fragment (Figure 7A). 
After 3 hours, sIgA1 degraded mostly to the ~100 kDa species. This result is consistent 
with known Fc susceptibility to pepsin digestion into smaller MW peptides while the more 
resistant F(ab’)R2 Rfragment remains intact.48,49 As expected, the sIgA1 was essentially 
completely protected with co-addition of a sodium bicarbonate buffer (Figure 8A). Overall 
similar observations were made with the sIgA2 mAb as shown in Figure 8B, however, 
one difference was noted: in addition to the major digestion species of F(ab’)R2R, another 
protein species was detected at ~50 kDa which was likely the Fab fragment. Addition of 
the bicarbonate buffer played a similar role in protecting sIgA2 from digestion by 
increasing solution pH. In contrast, IgG1 displayed an accelerated digestion profile when 
compared to the sIgAs (Figure 8C). After the first time point (5 min), almost all of the IgG1 
was digested to F(ab’)R2R fragments, and these remained after overnight incubation (Figure 
8C). The protective effect of bicarbonate buffer addition was also observed for IgG1. To 
more directly compare digestion profiles of the three mAbs by non-reduced SDS-PAGE, 
densitometry analysis of the native mAb band was performed (Figure 8D). Although each 
of the intact mAbs were fully digested after overnight incubation (without addition of 
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bicarbonate buffer), the rate of digestion of the sIgAs was much slower when compared 
to IgG1, indicating an increased resistance to acidic pH and pepsin digestion.  
Finally, SE-HPLC was also used to determine the size degradation profile of the 
three anti-LT mAbs (under non-denaturing conditions) by quantifying the decrease of the 
intact protein species and increase of the corresponding degradation products (Figure 9). 
In this experiment, immobilized pepsin was utilized to easily remove the pepsin from the 
solution, since injection of pepsin containing solutions onto the SEC column resulted in 
co-elution of the protease with the sIgA degradation products (data not shown). Three 
major peaks were identified in the SEC chromatograms and were assigned as follows: 
the main species, large fragments, and small fragments (Figure 9A). Presumably, the 
intact protein is the large species, while the F(ab’)R2 R/F(ab) are the large fragments and 
smaller peptide byproducts represent the small fragments. As shown in Figure 9A, 
digestion of sIgA1 was observed as a function of time where the main peak area was 
reduced at each time point, while there was a concurrent increase in the large and small 
fragments. For sIgA2, similar trends were observed (Figure 9B). For IgG1, three peaks 
were also observed, however, the digestion occurred more rapidly (when compared to 
the sIgAs) based on the reduction of the main peak area (Figure 9C). To facilitate 
comparisons, the percent of intact mAb as a function of digestion time was determined. 
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Both sIgA1 and sIgA2 demonstrated greater resistance to pepsin digestion when 
compared to IgG1, with no notable differences between sIgA1 and sIgA2 (Figure 9D). 
4.3.5. Comparisons of Stability/Solubility Profiles of sIgA1, sIgA2 and IgG under 
Various Conditions  
To better summarize and compare the stability results described above as a 
function of solution pH and molecule type (sIgA1, sIgA2, IgG1), a “relative stability index” 
was determined (Figure 10). Briefly, Figure 10 displays the results of the relative stability 
comparisons between the three anti-LT mAbs in terms of conformational stability at pH 
7.2 and 3.0 (vs. temperature and vs. GdnHCl) as shown in Figure 10A, the relative 
apparent solubility at pH 7.2 and 3.0 as shown in Figure 10B, and finally, the stability 
profile during incubation in the in vitro digestion model (37°C, pH 3.5 with pepsin) as 
shown in Figure 10C. For each condition, three values (1, 2, and 3) were assigned to 
each of the three mAbs corresponding to their relative rank ordering in stability (highest, 
intermediate, and lowest). These values in Figure 10A and B were determined from the 
replotting of Figure 6 data as shown in Supplemental Figure S1.  
As shown in Figure 10A (top panel), the physical properties of the three mAbs at 
pH 7.2 were ranked ordered as described above, and then the results were combined 
(bottom panel). It can be seen that sIgA1 scored as having the best physical properties 
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(combination of results from thermal and denaturant unfolding as well as relative 
solubility), followed by sIgA2 with intermediate behavior, and IgG1 as the least desirable 
properties overall. The same evaluation was carried out at pH 3.0 as shown in Figure 
10B, and the same rank ordering of desirable physical properties was calculated at pH 
3.0 with sIgA1 > sIgA2 > IgG1. Results of relative stability index during incubation in the 
in vitro gastric digestion model are shown in Figure 10C based on rank ordering the 
results from the ELISA, SDS-PAGE and SEC analyses (see Figures 7, 8, 9). The sIgA1 
and sIgA2 mAbs showed an overall similar ranking in terms of relative stability under 
conditions that mimic oral delivery, with IgG1 displaying the lowest stability overall under 
these conditions.  
4.4. Discussion 
Monoclonal antibodies (mAbs) are now widely used for treating a variety of 
diseases especially pre-exposure prophylaxis (PreP) for infectious diseases, autoimmune 
disorders, and cancers.50 Approximately 70 mAbs are now approved for various 
therapeutic uses by regulatory agencies, and the vast majority are comprised of the IgG1 
antibody subtype and are administered to patients by parenteral injection (intravenous or 
subcutaneous routes). From a product development point of view, key structural attributes 
of IgG1 mAbs, which need to be maintained and closely monitored during manufacturing, 
storage and transport, are now well-established including determination of primary 
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structure and post-translational modifications (e.g., glycosylation), size and aggregation 
propensity, higher-order structural integrity and biological activities including antigen 
binding, and in some cases, effector function.51-53  
In contrast, we evaluated analytical and formulation challenges with a different 
class of monoclonal antibodies (secretory IgAs) for administration by a different route (oral 
delivery) for a different application (passive immunization to protect against enteric 
diseases in the developing world). Specifically, sIgA1, sIgA2 and IgG1 mAbs targeting 
heat labile enterotoxin (LT), a major virulence factor of Enterotoxigenic E. coli (ETEC), 
were examined in this work. The potential therapeutic use of sIgAs for passive 
immunization are of particular interest since they are the predominant immunoglobulin 
isotype in tears, saliva, breast milk, colostrum, and mucosal surfaces such as the 
gastrointestinal as well as genitourinary tracts.26 Regardless of ultimate success of using 
anti-LT sIgA mAbs for passive immunization against ETEC infections in vivo (preclinical 
animal studies ongoing), generation of milligram quantities of these anti-LT sIgA 
monoclonal antibodies provided the opportunity to evaluate sIgA mAbs in terms of 
pharmaceutical development challenges including analytical characterization, 
stabilization and formulation for oral delivery.  
One key challenge to perform extensive analytical and formulation evaluations was 
the limited amount of purified sIgA material that was available given the early stage of 
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preclinical development. To this end, with only ~5-10 mg of available material for this 
work, we first developed a series of analytical tools to assess structural integrity, post-
translational modifications, size and aggregation, conformational stability, relative 
solubility and antigen binding activity. In addition, we aimed to perform many of these 
assessments under conditions of neutral pH as well as more acidic pH (during incubation 
in an in vitro gastric digestion model). The main objective was to not only better 
understand the key structural attributes of sIgA mAbs when formulated for oral 
administration, but also to compare the results to the much more widely studied IgG1 
mAb. This was accomplished by examining three anti-LT mAbs produced in CHO cells 
as described above.  
A combination of LC-MS peptide mapping, N-glycan analysis and size 
comparisons under denaturing (SDS-PAGE) and non-denaturing conditions (SEC and 
SV-AUC) established the increased structural complexity and heterogeneity of sIgA 
compared to IgG1 mAbs. For example, the multi-chain composition and higher molecular 
weight of monomeric sIgA mAbs, along with their more abundant and complex 
glycosylation patterns, were confirmed. In addition, a higher relative percent of higher 
molecular weight, multimeric species was demonstrated both the sIgA1 and sIgA2 mAbs 
vs the IgG1 mAb. Nonetheless, the sIgA mAbs were more physically stable and pepsin-
resistant (during incubation at 37°C at pH 3.5) and thus likely more suitable for oral 
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delivery. This is not unexpected considering sIgA is the most abundant antibody isotype 
in external secretions and mucosal membranes.20,54 Based on these results, three key 
structural attributes for sIgA mAbs were identified in this work including (1) N-glycan 
profiles, (2) size heterogeneity/aggregation and (3) stability under conditions to mimic oral 
delivery as discussed in more detail below.  
When considering the total amount of carbohydrate and N-linked glycosylation 
profiles, significant differences were observed between sIgA1 vs. sIgA2 (~18% total 
carbohydrate with 23-24 different N-glycan oligosaccharides) vs. IgG1 (~1% total 
carbohydrate with 5 different N-glycan oligosaccharides) expressed in CHO cells. It is 
expected the glycosylation pattern for sIgA mAbs will be a critical structural attribute to 
monitor since in nature their heavily glycosylated nature facilitates antibody binding to 
various pathogens and receptors.36 For example, the N-glycans on the J chain are usually 
required for dimer or oligomer formation of sIgAs, and can also bind to polymeric 
immunoglobulin receptors (plgR).55 The secretory components (SC) of sIgAs are also 
heavily glycosylated, and the wide range of N-glycans on the SC creates diverse glycan 
epitopes, which can function as targets for lectins and bacterial adhesins.36,56,57 As a 
result, glycosylated SC can inhibit bacteria adhesion and prevent the establishment of an 
infection.57,58 In addition, the galactose-terminating N-glycans are potential ligands for the 
asialoglycoprotein receptor (ASGP-R) that could mediate the clearance and half-life of 
196 
 
IgAs.59,60 Although a relatively simpler N-glycan profile was obtained for IgG1, these 
glycans are required for maintaining protein stability, increasing solubility, maintaining Fc 
effector functions, and receptor binding (e.g., Fcγ).36,61 In terms of future work, 
identification of the O-glycosylation profile for sIgA mAbs will be important to better 
understand because of the crucial role it may play in pathogen binding. In addition, batch-
to-batch variability of the glycan profiles as well as their effects on sIgA mAb stability (in 
terms of overall flexibility of the hinge region and protection of the hinge region from 
protease digestion36) will be of interest to further evaluate.  
As for size heterogeneity of these three anti-LT mAbs, the IgG1 mAb was relatively 
more homogeneous containing 91-96% monomeric species with smaller amounts of 
higher molecular weight (HMW) species (4-9%) as measured by SE-HPLC and SV-AUC. 
In contrast, both sIgA mAbs not only contained much lower amounts of the monomeric 
sIgA (50-57% for sIgA1 and 18-22% for sIgA2), but also had much higher levels of HMW 
species (43-50% for sIgA1 and 78-82% for sIgA2). Since there are several cysteine 
residues in each J-chain that usually form both inter- and intra-chain disulfide bonds, it is 
likely that disulfide bond scrambling leading to formation of inter-chain disulfide bonds 
between the tailpiece and cysteine residues in the heavy chains can occur.62,63 Thus, the 
J chain has the potential to be a hotspot for cross-linking oligomers for sIgAs.62-65 In this 
work and consistent with published data, the J-chain was not detected by SDS-PAGE 
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under reducing or non-reducing conditions (although it was readily identified by LC-MS 
peptide mapping).66 One possible explanation from previous reports is that the J-chain 
remains associated with light chain of sIgAs as a complex, and thus co-migrated with the 
light chain66,67, although we did not observe such a complex by SDS-PAGE in terms of 
MW migration (Figure 1B).  
It is expected that presence of aggregates will be a critical structural attribute to 
monitor with sIgAs. Aggregation is of concern with parenterally administered mAbs due 
to the loss of potency and the potential for anti-drug immune responses that limit efficacy 
and potentially affect safety.68 However, it is not known to what extent this would be a 
concern during oral delivery of sIgAs. In fact, the polymeric nature of sIgA may not 
necessarily be a negative attribute in terms of efficacy during oral delivery for passive 
immunization (as long as mAb drug is not lost due to precipitation and no unwanted 
immune responses are generated). The biological potency of polymeric sIgAs has been 
previously reported to be preserved along with some protease resistance.69 Furthermore, 
polymeric sIgA may elicit intracellular signaling by binding to pIgRs, and potentially inhibit 
intracellular virus replication.70-72 Interestingly, polymeric sIgA can display greater activity, 
when compared to monomeric sIgA, with regards to neutralizing toxins or whole bacterial 
cells, such as neutralizing proinflammatory antigens located in the apical recycling 
endosome.62,73,74 Since it is likely that both covalent crosslinking as well as non-covalent 
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interactions between sIgA molecules play a key role in formation of multimers, future work 
will focus on better understanding the aggregation mechanisms of the sIgA mAbs, not 
only during production but also during long-term storage over time. The batch-to-batch 
variability of size distribution and aggregate content of sIgAs will also be of interest to 
further evaluate. 
Finally, another potential critical structural attribute identified in this work is the 
stability of sIgA1, sIgA2 and IgG1 mAbs under conditions that mimic oral delivery. We 
adapted a previously reported in vitro gastric model for evaluating the fate of various food 
products and supplements during transit through the digestive tract (see Methods).30 Due 
to limited material availability, we focused our experiments on a scaled down version of 
the gastric phase of digestion, since this is the first major stage that is encountered in vivo 
and contains pepsin that can readily degrade proteins.75 As a preliminary formulation 
assessment, we also tested a bicarbonate formulation buffer, which has been 
successfully used as part of a rotavirus vaccination program during oral vaccination.33 
The stability profile of the mAbs was monitored by ELISA, SDS-PAGE and SEC. Although 
possessing a trend toward relatively lower binding affinity at time zero, sIgA mAbs showed 
greatly improved stability of antigen binding properties as measured by ELISA over 24 hr 
incubation in the in vitro gastric digestion conditions (37°C, pH 3.5 in the presence of 
pepsin). The major digestion product after pepsin digestion was the F(ab’)R2R fragment for 
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each of the three mAbs as determined by SDS-PAGE and SE-HPLC. Nevertheless, the 
antigen binding values varied over time between the three mAbs. These observations 
indicate that not all F(ab’)R2 Rfragments retained antigen binding activity to the same extent 
in comparison to the full length, undigested mAbs. Potential conformational structure 
changes, allosteric effects, and/or glycosylation may influence these properties.54,76-79 In 
terms of future work, sIgA stability profiles under conditions that mimic sequential 
digestion (including oral, gastric, and intestinal phases) should be evaluated to better 
understand the stability profile of sIgA candidates under conditions that mimic oral 
delivery. In addition, these in vitro digestion models can be utilized in the future to screen 
for formulation excipients that may help improve stability and retain potency during oral 
delivery. The concept was established in this work by demonstrating the protective effect 
of co-addition of bicarbonate buffer in terms of stabilizing the three anti-LT mAbs during 
incubation in the in vitro gastric digestion model (see Figures 7, 8 and 9).  
Smaller molecular weight protein therapeutic drugs (e.g., insulin) have been 
evaluated for systemic use by oral delivery80-82, and face several significant barriers 
including poor stability (due to acidic pH and digestive enzymes) and very low protein 
bioavailability. It has been reported that advanced drug delivery systems can be used to 
improve oral delivery of insulin, e.g. polymeric nanoparticles, micelles, liposomes, 
microspheres, or pH responsive complexation gels.80,82-84 In contrast, the goal of this work 
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is local delivery of the sIgA mAbs to bind and neutralize Enterotoxigenic E. coli (ETEC) in 
the GI tract. Thus, passive immunization with sIgA mAbs may be a more successful 
approach than systematic delivery by the oral route of administration. However, for 
passive immunization applications in low-income and developing countries, low cost 
formulations of sIgA mAbs for treatment of diarrheal diseases is critical, making the use 
of complex formulations such as advanced delivery technologies less desirable. Thus, 
longer term, simple liquid formulations (perhaps as an oral supplement) that provide good 
long-term storage stability of the sIgA mAbs, and also provide protection from acidic 
pH/proteases degradation during oral delivery would be ideal. In the shorter term, the goal 
is to facilitate first-in-human clinical studies with sIgA mAbs, not only by further developing 
the analytical tools utilized in this work to reproducibly prepare and quality control test 
sIgA mAbs as therapeutic drug candidates, but also to design stabilized formulations for 
oral administration for use in initial clinical studies. 
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4.6. Figures and Tables 
 
 
 
 
 
Figure 4.1. Structural overview and SDS-PAGE purity analysis of sIgA1, sIgA2 and IgG1 
mAbs used in this study. (A) Schematic representation of immunoglobulin domains within 
sIgA1, sIgA2, and IgG1 antibodies. The LC, HC, SC and J polypeptide chains, along with 
sites of post-translational N- and O-linked glycosylation, are indicated (see text). (B) 
Representative SDS-PAGE analysis of three anti-LT mAbs under non-reducing and 
reducing conditions with and without removal of N-glycans by PNGase F treatment. The 
molecular weight markers are on the far left lane. All bands assignments were based on 
molecular weight migration only. 
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Figure 4.2. Representative LC-MS peptide mapping chromatograms of sIgA1, sIgA2 and 
IgG1 to confirm the primary sequence of each mAb and to evaluate for chemical post-
translational modifications (see text). (A) Representative LC base peak chromatograms 
of each mAb after trypsin digestion; (B) Percentage primary sequence coverage on each 
polypeptide chain found in each of the three mAbs. 
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Figure 4.3. Glycosylation analysis of sIgA1, sIgA2 and IgG1 mAbs produced in CHO 
cells. (A) total carbohydrate content. (B, C, D) Representative chromatographic profiles 
of Fluor-MS N-linked glycans removed from the mAbs are shown for (B) sIgA1, (C) sIgA2, 
and (D) IgG1. Fluorescence and mass spectrometry results are indicated and peaks are 
numbered as a series of different N-glycans. See Figure 4 for summary of results. All data 
are presented as mean ± SD; n = 3.  
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Figure 4.4. Identification and percent composition of each N-glycan type found in sIgA1, 
sIgA2 and IgG1 mAbs (produced in CHO cells) as determined by Fluor-MS N-linked 
glycan analysis. The total number of N-glycans, their respective oxford notations and 
structures, as well as the relative percentage of the total N-glycans for each mAb is 
shown. See Figure 3 for representative chromatograms. All data are presented as an 
average value; n = 3. 
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Figure 4.5. Size analysis of anti-LT sIgA1, sIgA2 and IgG1 mAbs as measured by SV-
AVC and SE-HPLC. (A) Representative SV-AUC analysis of the three mAbs. Peaks 
(monomer or HMW species) were assigned based on sedimentation coefficient values 
and estimated molecular weight determinations as shown in Supplemental Table S1. (B) 
Representative SE-HPLC chromatograms of the three mAbs. Peaks (monomer or HMW 
species) were assigned based retention time values and estimated molecular weight 
values (based on gel filtration standards) are shown in Supplemental Table S1. Note, a 
different SEC column was used for IgG1 vs. the two sIgAs mAbs. (C) Relative amount of 
each species calculated based on the total peak areas for both SV-AUC and SE-HPLC. 
Representative SV-AUC profiles and SEC chromatograms are shown and percent 
species are presented as average value; n = 2 for SV-AUC and n = 3 for SE-HPLC, with 
range and standard deviation values of 0.1 to 4.4% and from 0.1 to 0.6%, respectively.  
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Figure 4.6. Comparison of conformational stability and relative apparent solubility profiles 
of anti-LT sIgA1, sIgA2, and IgG1 mAbs at pH 7.2 vs. pH 3.0. (A) thermal unfolding as 
measured by the shift of MSM peak position as a function of temperature, and (B) GdnHCl 
unfolding as a function of denaturant concentration, both measured by intrinsic Trp 
fluorescence spectroscopy. (C) relative protein concentration of each mAb as a function 
of PEGR10,000R concentration (w/v) as measured by UV-visible spectroscopy. All data are 
presented as mean ± SD; n = 3. 
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Figure 4.7. Comparison of LT-antigen binding curves for the three anti-LT mAbs after 
incubation in the in vitro gastric digestion model as measured by ELISA including (A) 
sIgA1, (B) sIgA2, and (C) IgG1. (D) Comparison of the relative percent LT antigen binding 
remaining for each of the three mAbs based on normalization to the time zero binding 
curve (with or without bicarbonate buffer) are displayed (mean ± SD; n = 3). 
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Figure 4.8. Comparison of structural integrity of the three anti-LT mAbs after incubation 
in the in vitro gastric digestion model as measured by SDS-PAGE: (A) sIgA1, (B) sIgA2, 
and (C) IgG1. Representative SDS-PAGE results of digested mAb samples by time 
course with or without co-addition of sodium bicarbonate buffer (0.03 M trisodium citrate 
and 0.3 M sodium bicarbonate at pH 8.5) (D) Comparison of the relative percent main 
species remaining over time for each of the three mAbs based on densitometry analysis 
of the main species (intact mAb) normalized to values at time zero (mean ± SD; n = 3). 
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Figure 4.9. Comparison of the structural integrity of the three anti-LT mAbs during 
incubation in the in vitro gastric digestion model as measured by SE-HPLC: (A) sIgA1, 
(B) sIgA2, and (C) IgG1. Representative SE-HPLC chromatograms with UV 214nm 
detection are displayed. Samples were incubated in presence of immobilized pepsin as 
a function of time and analyzed after removal of pepsin-agarose. (D) Comparison of the 
relative percent main species remaining over time for each of the three mAbs based on 
main SEC peak integration and normalization to time zero (mean ± SD; n = 3). 
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Figure 4.10. Comparison and rank ordering of desirable physical properties and stability 
profiles of sIgA1, sIgA2 and IgG1 mAbs (“relative stability indexes”) including (A) physical 
properties at pH 7.2, (B) physical properties at pH 3.0, and (C) relative stability after 
incubation at 37°C, pH 3.5 with pepsin in the in vitro gastric digestion model. See Figure 
6 and Supplemental Figure S1 for data sets used in (A) and (B). See Figures 7-9 for data 
sets used to rank order mAbs in (C).  
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Supplemental Figure 4.1. Replotting of conformational stability and relative apparent 
solubility data sets for the three anti-LT mAbs in Figure 6 including intrinsic fluorescence 
peak emission maximum (MSM) values for each protein vs (A) temperature, and (B) 
GdnHCl concentration. (C) Relative mAb concentration in solution vs. amount of added 
PEG 10,000. Data sets compare and provide relative rank-ordering of the three mAbs at 
both pH 7.2 and 3.0 as shown in Figure 10. All data are presented as mean ± SD; n = 3. 
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Supplemental Table 4.1. Estimation of molecular weight values of various species in 
solutions of the three anti-LT mAbs as determined from (A) sedimentation coefficient 
measurements from SV-AUC, and (B) retention time measurements from SE-HPLC 
(standard curve established using gel filtration molecular weight standards). 
Nomenclature of SV-AUC species (peaks 1-4) and SE-HPLC (peaks A-C) correspond to 
peaks from corresponding S values and retention times, respectively, as shown in Figure 
5 (from left to right). Duplicate and triplicate measurements were performed for SV-AUC 
and SE-HPLC, respectively. 
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Chapter 5  
 
Summary, Discussions, and Future Directions 
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5.1. Overview 
The first major part of this Ph.D. thesis project focused on the systematic 
characterization of solution properties and molecular behaviors of two different human 
IgG1 mAbs at high protein concentrations in the absence/presence of excipients using 
both biophysical analytical techniques combined with HX-MS studies. Subcutaneous 
(SC) administration of mAb therapeutic drugs is an increasingly common and convenient 
route for patients to be able to do home-based treatments.1 Due to small injection volume 
limitation, it necessitates the development of high-concentration mAb formulations, which 
can possess many pharmaceutical challenges during manufacturing, storage, and 
delivery,2,3 including increasing solution viscosity and turbidity, decreasing solubility and 
protein physical stability, and even promoting phase separation.2,4,5 Although protein 
engineering of mAbs by point mutations can efficiently reduce PPI propensity leading to 
RSA at high protein concentrations, such changes in sequence can alter other properties 
such as conformational stability or biological affinity to different extents.6,7 As an 
alternative strategy, formulation approaches can significantly mitigate RSA without 
dramatically affecting these other desirable properties of mAbs through application of 
specific excipients and/or solution conditions. By understanding the predominant 
molecular regions of interaction and non-covalent forces responsible for IgG1 RSA, based 
on hydrogen exchange-mass spectrometry (HX-MS) studies, particular excipients were 
selected and then examined on their effects of promoting or disrupting reversible protein-
protein associations at high protein concentrations.  
In comparison, the second major part of this thesis project focused two different 
classes of immunoglobulins (secretory IgA and IgG) for potential use for passive 
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immunization by oral delivery to infants. The model system for this work evaluated mAbs 
against enterotoxigenic Escherichia coli (ETEC), a bacterium which is a major cause of 
diarrheal disease in developing countries, especially among children and infants <5.8,9 
The potential advantages of oral delivery to infants in the developing world not only 
include disease treatment, but also reduced cost, simplicity of administration and “instant 
protection” by localized treatment within the GI tract. One major challenge of this 
approach is the instability of such therapeutic mAb molecules during both oral delivery (in 
the digestive tract) and in solution during long-term storage.10 In this work, heat labile 
toxin (LT) was used as the target antigen, which is one of the major virulence factors of 
ETEC, playing key roles of inducing water and electrolytes loss in the gastrointestinal (GI) 
tract of infected subjects.11,12 Two main types of immunoglobulins (secretory IgA and IgG) 
against LT antigen were used as model therapeutic mAbs for developing analytical 
techniques and assessing stability (physicochemical as well as in vitro immunological 
binding) under various conditions. A combination of biochemical and biophysical methods 
were employed to comprehensively characterize and compare three mAbs (sIgA1, sIGA2 
and IgG1) including primary structure, post translational modifications (i.e., N-linked 
glycans), size, higher order structural integrity, conformational stability, apparent relative 
solubility, and in vitro antigen binding activity. In this work, we also monitored and 
compared the stability profiles of these three mAbs using an in vitro oral digestion model 
(to mimic in vivo degradation conditions due to gastric acid).  
5.2. Chapter Summaries and Future Work 
5.2.1. Chapter 2 
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This chapter describes the solution and molecular properties of an IgG1 antibody 
(mAb-J) that undergoes extensive RSA, and the effects that different excipients have on 
altering mAb-J RSA propensity especially at high protein concentrations. Based on a 
previous work of mAb-J,2 RSA sites and potential non-covalent interaction forces have 
been determined. Based on these results, five different ionic excipients, including salt 
(NaCl) as well as positively and negatively charged amino acids, were chosen and 
examined for their ability to disrupt the RSA of mAb-J driven primarily by electrostatic 
interactions. Among the five excipients, all of which followed a concentration-dependent 
pattern, Arg had the greatest effects of mitigating mAb-J RSA. All of the five additives 
affected mAb-J at high concentration (to varying extents) resulting in decreasing solution 
viscosity and opalescence, reducing mAb hydrodynamic size (increasing monomer 
fraction) and improving relative solubility while minimizing or even preventing phase 
separation. However, according to HX-MS results, a small protection was still observed 
at CDR L2 when comparing high vs. low protein concentrations in the presence of Arg, 
indicating potential residual RSA interactions involved with Fab domain. Based on the 
biophysical studies, such protection is potentially a signature of the difference between 
mAb-J dimeric and monomeric forms. Similar observations were found with Lys, but the 
RSA-disrupting efficiency was to a lesser extent. The other three excipients, including 
Glu, Asp, and NaCl, demonstrated even less efficacy on RSA disruption than positively-
charged amino acids, even though they all improved mAb-J colloidal stability and solution 
properties. This study illustrated that although electrostatic interactions are probably the 
dominant force responsible for mAb-J RSA, other non-covalent forces, such as 
hydrophobic or dipole-dipole interactions, could also contribute to protein-protein 
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interactions leading to RSA of mAb-J. For example, the RSA-disrupting efficiency of Arg 
with mAb-J could be due to, in addition to electrostatic charge, its zwitterionic as well as 
chaotropic properties.  
In terms of future work, although several five different ionic excipients have been 
studied and measured in terms of their ability to mitigate mAb-J RSA, more classes of 
excipients and more charge-induced self-associating mAbs could be investigated to 
better understand the applicability and usability of formulation strategy regarding 
minimization (or elimination) of RSA at high mAb protein concentration. In addition, 
solution pH and buffering agents also play important roles in affecting protein properties, 
especially the charge profile, which would be of high interest to explore in this context. 
Furthermore, phase separation is an important phenomenon induced by protein-protein 
associations at high protein concentrations, which not only can have critical biological 
functions inside cell, but in addition, in terms of developing protein therapeutic products, 
phase separation leads to notably reduced protein physical stability.13,14 Therefore, it will 
be interesting to study protein liquid-liquid phase separation, including reversibility, 
solution viscosity, potential molecular mechanisms and interaction site, and effect of 
temperature and excipients with additional mAbs. Last but not least, long-term. real-time 
storage stability studies could be performed at high protein concentrations in the 
absence/presence of the same excipients in order to determine how such observations 
(of excipient effects on solution and molecular properties of mAb-J) predict the 
aggregation profile of over time, especially when these excipients have potential impacts 
on both the conformational and colloidal properties of a mAb-J protein. 
5.2.2. Chapter 3 
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In a companion study, Chapter 3 also focused on RSA of a human IgG1, but with 
a different mAb called mAb-C, which has been identified previously to undergo reversible 
self-associated by primarily intermolecular hydrophobic interactions.15 Different from 
previous research on mAb-C performed at pH 7.0, more regions on mAb-C in this study 
were involved in protein-protein interactions at pH 7.5 because of probably differences in 
charge interactions at relatively higher pH. These regions of RSA interactions in mAb-C, 
consistent with previous work, are in rich of aromatic or hydrophobic amino acids, further 
confirming the hydrophobic interactions as the dominant force for mAb-C associations. In 
this work, a set of additives were selected to examine their effects on promoting or 
disrupting mAb-C RSA, including chaotropic, kosmotropic, and hydrophobic salts, 
aromatic amino acid derivative, and addition of a less polar solvent (in comparison to 
water). As a result, varying effects were found among these additives, where sodium 
sulfate promoted mAb-C RSA, while others demonstrated their ability to disrupt protein-
protein interactions, albeit to notably different extents. Specifically, sodium sulfate, 
enhanced solution viscosity, hydrodynamic size (and fraction of oligomeric species). By 
HX-MS analysis, sodium sulfate induced enhanced and more extensive protections (i.e., 
sites of PPIs). However, in terms of relative solubility, sodium sulfate (150 mM) showed 
positive effects probably due to the salting-in effects, while 0.5 M of sodium sulfate 
decreased relative solubility likely via salting-out effects. In comparison, the other 
remaining additives reduced RSA propensity for mAb-C, and thus improved solution 
properties especially at high protein concentrations, with guanidine hydrochloride (0.5 M) 
showing the highest efficiency. Furthermore, in HX-MS studies, not all protected regions 
were disrupted in the presence of these additives, and divergent regions within mAb-C 
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were affected between different additives. In addition, homology modeling and patch 
analysis were performed in this study, showing consistent results with biophysical and 
analytical measurements, which further confirmed the molecular properties of mAb-C and 
potential RSA mechanism. Therefore, in this study, behavior of mAb-C RSA varied 
significantly depending on the type and amount of additives, temperature, and buffer pH. 
As for possible future plans for this research, although guanidine hydrochloride 
had the biggest disrupting effects on mAb-C RSA, the amount used was also the highest 
(0.5 M). Therefore, relative efficacy of lower-amounts guanidine hydrochloride, such as 
150 mM, or concentration-activity relationship would be of great interest to investigate in 
the future. Furthermore, additional hydrophobic salts or aromatic amino acids could be 
examined for their effects on both mitigating mAb-C reversible self-associations and 
improving solution or molecular properties. Such additional studies should lead to 
elucidation of some potential relationships between additive hydrophobicity and RSA-
disrupting properties. In addition, unlike mAb-J, no phase separation was observed for 
mAb-C even with sodium sulfate in solution. As a result, knowledge of the causes and 
mechanisms of why RSA results in phase separation in some cases, and not in others, 
will provide more information for helping to better formulate and stabilize RSA-intensive 
mAb therapeutics. Finally, additional studies on additive-induced protein conformational 
and colloidal stability profiles, including for example during long-term, real-time stability 
studies of mAb-C, would be an important attribute to further investigate in order to assess 
the effect of hydrophobic additives when developing stable formulations of therapeutic 
protein candidates. 
5.2.3. Chapter 4 
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With the long term goal to develop a low-cost, orally delivered mAb drug product 
to treat ETEC-induced diarrheal disease in infants in the developing world, the work in 
this chapter compared two secretory IgAs (sIgAs) and an IgG1 mAbs (against the same 
molecular antigen) in terms of sample heterogeneity, protein primary sequence, post-
translational modifications, physical stability and stability in an in vitro digestion model to 
mimic oral delivery in vivo. Based on the results of SDS-PAGE, SE-HPLC, and SV-AUC 
analyses, both sIgAs had relatively large amounts of higher molecular weight species in 
solution, especially sIgA2, while high monomeric content was detected for IgG1. Since 
such observations were found in during analysis under denaturing and non-denaturing 
conditions, some covalent connections such as non-native disulfide bonds, may have led 
to heterogeneous, oligomeric nature of the sIgA samples. Furthermore, high percentage 
coverage of primary sequence was found for each chain of three immunoglobulins by 
tryptic peptide mapping, except the heavy chain of sIgA1, which may be due to the O-
linked glycosylation on the hinge region (needs to be confirmed in future work). In 
addition, very different amounts of total carbohydrate and N-glycan oligosaccharide 
composition profiles were determined for sIgAs and IgG1. Both sIgA1 and sIgA2 
contained >18% (w/w) total carbohydrate and showed >=23 various types of N-glycans 
on heavy chain, secretory component, and J chains. In comparison, IgG1 had ~2% (w/w) 
total carbohydrates with only 5 different N-linked glycan types on the heavy chain. 
Furthermore, higher physical stability and lower relative solubility were observed for all 
three mAbs at pH 7.2 vs. pH 3.0 based on the results of thermal melting, isothermal 
chemical denaturation, and PEG-induced precipitation assays, respectively. Comparing 
these three molecules, sIgA1 demonstrated the highest stability at both pHs, and sIgA2 
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was the second, while IgG1 displayed the least stable profile. Protease digestion stability, 
as measured by means of an in vitro gastric model, was performed on the three mAbs by 
three techniques, including SDS-PAGE, SE-HPLC, and ELISA, to characterize their 
digestion products and corresponding antigen-binding affinity. It was observed that sIgAs 
had relatively greater pepsin-resistant properties than IgG1, demonstrating a time course 
difference of 3 hours (sIgAs) vs. 5 minutes (IgG1) for complete digestion of intact proteins 
at low pH and 37°C. Although the major protease digestion byproduct was F(ab’)R2R for all 
three mAbs, antigen-binding affinity varied notably between that coming from sIgAs or 
IgG1. Specifically, the F(ab’)R2R of sIgAs were observed to bind antigen to a greater extent 
in comparison to that of IgG1 (needs to be further evaluated in future work). In summary, 
although the physicochemical and antigen binding differences in stability profile of sIgA1 
and sIgA2 were not notable based on in-solution and in vitro digestion studies, both sIgA 
molecules displayed greater stability properties than IgG1, indicating the superiority of 
sIgA as potential mAb drug candidate for oral delivery. 
In terms of future work, more mAbs, including additional sIgAs, IgGs, and even 
VHHs, targeting a different ETEC antigen such as CfaE, will be studied. For these studies, 
an intestinal phase in vitro digestion model, addition to the gastric phase model described 
in this work, is required and thus needs to be developed in the future to fully assess the 
overall in vitro digestion stability profile of various mAbs in the GI tract. Lead sIgA 
candidates will also be further studied and examined in terms of formulation development 
including determining the molecular mechanisms of degradation due to exposure to 
environmental stresses encountered manufacturing and storage as well as during oral 
delivery (the latter including acidic pH, elevated temperature and proteases) using a 
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variety of physicochemical and in vitro binding assays. In addition, analytical 
characterization methods will be used for excipient screening assays to identify specific 
pharmaceutical excipients that stabilize the mAbs during storage and during oral delivery. 
Optimized liquid formulations will therefore be not only be developed to improve the 
physicochemical and storage stability of sIgAs as potential drug candidates, but also for 
their ability to maintain the potency of these molecules during in vivo conditions of oral 
delivery.  
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